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Titre :  Potentiel vaccinal d'adénovirus porteurs d'épitopes h terologues insérés dans les protéines de 
capside. 
Mots clés : adénovirus, vaccination, HCV 
 
Résumé : Les vecteurs adénoviraux ont été 
utilisés dans de nombreuses approches 
vaccinales en exprimant la protéine d’intérêt à 
l’aide du transgène. Néanmoins, leur efficacité 
est limitée par la forte séroprévalence chez 
l’homme des anticorps anti-Ad capables 
d’inhiber le transfert de gène. Afin de 
s’affranchir de cette étape, mon laboratoire a 
opté pour une stratégie d’insertion d’épitopes 
dans les protéines de capside virale (epitope 
display). 
La première partie de ma thèse a cherché à 
comprendre les paramètres contrôlant 
l’immunogénicité de l’approche epitope display. 
Ainsi, en utilisant différents Ad porteurs d’un 
épitope B dérivé de l’ovalbumine (Ova), j’ai 
montré que l’ablation des interactions des Ad 
avec leurs récepteurs (CAR, intégrines, 
héparane sulfate) ne modifiait pas leur capacité 
à induire une réponse humorale contre l’Ova. 
Ces résultats suggèrent que le processus 
d’infection virale n’est pas requis pour 
l’induction d’une réponse humorale par les Ad 
porteurs d’épitopes Ova. Parallèlement, j’ai 
évalué l’impact de différents systèmes senseurs 
de l’immunité innée sur la réponse anticorps 
induite par les vecteurs porteurs de l’épitope 
Ova. Les résultats obtenus basés sur l’utilisation 
de modèles de souris génétiquement déficientes 
pour les protéines MyD88 ou MAVS indiquent 
que les voies des Toll-like receptor et RIG-I-like 
receptor ne sont pas indispensables ou jouent 
des rôles redondants dans le contrôle du 
potentiel immunogénique des Ad porteurs 
d’épitope Ova.  
  
 
 
Le second objectif de ma thèse a été d’évaluer 
la capacité de l’approche d’epitope display  à 
induire des réponses cellulaires chez la souris. 
Des vecteurs Ad à capside modifiée par 
insertion d’un épitope T dérivé de l’antigène 
modèle Ova ont été produits et nous avons mis 
en évidence que ces vecteurs induisaient des 
réponses cellulaires de type CD8+. Nous avons 
observé que (1) ces réponses immunitaires sont 
quantitativement plus importantes quand 
l’épitope T est inséré dans la protéine hexon 
plutôt que dans la fibre (2) et sont réduites chez 
les animaux immuns pour l’Ad 
comparativement aux animaux naïfs. 
Parallèlement, nous avons voulu analyser la 
capacité de la stratégie d’epitope display à 
induire des réponses cellulaires de type 
cytotoxiques contre une cible thérapeutique, le 
virus de l’hépatite C. Différents Ad porteurs 
d’épitopes T dérivés de la protéine NS3 d’HCV 
ont été produits. Après administration des Ad à 
des souris transgéniques pour HLA-A2, nous 
avons mis en évidence l’induction de réponses 
cellulaires de type CD8+ dirigées contre la 
p otéine NS3 du VHC. 
L’ensemble de mes travaux de thèse permet de 
mieux comprendre les paramètres qui contrôlent 
la vaccination par epitope display à l’aide d’Ad. 
Ils constituent une étape dans la mise au point 
de vaccins qui bénéficient des propriétés 
adjuvantes de l’Ad et présentent des effets 
secondaires réduits. 
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Title :  Vaccination potential of adenoviral vectors displaying heterologous epitopes in their capsid 
proteins. 
Keywords : adenovirus, vaccination, HCV, epitope display 
Abstract :  Recombinant adenoviruses (Ad) 
have recently been employed in a wide range of 
vaccination strategies. Unfortunately, highly 
prevalent pre-existing neutralizing antibodies 
reduce their ability to trigger transgene 
expression. To avoid the step of gene transfer a 
new vaccination strategy has been proposed 
based on the use of Ad displaying epitopes 
inserted into their capsid proteins.  
In the first part of my thesis, we sought to 
better understand the molecular mechanisms 
dictating the vaccination potential of epitope 
display strategy. To that end, Ad vectors 
displaying B cell ovalbumin (Ova) epitope in 
fiber protein and ablated in interactions with 
their natural receptors (CAR, integrins, heparan 
sulfates) were produced and characterized in 
vitro. After their administration to C57BL/6 
mice, these vectors led to unmodified anti-
epitope humoral responses, suggesting that 
their efficacy does not depend on their ability 
to transduce cells. In parallel, we sought to 
evaluate the impact of innate immune pathways 
on the outcome of anti-epitope adaptive 
immune responses. Upon immunization of 
MyD88- and MAVS-deficient- mice we 
observed that humoral responses induced in 
both knock-out mice strains were as potent as 
in wild-type mice. This indicates that the 
signalization pathways of Toll-like receptors 
and RIG-I-like receptors are not crucial or play 
a redundant role in controlling the vaccination 
potential of Ad displaying Ova epitopes. 
 
In the second part of my thesis, we assessed the 
capacity of epitope display strategy to induce 
cellular responses in mice. Ad vectors 
displaying T cell epitopes derived from the 
model antigen Ova were constructed, produced 
and characterized in vitro. Afterwards, 
C57BL/6 mice were immunized with Ad 
displaying T cell epitopes and cellular 
responses were assessed by measurement of 
cytokine production by splenocytes upon in 
vitro antigen restimulation or directly by 
quantification of epitope-specific T cells. The 
results indicate that (i) CD8+ cellular responses 
are more potent when T cell epitope is inserted 
into Ad hexon and not fiber protein and (ii) 
pre-existing anti-Ad responses limit the 
induction of anti-epitope cellular immunity. 
Finally, we sought to evaluate the potential of 
epitope display strategy in mounting cellular 
responses directed against a therapeutic target, 
hepatitis C virus (HCV). Thus, Ad vectors 
displaying T cell epitopes from HCV protein 
NS3 inserted either into hexon or fiber were 
constructed and characterized. Remarkably, 
vector administration into HLA-A2 transgenic 
mice triggered the induction of HCV-specific 
CD8+ cellular responses  
Altogether, our work allows better 
understanding of the epitope display 
vaccination strategy and provides the 
foundations for the development of Ad-based 
vaccines with minimized side effects and 
unaltered adjuvant properties. 
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Abbreviations 
aa : amino acid 
Abs : antibodies 
Ad : adenovirus 
APCs : antigen presenting cells 
CAR : coxsackie-adenovirus receptor 
CTL : cytotoxic CD8
+
 lymphocytes 
Dd : dodecahedron 
DCs : dendritic cells 
FX : factor X 
HCV : hepatitis C virus 
HIV : human immunodeficiency virus 
HLA : human leukocyte antigen 
HSPG : heparan sulfate proteoglycans 
HVR : hyper variable regions 
i.m. : intramuscular 
i.n. : intranasal 
i.p. : intraperitoneal 
i.v. : intravenous 
IFN : Interferon 
Ig : Immunoglobulin 
IL: Interleukin 
MAVS : mitochondrial antiviral signalling 
protein 
MHC : major histocompatibility complex 
MHC-I : MHC class I molecule 
MHC-II : MHC class II molcule 
MVA : modified vaccinia Ankara virus 
MyD88 : myeloid differentiation primary 
response 88 protein 
nAbs : neutralizing antibodies 
Ova : ovalbumin 
PAMPs : pathogen-associated molecular 
patterns 
PRRs : pattern recognition receptors 
RIG-I  : retinoic acid inducible gene I 
RLRs : RIG-I-like receptors 
SDS-PAGE : sodium dodecyl sulfate 
polyacrylamide gel electrophoresis 
TCM : central memory T cells 
TEM : effector memory T cells 
Th : helper T cell 
TLR : toll-like receptor 
VA-RNA : virus-associated RNA 
VLP : virus-like particles 
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1 Immune System and Vaccination 
1.1 Introduction to the Immune System  
Historically, the Immune System was defined as a totality of cells and molecules conferring 
protection against infectious diseases. However, the fact that immune responses can also be elicited 
by non-infectious foreign substances as well as description of various autoimmune pathologies shed 
a new light on the complexity of this system.  A more inclusive definition was proposed, describing 
the Immune System as a complex set of protective mechanisms distinguishing Self from Non-self and 
allowing for protection against pathological microbes and toxic or allergenic proteins, defined from 
now on as antigens (Chaplin, 2010). Once a non-self element is present in the organism, two layers of 
defense are set in action: innate immunity and adaptive immunity. In the first turn innate immunity is 
activated, conferring immediate but non-specific protection. The main goal of this germ line-encoded 
layer of defense is to limit the infection during the first days, before adaptive response is established. 
This chapter will describe in a general manner the main elements and mechanisms of both innate 
and adaptive immune responses. The immune responses induced by adenovirus will be described in 
chapter 2. 
1.1.1  Innate immunity  
This evolutionary older defense is implicated in the first events after the antigen encounter. 
Innate immunity mechanisms are poorly specific and do not generate immunological memory, 
although the development of memory Natural Killer cells has recently been reported (reviewed in 
O’Sullivan et al., 2015). Deficiencies in this branch of immunity are associated with recurrent 
infections, which underlines its importance (Janeway, 2002). 
1.1.1.1 Molecular components of innate immunity  
Among the main components of this robust antimicrobial protection we can distinguish 
physical barriers, such as tight cell-cell interactions, mucosal protection found in respiratory and 
gastrointestinal tracts as well as various soluble proteins (complement factors, cytokines, 
chemokines and defensins). Most importantly, specific types of receptors, called pattern recognition 
receptors (PRRs) are found on the membranes and in the cytosol of various cells. Among them, Toll-
like receptors (TLRs), RIG-I-like receptors (RLRs), Nucleotide-binding and oligomerization domain 
 
 
(NOD)-like receptors (NLRs), and C
different microbes, known as pathogen
2010).  
1.1.1.1.1 Toll
Among the PRRs of particular interest are 
families of PRRs in mammals. Ten human and 
sensing different ligands (Table 1
 
Table 1.1. TLRs and their ligands
indicating their localization, ligand and ligand origin (Takeuchi 
 
Located on the cell surface or in the endo
membrane glycoproteins contain
homology (TIR) domain (Bowie and O’Neill, 2000)
(homodimerization) or two different (heterodimerization, e
proteins is required to activate downstream signaling 
pathways, depending on the type of 
response gene 88 (MyD88), TIR domain
TRIF-related adaptor molecule (TRAM), and Sterile
(SARM) also contain TIR domains, through which they are recruited to TLRs
Yamamoto et al., 2002). The signaling pathways triggered by MyD88 and TRIF are different 
lead to the production of pro-inflammatory cytokines and 
-type lectin receptors are capable of sensing structures 
-associated molecular patterns (PAMPs) (
-like receptors (TLRs) 
TLRs, one of the major interferon
twelve murine TLRs have been identified until now, 
.1). 
. Table summarizes the Toll-like receptors described until today, 
and Akira, 2010). 
lysosomal membranes, TLRs are
ing N-terminal leucine-rich repeats and cytoplasmic 
. After ligand binding, dimerization of two identical 
.g. TLR2:TLR6) TIR domains of 
cascades. These can pass through 
recruited adaptor molecules. Myeloid differentiation primary 
-containing adaptor inducing IFN-β
-alpha and Armadillo motif
 (Oshiumi et al., 2003; 
type I IFNs (Figure 1.1)
15 
shared by 
Takeuchi and Akira, 
 (IFN)-inducing 
 
 type-I integral 
Toll/IL-1R 
TLR 
distinct 
 (TRIF), TIRAP/MAL, 
-containing protein 
but both 
.  
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Figure 1.1. Overview of TLR signaling pathways. TLR3, TLR4 and TLR9 signaling pathways are 
depicted as examples. Activated cell-surface TLR4 or endosomal TLR9 recruit adaptor protein MyD88, 
and with the participation of MAL and IRAK1/4 form structure called Myddosome. Active IRAK kinase 
activates TRAF6, ultimately leading to NF-κB, IRF5, AP-1 and CREB translocation to the nucleus and 
pro-inflammatory cytokine production. Alternatively, TLR3 activation, through recruitment of TRIF, 
induces TRAF3/6 signaling cascade. This results in activation of IRF7 and IRF3, their migration to the 
nucleus and production of type I IFNs or induction of cytokine production through RIP1/ NF-κB 
pathway. TLR4, by recruiting TRAM, can also follow TRIF signaling pathway (de Nardo, 2015).   
 
Signaling through MyD88 occurs upon stimulation of all TLRs with the exception of TLR3, 
and in the case of TLR2 and TLR4 TIRAP/MAL is additionally needed for MyD88 bridging (Fitzgerald et 
al., 2001; Horng et al., 2001 and 2002). In addition to TIR domain, in the structure of this adaptor 
protein we can also distinguish a death domain (DD) that interacts with DD of IL-1R-associated kinase 
4 (IRAK-4) and IRAK-1, leading to the formation of a supramolecular organization center (SMOC) 
called myddosome (Kagan, 2014). IRAKs subsequently dissociates from SMOC and interacts with 
TNRF-associated factor 6 (TRAF6), displaying an E3 ubiquitin protein ligase activity (Li et al., 2002). 
TRAF6, along with ubiquitination E2 enzyme complex consisting of Ubc13 and Uev1A, catalyzes the 
17 
 
 
formation of a lysine 63-linked polyubiquitin chain on TRAF6 itself as well as on IKK-γ / NF-κB 
essential modulator (NEMO) (Deng et al., 2000). TGF-β-activated kinase 1 (TAK1) and the TAK1 
binding proteins TAB1, TAB2, and TAB3 are then recruited to TRAF6, allowing TAK1 to phosphorylate 
IKK-γ and MAP kinase kinase 6 (MKK6) (Wang et al., 2001). Subsequently, IKK complex (NEMO, IKKγ, 
IKKα and IKKβ) phosphorylates Ikβ, withdrawing its inhibitory effect on NF-κB, resulting in its 
translocation to the nucleus and activation of pro-inflammatory cytokine genes. MAP kinase 
cascades, on the other hand, activate AP-1 and CREB transcription factors, also targeting cytokine 
genes involved in inflammation (Takeuschi and Akira, 2010). In parallel, IRF-5, another transcription 
protein crucial for pro-inflammatory cytokine production, moves to the nucleus (Takaoka et al., 
2005).  
In the group of TLRs recruiting TRIF as an adaptor molecule we find TLR3 and TLR4, whose 
interaction with TRIF is mediated by TRAM (Fitzgerald et al., 2003b, Yamamoto et al., 2003). 
Stimulation of these PRRs induces the production of type I IFNs through TRAF 
family-member-associated NF-κB activator (TANK)-binding kinase 1 (TBK1), phosphorylating IRF-3 
and IRF-7 and allowing its binding to Interferon-sensitive response element (ISRE) (Fitzgerald et al., 
2003a). On the other hand, through RIP1 signaling, TLRs involving TRIF are also inducing NF-κB 
activation (Meylan et al., 2004). A distinct pathway is found in plasmacytoid dendritic cells (DCs) 
following TLR9 stimulation. It involves MyD88 and IRAK-1 proteins, and in a TBK1-independent 
manner results in significant IFN-α production (Uematsu et al., 2005) 
1.1.1.1.2 RIG-I-like receptors (RLRs) 
Another important group of PRRs are RLRs, which are the main element of the host 
machinery responsible for sensing foreign RNA. RLRs family comprises retinoic acid inducible gene I 
(RIG-I), melanoma differentiation associated gene 5 (MDA5) and laboratory of genetics and 
physiology 2 (LGP2), proteins present in the cytosol of different cell types (Yoneyama et al., 2004). 
They sense distinct viral RNAs and through the interaction with their adaptor protein, mitochondrial 
antiviral signaling (MAVS) protein, also known as IPS-1, trigger the production of type-I interferons 
(IFN-I) and type-III interferons (IFN-III).  
In the structure of RIG-I, MDA5 and LGP2 we can distinguish DExD/H-box RNA helicase 
domain, responsible for sensing viral RNA and a C-terminal domain (CTD) (Figure 1.2). Additionally, 
RIG-I and MAD5 possess in their N-terminus a tandem of caspase recruitment domains (2CARD), 
through which they can interact with MAVS.  Since LGP2 does not possess CARD domain but still 
binds RNA with high affinity, this protein was initially described as RIG-I and MDA5 regulator 
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(Yoneyama et al., 2005). Nevertheless, a recent study reports that it may cooperate with MDA5 
during viral RNA recognition (Deddouche et al., 2014). MAVS protein displays a CARD domain in 
N-terminus, a central region consisting of two TRAF binding motifs (TBM) TBM1 and TBM2, with 
additional TBM3 next to the transmembrane domain at the C-terminus. Transmembrane domain 
anchors MAVS in the membranes of mitochondrium, peroxisomes and ER subdomain called 
mitochondrion-associated membrane (MAM) (Dixit et al., 2010; Horner et al., 2011; Seth et al., 
2005). 
 
 
 
Figure 1.2. Structures of RLRs and MAVS. All three RLRs contain helicase domains 1 (Hel1) and 
2 (Hel2), Helicase insertion domain (Hel2i), bridging/pincer domain and C-terminal domain (CTD). 
Additionally, RIG-I and MDA5 have a tandem of CARD domains (2CARD). In the structure of MAVS 
protein we distinguish three TRAF binding motifs (TBM), a CARD domain in N-terminus and a C-
termina transmembrane domain (TM) (Yoneyama et al., 2015). 
 
RIG-I senses a short double-stranded RNA which contains 5’-triphosphate (5’ppp). This RNA 
structure should also possess complementary end and/or a poly-U/UC rich double strand fragment 
(Weber et al., 2013). More recent paper reports that RIG-I can also recognize viral RNA bearing 
5’-diphosphate (5’pp) moiety (Goubau et al., 2014). MDA5, on the other hand, recognizes long dsRNA 
(>1kbp). In an inactive state both RIG-I and MDA5 are phosphorylated, the former at 2CARD and CTD 
and the latter exclusively at 2CARD (Sun et al., 2011). In virus-infected cells a series of events takes 
place in order to switch RIG-I and MDA5 from inhibited to activated state (Figure 1.3). Upon PAMP 
binding, RIG-I undergoes conformational changes which release 2CARD from auto-repression and 
allow them to interact with MAVS (Kowalinski et al., 2011). Both RIG-I and MDA5 are 
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dephosphorylated by phosphatase 1 (PP1) (Wies et al., 2013) and subsequently undergo full 
activation upon K-63 ubiquitination on their CTD and 2CARD domains (Peisley et al., 2014). 
 
 
 
Figure 1.3. Overview or RLRs signalization pathways. In a resting state RIG-I and MDA5 are 
phosphorylated and inactive. Upon recognition of specific non-self RNA structures, PP-1 phosphatase 
dephosphorylates both proteins, which are then Lys63 ubiquitinated. Active RLR proteins form 
filamentous structures on the foreign RNA, presumably in cytosolic aggreagates resembling stress 
granules (SG). This oligomerization generates formation of 2CARD tetramers, able to interact with 
aggregates of MAVS protein, an adaptor protein anchored in mitochondrion membrane. 
Subsequently, through TRAF and IKK signaling production of IFN type I and III is set in motion 
(Yoneyama et al., 2015). 
 
Recent reports demonstrate that viral infection induces in the cytoplasm formation of 
so-called stress granule (SG)-like aggregates (Onomoto et al., 2012), and inhibition of formation of 
these structures interferes with the IFN-I production in infected cells. SG are thought to serve as 
a platform, where RLRs recognize their PAMPs. Activated RIG-I and MDA5 are able to form 
filamentous structures on the viral RNA, which results in the creation of tetrameric CARD structures, 
interacting with prion-like MAVS aggreagates, anchored in the mitochondrial membranes (Hou et al., 
2011). Recent studies propose a model, where mutlimolecular aggregates of RIG-I/MAVS or 
MDA5/MAVS are formed, through which signaling takes place.  
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RLR interaction with MAVS passes through TRAF3 and TRAF6 and activates kinases of IKK 
family. Through their phosphorylation activity, these kinases remove NF-κB inhibition and in parallel 
activate IRF3 and IRF7. Then, the transcription factors translocate to the nucleus and induce the 
expression of genes encoding IFNs and pro-inflammatory cytokines. 
1.1.1.1.3 NOD-like receptors 
NOD-like receptors are another family of PPRs, recognizing various PAMPs and DAMPs. In 
the structure of all proteins we can distinguish central NACHT domain (NAIP, CIITA, HET-E, and TP-2), 
implicated in dNTPase activity and oligomerization. Located at C-terminus, LRR domains are involved 
in sensing activators. NLR proteins depending on their N-terminal domain can be divided into four 
subfamilies (Figure 1.4). NLRA subfamily possess acid transactivation domain and includes only one 
member, CIITA performing a role of   MHC-II transactivator. NLRB subfamily has the baculoviral 
inhibitory repeat-like (BIR) domain in its N-terminus and is represented by only one protein, NAIP. 
NLRC subgroup displays the caspase recruitment and activation domain and comprises six different 
members: NOD1, NOD2, NLRC3, NLRC4, NLRC5 and NLRX1. Finally, NLRP subfamily includes fourteen 
proteins named NLRP1 -14. 
 
 
Figure 1.4. Protein structure of NLR receptor family. Depending on the N-terminus domain 
type, NLR proteins can be divided into four subfamilies. NLRA, NLRB, NLRC and NLRP subfamilies 
possess, respectively, AD domain, BIR domain, CARD domain and PYD domain. All proteins exhibit in 
their central part NATCH domain (NAIP, CIITA, HET-E, and TP-2) (Kim et al., 2016). 
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NLRs members are implicated in various cell mechanisms (Figure 1.5). NLRs can interfere 
with signal transduction, influencing NF-κB activity. NLRP/4 are negatively regulating NF-κB activation 
by inhibiting TRAF6 (Fontalba et al., 2007). NOD1 sense Gram-negative molecules containing 
D-glutamyl-meso-diaminopimelic acid (iE-DAP) moiety (Girardin et al., 2003a) and NOD2 recognize 
muramyl dipeptide (MDP) from both Gram-negative and Gram-positive bacteria (Girardin et al., 
2003b). Both activate NF-κB by interacting with receptor interacting protein 2 (Rip2). NOD2 is also 
implicated in autophagy induction by recruiting ATG16L1 proteins to the site of pathogen entry 
(Travassos et al., 2010). NLRC5 and CIITA in response to IFN-γ increase the production of MHC-I and 
MC-II molecules, respectively, enhancing induction of adaptive immunity (Chang et al., 1996; Staehli 
et al., 2012).  
 
 
 
Figure 1.5. Overview of NLR functions.  NLR activities can be divided in four main categories: 
signaling, inflammasome formation, autophagy, and transcriptional activation. NOD1 and NOD2 are 
positive regulators of NF-κB signaling, while NLRP2/4 blocks NF-κB activation. NOD2 is also involved 
in autophagy process by localizing ATG16L1 at the pathogen entry site. NLRC5 and CIITA are 
implicated in the transcription of MHC-I and MHC-II molecules, respectively and influence induced 
adaptive immunity. NLRP1, NLRP3 and NLRP4 induce inflammasome assembly, resulting in 
production of active form of IL-1β and IL-18 (Motta et al., 2015). 
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Another important role played by NLRs is the formation of inflammasomes, multimeric 
protein complexes activating caspase-1 (Davis et al., 2011). Active caspase-1 is crucial for processing 
and maturation of IL-1β and IL-18 pro-inflammatory cytokines. Inflammasomes are formed with the 
help of NLRs members which serve as a support for interaction with pro-caspase-1. Among the four 
identified inflammasomes types three are regulated by NLR proteins, NLRP1, NLRP3 and NLRC4, with 
the remaining one regulated by absent in melanoma (AIM-2) protein, a cytosolic sensor of foreign 
dsDNA. NLRP1 recognizes MDP and anthrax lethal factor. NLRP3, one of the best characterized 
members of NLRs senses different PAMPs derived from viruses (e.g. RNA), bacteria, fungi and 
protozoa (Allen et al., 2009). It also detects endogenous components like ATP, hyaluronan, 
monosodium urate crystals, and β-amyloid. NLRC4 detects flagellin and bacteria like P. aeruginosa or 
Shigella flexneri. Inflammasome formation is initiated by NLRs detecting its PAMP or other activators, 
which induces oligomerization of NLR proteins. Bridging of the adaptor protein ASC allows to bind 
pro-caspase-1 and fully activate inflammasome. Recent studies report the formation of 
inflammasomes based on NLRP6, NLRP7, and NLR12, which could lead to inflammatory disease and 
tumorigenesis (Rubino et al., 2012). 
1.1.1.2 Effector mechanisms of innate immunity 
The inflammation process, triggered mostly by macrophages, leucocytes, mast cells and, 
less frequently, by endothelial non-professional immune cells is one of the main elements of innate 
defense. The innate immune system contributes to the development of inflammation through 
sensing of PAMPs or DAMPs (danger-associated molecular patterns) upon, respectively, microbial 
infection or tissue damage (Akira et al., 2006). Depending on the type of activated PRRs, different 
genes are upregulated, encoding pro-inflammatory cytokines (IL-1, IL-6 and tumor necrosis factor 
(TNF)), IFN-I, chemokines or antimicrobial proteins.  This leads to increase in vascular endothelial 
permeability, recruitment of blood cells to the inflamed tissues and production of acute phase 
proteins, all aiming at pathogen or tissue damage elimination (Medzhitov, 2008). Some of the 
recruited blood cells, such as neutrophils or macrophages, are able to engulf encountered microbes 
and kill them in phagolysosomes.  
Innate immunity is also implicated in the activation of acquired immunity. Microbe sensing 
by PRRs expressed by antigen presenting cells (APCs), such as DCs, leads to the activation of adaptive 
immune responses through upregulation of costimulatory molecules (CD80 and CD86) and 
stimulation of pro-inflammatory cytokine production. Stimulation of particular PRRs allows APC to 
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determine the antigen origin and the type of encountered infection, and results in skewing the 
lymphocyte developement into the appropriate effector subpopulation (Akira et al., 2006; Iwasaki 
and Medzhitow, 2015).  
1.1.2  Antigen presentation  
The initial recognition of a pathogen by previously described innate immunity elements is 
a crucial but not always sufficient event in eliminating the threat and re-establishing homeostasis.  
Pivotal role in linking innate immune response with an adaptive one is played by APCs, able to display 
a fragment of detected antigen, called epitope, to T lymphocytes.  Professional APCs include 
macrophages, B cells, some activated epithelial cells and most importantly DCs, playing critical role in 
naïve T cell activation, called priming. Antigen presentation can occur in two distinct pathways, 
described briefly as class-I and class-II presentation, depending on the epitope source and the type of 
involved major histocompatibility complex (MHC) molecule. Additionally, another process of antigen 
presentation was discovered, described as cross-presentation. For more detailed description of the 
processes presented below, see Rock et al., 2004; Blum et al., 2013 and Vyas et al., 2008. 
1.1.2.1 Major Histocompatibility Complex 
The major histocompatibility complex (MHC) is a set of genes, encoding molecules originally 
identified as a major factors in graft rejection. Its role has later been broaden, as it has been 
discovered to be strongly involved in the process of mounting an adaptive immunity. More precisely, 
MHC molecules play a crucial role in presenting epitopes to T cells, which in contrast to B cells are 
unable to recognize native antigens.   
In humans, MHC, described also as Human Leukocyte Antigen (HLA) system, is encoded on 
the chromosome 6 and comprises more than 200 genes.  Among them the most important are those 
encoding HLA molecules of class I and II, involved in antigen presentation, a process described in 
details in the next paragraph. The region encoding HLA system is considered to be the most 
polymorphic in our genome. Indeed, alternative forms and variants of HLA molecules have been 
identified at stable frequencies in the population, and certain loci display as many as 250 allelles. This 
polymorphism in parallel with co-dominant expression of all single gene variants encoded in 
a genome ensures the ability to present a wide array of epitopes, providing protection from quickly 
mutating pathogens. 
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1.1.2.1.1 Class I MHC molecule  
MHC class I molecules (MHC-I) are crucial in the activation of CD8
+ 
T cells. By binding class-I 
epitopes in their groove and subsequently interacting with TCR, they activate the specific CD8
+
 
T lymphocytes. MHC-I are expressed by many somatic cells, however their expression level differs 
between tissues. MHC-I molecule consists of two non-covalently linked polypeptide chains, α chain 
and a β2-microglobulin subunit (β2m) encoded outside the HLA locus. C-terminus of α chain resides 
inside the cytoplasm and, after crossing the cell membrane, α chain displays three-quarters of its 
length on the cell surface (Figure 1.6). The extracellular N-terminal fragment is organized in three 
domains, α1, α2 and α3. MHC-I molecule variability is located in α1 and α2, which form a platform 
for peptide binding. This peptide binding groove, closed at both ends, accommodates peptides of 
8-10aa in length. The conserved α3 domain is responsible for binding CD8 molecule on T lymphocyte 
and for non-covalent interaction with β2-microglobulin. The tethering of α3 to β2-microglobulin is 
stabilized by peptide anchoring to α1 and α2 and vice-versa, and so MHC-I reaches its full stability in 
the presence of all these three components. 
 
 
 
Figure 1.6. Structure of HLA Class I and Class II molecules. In the structure of MHC class I 
molecule we distinguish α-chain with two peptide-binding domains (α1 and α2) as well as α3 domain, 
transmembrane domain (TM) and cytoplasmic tail. The beta2-microblobulin (β2m) constitutes the 
second chain. MHC class II molecule is formed from two chains, α and β, both composed of two 
extracellular segments, transmembrane (TM) and cytoplasmic tail. Domains α1 and β1 are forming 
peptide binding groove (Kein, 2000). 
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There are around 20 class-I genes in the HLA region. Three genes encoding α chain, HLA-A, 
HLA-B and HLA-C were described as classical and are the most important due to their role in the 
adaptive response. They are present in two different copies in heterozygous individual and their 
codominant expression result in the presence of six different MHC-I molecules on the surface of one 
cell. In murine genome, HLA-A, HLA-B and HLA-C have their corresponding genes named H-2K, H-2D 
and H-2L. 
1.1.2.1.2 Class II MHC molecule 
MHC class II molecules (MHC-II) bind class-II epitopes and present them to CD4
+ 
T cell. Their 
expression is limited to cells of the immune system, including DCs, B cells, activated T cells, 
macrophages and thymic epithelial cells. 
In MHC-II structure two chains can be distinguished, α and β, both crossing the membrane 
with C-terminus inside the cell and with N-terminal end outside the cell surface (Figure 1.6). Both 
chains in their extracellular part are forming two domains. α2 and β2 domains are conserved, with β2 
involved in interaction with CD4 molecule on T cell. In contrast, α1 and β1 domains are highly 
polymorphic and together form the peptide-binding groove. While peptide binding groove of MHC-I 
molecules is closed at both ends, the one of class-II is open and able to accommodate longer 
fragments, up to 30aa in length.  
In humans, each parent provides its progeny with one allele of genes encoding α chain 
(DPα1, DQα1 and DRα1) and of genes encoding β chain (DPβ1, DQβ1 and DRβ1) as well as duplicated 
DRB gene that can encode additional alleles (DRB3, DRB4 and DBR5). Thus each heterozygote inherits 
six or eight types of MHC-II. In mice, MHC-II molecules are called H-2A (I-A) and H-2E (I-E). 
1.1.2.2 Class-I antigen presentation 
In the frame of the class-I presentation, epitopes coming from intracellular proteins are 
presented on the cell surface (Figure 1.7). They can be of intracellular bacteria, virus or tumor origin, 
but may also emerge from degradation of the host intracellular proteins as part of the process of 
protein turnover. Short peptides, around 4-15aa are generated as the ubiquinated proteins undergo 
proteasome cleavage in the cytosol. Less than 1% of these peptides is then transported into the 
endoplasmic reticulum (ER) lumen through Transporter associated with Antigen Processing (TAP), 
where it is loaded onto nascent MHC-I molecules. This step is coordinated by the so-called Peptide 
Loading Complex, consisting of tapasin and two housekeeping proteins found in ER, calreticulin and 
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ERp57. Upon peptide loading onto the MHC-I, its extremities can be additionally trimmed by 
amino-peptidases in order to fit within the binding groove. These events trigger its detachment from 
TAP and enables complex migration from ER through Golgi apparatus to the cell surface, where it can 
be recognized by specific CD8
+ 
T cell.  
 
 
 
Figure 1.7. Loading and trafficking of MHC class I molecules to the cell surface. 
Presentation of the antigen on the MHC-I molecule occurs in six major steps. 1) Antigens are 
generated, e.g. as a result of translation error. 2) Ubiquitination process marks proteins for 
degradation. 3) Ubiquitinated proteins are cleaved in proteasome. 4) Longer fragments are 
additionally cleaved by peptidases and generated peptides are transported to the ER 
endoplasmic reticulum (ER) lumen by the transported associated with antigen processing (TAP) 
complex. 5) Peptide is loaded on the nascent MHC-I molecule with the help of tapasin, ERp57 
and Calreticulin. 6) MHC-I with loaded peptide through Golgi complex are transported to the cell 
surface (Vyas et al., 2008). 
 
1.1.2.3 Class-II antigen presentation 
MHC-II antigen presentation pathway focuses on scanning extracellular space and allows for 
presentation of peptides coming from e.g., extracellular parasites, dead cells or tumor cells. Antigen 
is uptaken by APCs and directed into the vesicular pathway consisting of progressively more acidic 
and proteolytically-active compartments: early endosomes, late endosomes and lysosomes. 
Internalized proteins are enzymatically degraded and digested into a set of peptides (Figure 1.8). 
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MHC-II molecules are synthesized in the ER, and trafficked with their binding site blocked by 
invariant chain (Ii) to the endosomes, where they co-localize with digested extracellular proteins. 
Fusion of lysosome and MHC-II-containing vesicle results in degradation of Ii, release of residual 
amino acid chain called class II-associated invariant-chain peptide (CLIP) and peptide loading into the 
molecule cleft. The final length of trimmed peptide varies between 10 and 30aa.  The proposed 
mechanism of MHC-II:peptide complex transport to the cell surface is thought to involve the 
transformation of compartments containing MHC-II into tubular structures, reaching  site of 
CD4
+
 T cell interaction at the APC cell surface, where it can be found in clusters with tetraspanin-rich 
microdomains or lipid rafts (Hiltbold et al., 2003). 
 
 
Figure 1.8. Loading and trafficking of MHC class II molecules to the cell surface. Upon 
pathogen engulfment, TLR becomes activated, dictating the nature of phagosome maturation. 
Phagosomes fuse with lysosomes which contain MHC-II. Proteases found in lysosomes cleave 
pathogen proteins, and generated peptides are then loaded into the MHC-II groove. 
Autophagosomes containing e.g. damaged organelle can also fuse with lysosomes to provide them 
with endogenous peptides for MHC class II presentation. MHC-II molecules with loaded peptide, 
along with other lysosomal proteins, such as tetraspanins, are transported to the cell surface through 
the endolysosomal tubules (Vyas et al., 2008). 
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1.1.2.4 Cross-presentation 
MHC-I presentation serves as the reporter of intracellular environment, while MHC-II 
senses antigens present in the extracellular milieu. However, APCs are also able to present on MHC-I 
molecules peptides derived from exogenously acquired antigens. This process, called cross-
presentation, was first described almost 40 years ago (Bevan, 1976). Important and dangerous 
events, such as viral infection or malignant transformation, occurring in non-professional immune 
cells need to be surveyed and detected by adaptive responses. Cross-presentation process ensures 
stimulation of CD8
+
 T cells responding to pathogens which do not directly infect DCs. Although 
different non-professional immune cells, such as epithelial cells (Bagai et al., 2005) were shown to be 
able to perform this process, the most potent cross-presenting cells in vivo are DCs (Jung et al., 
2002).  
The exact mechanism of how exogenous antigens can enter the MHC-I maturation and 
peptide-loading pathway remains an intensively investigated subject. Many possible pathways of 
cross-presentation have been proposed (Figure 1.9). One of them, called “cytosolic”, suggests 
antigen processing in the endocytic vesicles and/or in the cytosol upon leaving the vesicular pathway, 
allowing generated peptides to gain access to the MHC-I in the ER. Alternatively, TAP and MHC-I 
loading complex would be recruited to phagosomes or endosomes and peptide loading could take 
place directly in these endocytic compartments (Guermonprez et al., 2003, Houde et al., 2003). This 
is ensured by interaction of ER–Golgi intermediate compartment (ERGIC) associated protein, SEC22B 
with Syntaxin4 found on phagosomes. In a “vacuolar” scenario, on the other hand, both antigen 
processing and loading on MHC-I molecule occur in endocytic compartments. Nevertheless, the exact 
molecular regulations of cross-presentation remains to be fully elucidated. 
 
 
29 
 
 
 
 
Figure 1.9. Intracellular pathways for cross-presentation in dendritic cells. In the 
cytosolic model phagocytosed, exogenous antigens can be released into the cytosol, making them 
available for the proteasome degradation. Subsequently generated peptides may enter classical 
MHC-I antigen presentation pathway and be loaded on MHC-I molecules in the endoplasmic 
reticulum (ER). Alternatively, peptides can re-enter the phagosome in order to be loaded on MHC-I 
molecules. Protein called SNARE SEC22B, found in the ER–Golgi intermediate compartment (ERGIC) 
through its interaction with syntaxin 4 present on phagosomes, coordinates bridging the ER 
subcomponents containing transporter associated with antigen processing (TAP) to the phagosome. 
In the vacuolar pathway antigen does not enter the cytosol, instead it is degraded in the phagosome 
where it is then loaded on MHC-I molecule (Joffre, 2012). 
 
1.1.3 Adaptive immunity 
The adaptive response corresponds to a sophisticated and highly specific set of biological 
mechanisms, involving humoral and cellular responses. The mechanisms of adaptive immunity, in 
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contrast to innate immune responses, are highly specialized and able to provide immunological 
memory. 
1.1.3.1 Cellular responses  
The cellular responses assure protections against pathogens residing and replicating within 
phagocytic or non-phagocytic cells. The most important cells are T lymphocytes. 
1.1.3.1.1 Development and activation of T lymphocytes 
T cells originate from bone marrow but mature fully in the thymus. This primary lymphoid 
organ is a place where αβ T cells undergo positive selection, allowing for survival of MHC-binding 
lymphocytes. Subsequently, cells that avidly recognize self-structures are eliminated in the course of 
negative selection to prevent auto-immunity. After these checkpoints, lineage commitment takes 
place, directing the maturating T cells in two major subsets, CD4
+
 and CD8
+
. The less frequent 
subpopulation of γδ T cells which derives from the same bone marrow precursor but matures in 
thymus as a separate lineage will not be discussed here.  
Naïve T cells migrate to the secondary lymphoid organs, where upon encountering mature, 
epitope-presenting APCs they become activated. A few crucial elements are needed in order to fully 
activate T lymphocytes and induce their clonal expansion (Figure 1.10). The first one depends on 
T cell receptor (TCR) binding to a peptide-MHC molecule complex (MHC-I for CD8
+ 
T cells and MHC-II 
for CD4
+ 
T cells). A second signal comes from co-stimulatory signaling, assured e.g. by interaction of 
T cell CD28 receptor with B7-1 (CD80) and B7-2 (CD86), whose expression on DCs up-regulated upon 
response to PAMPs. This interaction between T cell and DC is localized to a specific zone called the 
immunological synapse, created by the surfaces of both cells and clustering all molecules involved in 
T cell activation (Huppa and Davis, 2003). The cytokines produced by DCs are the third important 
signal, providing stimulation for differentiation of epitope-specific clones. This results in rapid 
amplification of cells which will either become effectors, eliminated after antigen eradication, or will 
persist in the organism as a long lasting memory cells.  
Worthy of note, the pivotal role of co-stimulatory molecules in cellular response induction 
and the influence of PRR signaling on the level of their expression highlights the need for a suitable 
adjuvant addition during vaccine development. 
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Figure 1.10. T cell activation signals. The first signal is the presentation of the peptide loaded 
on the MHC molecule and its recognition by the antigen-specific T cell receptor (TCR). The second 
signal is provided by interaction of co-stimulatory molecules present on the surface of APCs and 
T cells, e.g; such as CD28 and CD80/86. The last signal is provided by APC through the secretion of 
specific cytokines (Gutcher et al., 2007). 
1.1.3.1.2 Effector functions of T-lymphocytes 
• Cytotoxic CD8+ lymphocytes (CTL) 
This subset is especially important in fighting intracellular pathogens and eliminating tumor 
cells. CTL are recognizing TCR-specific class-I epitopes, displayed on the surface of the target cells on 
MHC-I molecules. This leads to the production of effector cytokines by CTLs, among which the most 
important is IFN-γ, playing a pivotal role in fighting intracellular microbes. Recognition of specific 
peptide-MHC-I complex results in the formation of a junction between the CTL and target cell. 
Through this membrane fusion cytotoxic molecules stored in CTL cytoplasmic granules, such as 
perforin and granzymes, are transported into target cells and trigger an apoptotic process. Apoptosis 
can be also induced by binding of FasL, expressed on the activated CTL to the Fas death receptor, 
expressed by many cells. After delivering the “lethal hit” the CTL is able to detach from the dying cell 
and act on another target expressing the same peptide-MHC-I complex. 
 
• Helper CD4+ T-lymphocytes 
Helper T lymphocytes (Th) are important cells performing auxiliary functions and reinforcing 
performance of both humoral and cellular immunity. The type of stimuli presented in the early stages 
of immune response defines the subset in which CD4
+ 
T lymphocytes will differentiate: Th1, Th2, Th17, 
TFH or Treg (Figure 1.11). The distinction between these subsets is made based on their capabilities to 
produce cytokines (Magombedze et al., 2013). 
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Th1 cells are involved in fighting the microbes residing inside the phagosomes of the 
phagocytes.  Since many types of pathogens developed mechanisms allowing them to persist and 
replicate inside these vesicles, innate immunity is not always sufficient to destroy them. Th1 cells, 
through their hallmark cytokines IFN-γ and TNF-α, are able to activate the phagocytes and enhance 
microbe killing through stimulation of the synthesis of reactive oxygen intermediates and nitric oxide. 
They induce Ab switching into IgG2a and IgG2b class of antibodies (described below), involved in the 
phagocytosis and complement activation. Additionally, when the antigen does not stimulate potent 
innate immune responses (low level of co-stimulatory molecule expression), Th1 cells might 
participate in CTL activation by providing the “second signal” through cytokine secretion or 
CD40-CD40L interaction with APC. This is particularly important in mounting immune response 
towards tumor cells or cells displaying viral antigens. In order to skew T cell differentiation into Th1 
subset, APCs or other surrounding cells need to produce IFN-γ and IL-12 cytokines (Figure 1.11).  
Helminthic parasites are eliminated with the assistance of Th2 cells. This subpopulation 
develops upon production of IL-4 by APCs, and in turn produces IL-4, IL-5 and IL-13. This branch of 
protection is developed when the antigens causes persistent T cell stimulation but does not induce 
strong inflammation or macrophage activation. Th2 cells promote eosinophil/mast-cell mediated 
immune reactions and stimulate B cell switching to the production of IgG1 and IgE antibodies, able to 
opsonize the helminths. Th2 axis also participates in immune responses to allergens. 
Naïve CD4
+
 T cells differentiate into IL-17 and IL-22 producing Th17 subset in the presence 
of IL-6 and transforming growth factor (TGF)-β. The main function of Th17 T cells to fight extracellular 
bacteria and fungi, mainly by neutrophil recruitment. Strong evidence also implicates Th17 lineage 
involvement in several autoimmune disorders. 
IL-6 and IL-21 favor the differentiation of follicular helper T cells (TFH). This T cell subset 
plays a pivotal role in humoral immunity by providing help in germinal center formation, 
differentiation of B cells into plasma and memory cells, and contributes to establishing long-lived 
memory humoral responses. 
Finally, under the influence of TGF-β and IL-2 regulatory T lymphocytes (Treg) can develop 
from naïve CD4
+ 
T cells (Magombedze et al., 2013). By producing anti-inflammatory cytokines (TGF-β 
and IL-10), they limit the magnitude of immune responses and contribute to immune homeostasis 
maintenance. 
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Figure 1.11. Pathways of CD4
+
 T lymphocyte lineage development.  Naïve CD4
+
 T cells, 
depending on the type of cytokines present in the environment, can differentiate into various 
subsets. Cell plasticity allows generated CD4
+ 
to
 
convert from one type into another (Magombedze et 
al., 2013). 
 
1.1.3.1.3 Memory T cells 
As soon as the threat is eradicated from the organism, the majority of effector cells 
undergo apoptosis in the so-called contraction phase. A small part of the responding cells, however, 
is able to persist and become long-lived memory cells (Figure 1.12) (Gasper et al., 2015). Thanks to 
the IL-7 and/or IL-15 cytokines, memory cells are homeostatically maintained, poised to respond 
rapidly to secondary infection (Schluns et al., 2003). The population of memory T cells is 
heterogenous, as it comprises CD4
+
 and CD8
+
 T cells on different stages of differentiation. Depending 
on their function and homing preferences they can be subdivided into T central memory cells (TCM) 
and T effector memory cells (TEM). In mice these two populations can be distinguished by different 
levels of CD62L and CD127 expression, with the CD127
+
 CD62L
+
 phenotype corresponding to TCM and 
TEM characterized by CD127
+
CD62L
-
. Additionally, TEM express CD44 on their surface which allows 
these cells to be retained in the extravascular sites where they are more prone to encounter an 
antigen. Another molecule allowing to distinguish between TCM and TEM is C-C chemokine receptor 
type 7 (CCR7). It is expressed at high levels on the surface of TCM, mediating their homing to the 
secondary lymphoid organs where they reside and function as a source of effector cells. They possess 
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intrinsic proliferative capacity that is activated upon antigen challenge but exhibit limited effector 
functions. TEM are lacking CCR7 molecule, and thus can be found in peripheral tissues, ready to 
produce cytokines such as IFN-γ upon antigen stimulation. Having low proliferation rate, they are 
considered to be responsible for a quick initial response, but the full eradication of secondary antigen 
exposure relies most probably on TCM. Thus, both populations provide important foundation for 
vaccine-induced immunity.  
More recently, another subset of memory T cells has been discovered, named 
tissue-resident memory T cells (TRM) (for a review see Schenkel and Masopus, 2016). This lineage is 
found in non-lymphoid tissues but not in peripheral blood and it is thought to derive from effector T 
cells that remained poised in the peripheral tissues. TRM are CD62L
-
 CD127
-
 and often display 
increased expression of CD103 and CD69, allowing for their retention in tissues. However, the 
phenotype of TRM differs depending on their location and thus the tissues of residence play an 
important role in shaping TRM signature, governing further changes in expression levels of surface 
molecules. The mechanisms of TRM establishment and maintenance are not clear and remain to be 
fully investigated, but most probably, they are tissue-dependent. 
 
 
 
Figure 1.12. Cytokine effect on T cell proliferation and memory cell generation.  
Different cytokines are crucial for T cell survival and development at different stages of the immune 
response. During T cell activation, interleukin-15 (IL-15) is important in order to activate dendritic-
cells (DCs). Upon priming, T cell clonal expansion is moderated by the presence of IL-2 and this 
process can be additionally enhanced by IL-15. In the late stage of clonal expansion, during the 
contraction phase, IL-2 can also induce T cell death. At this stage, however, IL-15 and IL-7 might 
prevent death of a part of T cell population which will generate memory population. Survival of those 
memory T cells is enabled by low level of their proliferation, ensured by IL-15. IL-7 is also implicated 
in sustaining the T cell memory by favoring its survival (Schluns et al., 2003). 
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1.1.3.2 Humoral responses  
The physiological functions of this branch of the adaptive response are mediated by 
antibodies (Abs). Humoral immunity is responsible mainly for eliminating extracellular microbes. 
Nevertheless, viruses before entering host cell or after being released from infected cell can also be 
neutralized along with produced virulent factors. 
1.1.3.2.1 Maturation and activation of B-lymphocytes 
B-lymphocytes originate from bone marrow and then populate peripheral lymphoid tissues. 
In a resting state, before encountering the antigen, they express on their surface immunoglobulin (Ig) 
IgM and IgD, performing the function of B cell receptors (BCRs). These molecules recognize specific 
portions of antigen, called B cell epitopes which vary significantly in length and can either be linear or 
conformational (Batista and Harwood, 2010). B cell stimulation by CD4
+
 T lymphocyte is required for 
mounting humoral response against antigens of protein origins, which are therefore described as 
T-dependent or thymus-dependent antigens. After engulfing this type of antigen, B cell functions as 
APC, displaying the peptides on its MHC-II to Th cell. On the contrary, multivalent antigens such as 
polysaccharides and lipids do not require T cell stimulation, as cross-linking of BCR is sufficient to 
activate B lymphocytes. Analogically, we describe these antigens as T-independent. Upon B cell 
activation plasma cells are generated, secreting huge amounts of Abs which correspond to BCRs 
deprived of membrane-anchoring domain.  
1.1.3.2.2 Properties and effector functions of antibodies 
Abs are proteins secreted by activated B cells, called plasma cells. In their Y-shaped structure 
we can distinguish Fc constant region, involved in various Ab-mediated immune responses and Fab 
region, extremely variable and responsible for antigen binding. Each immunoglobulin (Ig) is build up 
from two heavy chains and two light chains and all of them consisted of constant and variable part.  
The constant part of heavy chains are encoded in five different variants in the genome, and its type 
defines the Ig class, i.e. IgM, IgD, IgG, IgA and IgE. Naïve B cells express BCR in the form of IgM and 
IgD only. In case of T-dependent antigens, CD4
+
 T cells interact with B cells through CD40-CD40L axis 
and induce isotype class swiching. The type of heavy chain constant region determines the biological 
function of Ig and depends strictly on the type of cytokine secreted by helper T cells. IgM are 
secreted in primary response and are able to activate complement. During secondary responses the 
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most abundant Ab are IgG. They participate in phagocyte responses and are the only Ab which could 
cross placenta. IgG can be further divided in sub-classes, in mice named IgG1, IgG2a, IgG2b, IgG2c 
and IgG3 and in human described as IgG1, IgG2, IgG3 and IgG4 . IgA are associated with mucosal 
immunity while IgE participate in allergic reaction and immunity against helminths. In mice, in the 
context of Th1 stimulation, IgG2a and IgG3 Abs are mostly detected, while Th2 dictated switching to 
IgG1 and IgE, which complements effector functions of these responses. Antibody affinity maturation 
is also assured by helper T lymphocytes, more precisely by TFH subset. In this important process, 
B cells undergo somatic hypermutations in their Ig genes and subsequently enter clonal selection 
phase, where with the help of follicular dendritic cells and TFH cells B cell clones displaying the biggest 
affinity for the epitope will survive and expand. 
1.1.3.2.3 Memory B lymphocytes 
As a result of clonal expansion, some progeny of activated B cells acquire the ability to 
survive a long time. These memory B cells reside in lymphoid organs or recirculate between spleen 
and lymph nodes and are capable of mounting rapid and strong responses during subsequent antigen 
encounter. This process is CD4
+
 T cell dependent, as T-independent antigens do not induce immune 
memory. Owing to this memory B cell population, the secondary humoral response surpasses the 
primary one qualitatively and quantitatively.  
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1.2 Principle and purpose of vaccination  
 
Vaccination is considered to be the biggest success in the history of Public Health. During 
the last century it has resulted in increased control over many major infectious diseases, such as 
diphtheria, tetanus, yellow fever, pertussis, flu, measles, mumps, rubella, typhoid and rabies. Most 
remarkably, vaccine against smallpox led to the eradication of this virus, and in the case of 
poliomyelitis the disease occurrence dropped by 99% due to the discovery of two effective vaccines 
(Salk and Salk; 1984; Sabin, 1991).  
The principle concept of vaccination comprises induction of a protective immune memory 
and neutralizing Abs against the disease-causing agent without inducing the disease. This protection 
should result in fast and effective response during the actual pathogen challenge, preventing the 
infection or, in case of cancer vaccine, counteracting tumor growth. An ideal vaccine should be 
effective, safe, easy to produce and able to provide protection for a population with different, 
immunogenetically heterogeneous individuals. To meet this expectation various techniques of 
vaccines design were applied, roughly divided into a classic vaccines and new generation vaccines, 
described in this section. 
1.2.1 Classical vaccines 
 First attempts to induce protective immunity were based on administration of infected 
material to healthy individuals, a method known as “variolation”. This technique was used mostly in 
China, Middle East and Africa. The term “vaccination”, on the other hand, dates back to the end of 
XVIII century, when Edward Jenner observed that milkmaids exposed to cowpox were protected from 
smallpox disease (Plotkin, 2011). At that time little was known about the mechanisms of immune 
responses or the nature of infectious agents, limiting the progress in the area of vaccinology for more 
than a century after Jenner’s achievement. Brilliant works of researchers like Louis Pasteur or Robert 
Koch, who at the turn of the XIX and XX centuries started identifying the pathology-causing 
microorganisms, contributed significantly to further development in the area of vaccinology (Figure 
1.13)
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Figure 1.13. Timeline of the development of human vaccines.  *Capsular polysaccharide 
conjugated to carrier proteins. ‡Killed, recombinant B subunit, whole-cell vaccine. §Cholera toxin B 
combined with enterotoxigenic Escherichia coli. ||Now withdrawn (Plotkin, 2010). 
 39
1.2.1.1 Live attenuated vaccines  
The development of cell culture methods allowing for pathogen propagation ex vivo gave 
rise to a new strategy of vaccine formulation. Iterative rounds of microbe propagation in vitro 
rendered them non-pathogenic, presumably due to mutations accumulated in their genome. Live 
microorganisms upon administration provided long antigenic stimulation, giving sufficient time for 
establishment of strong adaptive responses. The excellent immunogenicity of this type of vaccination 
was burdened with their reduced safety, as administration of attenuated vaccines is poised by the 
risk of pathogen reversion to its virulent form.  
Live attenuated vaccines led to the formulation of e.g., yellow fever and tuberculosis 
vaccine in 1930s, measles, mumps, and rubella vaccines in 1960s (Hilleman, 1968) and during the 
following decade gave rise to the protection against zoster virus, japanese encephalitis virus and 
tick-borne encephalitis virus. Attenuated vaccines led to the biggest successes in the vaccination field 
i.e. the eradication of smallpox and significant reduction of poliomyelitis prevalence (Sabin vaccine).  
1.2.1.2 Inactivated vaccines  
This vaccination strategy developed in 1890s, when typhoid and cholera bacilli vaccines 
became available (Plotkin, 2014). Microorganisms were inactivated with physical methods, such as 
heat and UV or with the use of chemicals. It was crucial not to destroy protein structure and integrity 
in the process of inactivation, as this would led to a loss of antigenicity. Blocking microbe ability to 
efficiently infect host cell, replicate, produce their antigens etc., resulted in reduced immunogenicity 
vis-à-vis live attenuated vaccines. As a result, repeated administrations were required to trigger good 
protection level. Nonetheless, alterations in pathogen virulence assured better safety profile.  
Inactivation was applied for the development of vaccines against Bordetella pertussis, 
Influenza virus, Rickettsia, Poliovirus (Salk vaccine), Rabies virus or Hepatitis A virus.  
1.2.2 New approches of vaccination 
Conventional vaccination demonstrated its efficacy for many decades and deserves full 
acknowledgement for huge contribution to the Public Health. Nevertheless, a few drawbacks were 
associated with its usage, such as unnecessary antigenic load resulting potentially in reactogenic or 
allergenic responses. The development of various laboratory techniques along with the rise of 
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“Reverse vaccinology” concept allowed for high-throughput screening of potential vaccine 
candidates (Donati and Rappuoli, 2013). It became possible to dissect the pathogen and select and 
administer only the specific target of natural anti-pathogen immune responses. In order to assure an 
efficient protection against a given infectious agent, it was crucial to first identify the most relevant 
immunity components counteracting this pathogen. High affinity Abs are essential to neutralize many 
extracellular pathogens and their toxins. Eradication of intracellular microbes and cancer cells, on the 
other hand, relies mostly on the cytotoxic activity of CD8
+
 T cells. Understanding the direct 
mechanisms implicated in threat eradication facilitated the choice of optimal antigens that should be 
included in vaccine formulation. This could be the entire protein or polysaccharide (subunit vaccine), 
or just a peptide of interest containing a particular epitope (peptide vaccine). Other modern 
vaccination techniques are based on DNA plasmids (DNA vaccine) or viral/bacterial vectors serving as 
vaccine platforms (vectored recombinant vaccines). The main outlines and features of these new 
techniques of immunization are described below. 
1.2.2.1 Subunit vaccines 
The better understanding of anti-pathogen/anti-cancer immune responses and antigen 
structure allowed to determine the most immunogenic part of pathogens. This, along with the 
advances in the protein production and purification methods, enabled fractioning of desired antigen 
subcomponent from the remaining, unwanted material. Selected proteins or polysaccharides could 
alone provide a sufficient stimulation for mounting adaptive immune response. Decades of research 
precede the development of first, successful subunit vaccine. During influenza vaccine development 
solvents were used to disrupt the viral lipid envelope. More complex methods of eliminating 
biological impurities were introduced during pneumococci or pertussis vaccine design (Edwards and 
Decker, 2008). By eliminating the unwanted components of a pathogen, vaccines with reduced 
reactogenicity and improved safety profile were developed. The first vaccine against Hepatitis B virus 
(HBV) was formulated by purifying HBV surface antigen, HBsAg, from the plasma of infected 
individuals (Hilleman, 1983). Capsular polysaccharides from Haemophilus influenza, meningococci 
and pneumococci were turned into conjugated subunit vaccines upon linking them to carrier proteins 
(Fitzwater et al., 2012; Tan et al., 2010). This improved significantly polysaccharide immunogenicity, 
since their ability stimulate B cells was enhanced by T cell recognition of class-II epitopes in the 
sequence of the carrier protein. Also, helper CD4+ cells provided the stimulation pivotal in memory 
B cell development. 
 41
With the advances in genetic engineering it became possible to design recombinant subunit 
vaccines. Rather than purifying the desired antigen component, the gene of interest is introduced 
into bacterial, yeast, insect or mammalian cells and after large scale amplification can be purified in 
huge quantity. The most important example of this process is recombinant subunit vaccine against 
Hepatitis B virus.  The surface antigen HBsAg is obtained in high yield production in yeast or 
mammalian cells. HBV vaccine combines three main progresses in vaccinology: first viral subunit 
vaccine, first vaccine preventing human cancer and first recombinant-expressed vaccine (Hilleman, 
2000). Another successful achievement with this strategy is vaccine for Human Papilloma Virus 
(HPV), based on L1 coat protein able to assemble as virus-like particles (VLP), resembling capsid 
structure and deprived of any genetic material (Zhou et al., 1991). 
Of note, since these types of vaccines are based on highly purified molecules oftenly 
deprived of natural PAMPs, they require addition of suitable adjuvants in order to elicit an adaptive 
immune responses.  
 
Table 1.2. Examples of vaccine vectors. Examples of various bacteria- and virus-based vectors are 
listed in the table, along with their main advantages and disadvantages (Liu, 2010). 
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1.2.2.2 Recombinant vaccines  
Recombinant vaccines rely on genetic engineering methods, allowing to tailor and produce 
the antigen of interest. With the use of sophisticated techniques of molecular cloning or directed 
mutagenesis it became possible to suppress pathogen virulence in a more durable manner. After 
deleting or inactivating genes responsible for microbe pathogenicity, reverting to the virulent form 
upon in vivo administration became virtually impossible. This resulted in the development of 
vaccines with significantly improved safety compared to corresponding live attenuated vaccines.  
These attenuated viruses or bacteria could serve also as vectors carrying genetic 
information for a heterologous antigen.  By introducing genes of interest into vector genomes, the 
antigenic protein is produced by a recombinant bacteria or, in case of viral vehicle, expression takes 
place inside the infected cells. Viral recombinant vaccines are most often based on poxvirus, 
adenovirus, retrovirus or adeno-associated virus. Poxviruses were among the first viruses to be 
genetically altered. One member of poxvirus family, Vaccinia virus, was modified to encode rabies 
virus glycoprotein and has been used for immunization of wild animals for almost 20 years (Hanlon et 
al., 1998). Until today, progress in this vaccination field gave rise to vectors of various origin, 
encoding antigens from pathogens like HIV, dengue virus, Plasmodium falciparum or Mycobacterium 
tuberculosis. Clinical trials using adenoviruses as a vaccine platform will be described in 2.2.3. Even 
though they are less popular than the viral ones, bacterial vectors were also successfully used. They 
are based mostly on Shigella, Salmonella or Listeria (Liu, 2010). Another example is BCG, used as 
a vaccine against tuberculosis but also as a carrier of a heterologous antigen. Examples of vaccine 
vectors are listed in Table 1.2. 
The appealing advantage of recombinant vaccines is the induction of innate immunity by 
PAMPs associated with the vector. This may allow to circumvent the addition of a supplementary 
adjuvant. However, few key points still need to be considered while applying this method of 
vaccination. One of them is the safety of used vectors, especially those based on retroviruses which 
can integrate into host genome, causing mutations. Another burning issue is immunity to the vaccine 
vector. Both pre-existing immunity and anti-vector response developed after the first administration 
hamper transgene expression and result in reduced efficacy of immunization. Methods to overcome 
anti-adenovirus immunity will be detailed in Chapter 2 of this introduction. 
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1.2.2.3 DNA vaccines 
The observation that injection of DNA plasmid containing genes of interest results in their 
transcription and translation to proteins carried subsequently to APC in the bone marrow, laid 
a groundwork for development of DNA vaccines (Wolff et al., 1990). Although the first results 
showed rather poor Abs production, later improvements in the DNA delivery method and addition of 
adjuvants significantly increased its efficacy (Donnelly et al., 2005; Flingai, 2013). One of the firstly 
developed delivery techniques was DNA-coated golden particles, administered with the use of gene 
gun (Tang et al., 1992). Later, electroporation turned out to be the most impactful enhancement in 
the area of DNA delivery. Applied electric current resulted in more efficient DNA capture by the cells 
and induced local inflammation, both contributing to stronger immune reaction. Various additional 
components were also introduced, enhancing the generated immune response. One strategy 
includes co-administration of immunomodulatory proteins, either encoded in a separate plasmid or 
as a gene co-expressed with the antigen on the same plasmid. These genes might be coding for pro-
inflammatory cytokines (IL-12), IFN-γ, or molecules mediating recruitment and activation of APCs 
(Xiang et al., 1995; Sin et al., 1998). Another strategy introduces genes of co-stimulatory and 
adhesion molecules, such as CD80 and CD86, in order to improve T cell activation (Tsuji et al., 1997; 
Kim et al., 1999). 
DNA plasmids have a capacity to trigger Abs production and to prime T cell responses. DNA 
vaccine mimics the process of natural viral infection by delivering its genes to the host cell and 
leading to expression of encoded proteins. In case of direct DCs transfection, expressed class-I 
epitopes are presented on MHC-I molecule and prime CD8
+
 cells (classical pathway of class-I antigen 
presentation). Alternatively, in the process of cross-presentation DCs can present CD8
+
 epitopes 
obtained from extracellular milieu upon engulfing apoptotic or necrotic transfected cells or capturing 
secreted antigen protein.  Transfection of both professional and non-professional immune cells result 
in release of the antigen, making it available for B cell detection (Flingai, 2013). 
Within the past decade three DNA vaccines have been licensed for veterinary use: for 
treatment of West Nile virus in horses (Davis et al., 2001), hematopoietic necrosis virus in salmon 
(Garver et al., 2005) and melanoma in dogs (Bergman et al., 2006). Human clinical trials were 
performed with HIV DNA vaccine adjuvanted with IL-12 and cellular responses were detected 
(Kalams et al., 2012). DNA vaccination seems to be the most promising candidate for the priming 
step in heterologous prime-boost strategies. Despite all these advances, until today there is no DNA 
vaccine licensed for human use. Continuous refinements, however, bode well for this vaccination 
strategy. 
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1.2.2.4 Peptide vaccines  
Epitopes are specific fragments of macromolecules recognized by T cells or B cells and they 
serve as the main targets for adaptive immune responses. The blossom of “Reverse Vaccinology” 
provided an effective tools to identify, produce and purify these precise elements, reducing the 
antigen complexity to a single peptide fragment. Fragments which are selected during the vaccine 
formulation are usually around 10-30aa in length and comprise linear epitopes, whose 
immunogenicity does not depend on a three-dimensional structure of the protein. “Epitope display”, 
strategy of vaccination I evaluated during my thesis also belongs to this group of vaccines. It will be 
fully described in Chapter 3.  
Selection of the epitope is the first and most important step in the formulation of a peptide 
vaccine, and depending on the epitope type different aspects needs to be considered. In case of 
B cell epitope, its 3D accessibility is crucial and its integrity needs to be preserved by the choice of an 
accurate delivery method. Ideally, its sequence should also comprise CD4
+
 epitope, providing 
T helper stimulation, pivotal for affinity maturation and induction of memory B cells. As for the T cell 
epitope, efficient delivery to APCs should be considered. Also, the specificity of MHC molecules 
needs to be stressed, as e.g. peptide presented by HLA-A2 allele of MHC-I molecule might not be 
displayed in the context of HLA-A1 and vice-versa. Thus, prevalence of different MHC molecule 
alleles among individuals needs to be carefully considered in order to target various individuals in 
an immunogenetically heterogeneous population.  Finally, both B cell and T cell epitopes should be 
highly conserved in the pathogen sequence. This is emphasized especially in the case of highly 
variable pathogens like HCV or HIV where existence of numerous virus genotypes, differing 
significantly in their sequence, accentuates the significance of the identification of a common 
epitope. 
Various approaches employing in silico methods, experimental methods or a mix of both 
are undertaken during epitope search. One of the most powerful methods is algorithm motif 
prediction. With bioinformatics tools it became possible to propose potential epitopes based on 
parameters like peptide translocation to ER (MHC-I), cleavage in lysosomal compartments (MHC-II), 
peptide binding to MHC molecules or T cell receptor recognition. Methods allowing for epitope 
detection rely on X-ray crystallography and mass spectrometry (Hager-Braun and Tomer, 2005), use 
of phage display library (Panina-Bordignon et al., 1989) and on databases regrouping known T cell 
epitopes with supplementary information about their MHC binding, HLA restriction, etc. Another 
frequently used approach is overlapping peptide library derived from the protein of interest. Pools of 
peptides (9-20aa in length) are generated and overlap to ensure presence of each possible epitope. 
This allows for the discovery of both CD4
+
 and CD8
+
 epitopes in the context of several alleles of MHC 
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molecules. Also, in the frame of Immunoproteomic, it became possible to directly identify MHC 
class I-presented epitopes extracted from infected cells. An impediment of this strategy is the 
difficulty of separating the infection/cancer-related peptides from the non-relevant ones, 
constituting the majority of the isolated set. 
After carefully selecting the epitopes a suitable delivery method has to be chosen. Purified 
peptide is poorly immunogenic and needs to be administered in specially adapted form. Among the 
proposed strategies the most popular is embedding the peptide in an emulsion-based adjuvant. 
Stable emulsion obtained by vigorous mixing of water and oil phase ensures slow antigen release and 
prolonged stimulation. The most well-known example is Freund’s complete adjuvant, containing 
killed mycobacteria. Other option is delivering peptides in phospholipid bilayer structures called 
liposomes. Their composition can be tailored in order to facilitate uptake by APCs, and adjuvants can 
be encapsulated along with the antigen (Joshi et al., 2012). Studies showed induction of both 
humoral and cellular responses with these formulations (Nagata et al., 2007; Kohyama et al., 2009). 
Virosomes, liposomes carrying influenza envelope proteins have been developed and also provide 
increased angtigen uptake by APC and immune cell activation. The use of Immunostimulatory 
complexes (ISCOMs) has been reported, composed of antigen, cholesterol, phospholipid and 
saponin. Polymeric particles like albumin or collagen can also serve as a support. 
In the context of this work, peptide delivery by viral particles is of the biggest interest. Viral 
vectors have been already mentioned in the context of recombinant vaccines, where they were 
modified to encode the antigen of interest in their genome. With the tools of genetic engineering, it 
became possible to introduce epitope-encoding sequence inside the genes coding for capsid 
proteins. This resulted in recombinant viral vectors, displaying heterologous peptides on their capsid 
surface. The good immunogenicity of the viral vector performs an adjuvant role. Ease of 
manipulation is another quality of this method of vaccination. In our study we chose adenovirus as 
an epitope carrier due to its appealing features described in Chapter 2. Nevertheless, other viruses 
are also commonly used as a vaccine platform for heterologous peptides. Among them we can list 
AAVs (Manzano-Szalai et al., 2014), influenza virus (Langley et al., 2010) and human rhinovirus (Smith 
et al., 1998). 
Many peptide vaccines are currently being developed to protect against HIV (Liu et al., 
2007) malaria (Epstein et al., 2007), HCV (Kolesanova et al., 2013), influenza (Stanekova et al., 
2011), HPV (Solares et al., 2011) or different types of cancer, like pancreatic or lung cancer 
(Bernhardt et al., 2006; Brunsvig et al., 2011) (Table 1.3). However, no peptide vaccine has reached 
the market yet. 
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Table 1.3. Worldwide clinical trials of peptide vaccines from Li et al., 2014. 
1.2.2.5 Adjuvants 
In the classical vaccination strategy the whole pathogen is administrated in order to induce 
protection. This provided organism with a set of various epitopes and PAMPs, usually sufficient to 
induce effective stimulation. Modern vaccines, based on highly selected and purified proteins or 
peptides offer better safety profile but can lead to insufficient stimulation of innate immunity, thus 
resulting in reduced adaptive immune responses. In order to overcome this problem additional 
components called adjuvants were introduced during vaccine formulation (Figure 1.14).  
Adjuvants are crucial factors in mounting an effective immune protection, performing their 
function through various mechanisms. They can serve as the delivery system, enhancing the antigen 
uptake by APC and subsequently ensure its progressive release, slower clearance and better 
exposure to the Immune System. Adjuvants may also interfere at the different levels of adaptive 
response activation by affecting the PRRs stimulation, antigen presentation on MHC molecules or 
recognition of co-stimulatory signal (Leroux-Roels et al., 2010). They contribute to broad Ab 
response, increasing its magnitude and functionality. By leading to more potent immune responses 
they allow for reduction of injection number in vaccination schedule. Adjuvants are of great 
importance in the vaccines for the elderly, who display reduced T cell populations. Additionally, as 
previously mentioned in chapter 1.1.1.2, the type of stimulated PRRs shapes adaptive response by 
directing naïve T cells into different maturation lineages. This gives an opportunity to control the 
nature of induced adaptive responses by selecting proper adjuvants. Noteworthy, in the vaccination 
regimens performed during my thesis, no additional adjuvants were required nor added, thanks to 
the remarkable Ad immunogenicity. This property will be explained in paragraph 2.2.2. 
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Historically, the most extensively used adjuvants were based on aluminium salts. For more 
than 80 years they were included in various vaccine formulations, albeit the exact mechanism of 
their mode of action remained elusive. Recent studies reported that antigens absorbed on the 
aluminium salts are better presented and more efficiently internalized by APCs (Morefield et al., 
2005). Also, aluminium salts have been shown to activate inflammasome complex components 
(Lambrecht et al., 2009). One of their limitation is enhancement of Th2 response and weak effect on 
Th1, limiting their performance in vaccines against viral pathogens or cancer. Emulsions, briefly 
mentioned in previous paragraph, are another choice of adjuvants. Complete Freund adjuvant, based 
on water-in-oil emulsion with embedded mycobacterium particles was too reactogenic to be used in 
humans. Refinement of used materials resulted in safer combinations, acceptable in therapeutic 
vaccines formulation. Oil-in-water emulsions have also been developed, with MF59, AS03 and AF03 
being one of the most frequently selected. MF59 is included e.g. in seasonal influenza vaccine and 
has been shown to enhance the immune response in elderly (Podda, 2001). By inducing chemokine 
production it attracts monocytes and neutrophils to the immunization site, where they can take up 
the antigen (O′Hagan et al., 2012). Liposomes and virosomes, also mentioned in 1.2.2.4, are another 
type of frequently used adjuvants. They improve induction of immune response by increasing the 
level of antigen presentation (Ambrosch et al., 2007). Another type of delivery vehicles mentioned in 
1.2.2.4, ISCOMs, also has adjuvantic properties (Pearse, 2005). 
Among the novel adjuvants TLRs agonists are a promising example. MPL, TLR-4 antagonist 
based on LPS, is one of the leading immunostimulants, included e.g; in the Cervarix® HPV vaccine 
(from GSK). TLR9 ligands, such as CpG oligodeoxynucleotide (ODN) are also currently used. Different 
example of immunomodulatory molecules are plant-derived saponins which originally were used 
only in veterinary vaccination. After reducing their reactogenicity thanks to the improved purifity 
they are now used in human vaccine trials. It has been showed that addition of MPL to purified 
saponin from Quillaja saponaria (QS21) helps to mount strong humoral and cellular immune 
responses against hepatitis B surface antigen (Leroux-Roels et al., 2015). 
Recent data shows that choice of both antigen and adjuvant are equally important in 
a successful vaccine design. Adjuvant performance was shown to depend on administration route.  
Also, different formulations of the same adjuvant may induce substantially different immune 
responses. By carefully selecting and/or combining different adjuvants, enhanced immunity can be 
induced, improving the vaccination outcome.  
 
 
 
 
 48
2 Adenovirus and their use in vaccination  
2.1 Adenovirus 
Ad are a non-enveloped, double stranded DNA viruses isolated for the first time over 50 
years ago from human adenoid cells (Rowe, 1953). Since their discovery adenoviruses have been 
detected in various animals, and depending on the host type they have been classified into four 
groups: Mastadenovirus (mammals), Atadenovirus (ruminants and reptiles), Aviadenovirus (birds), 
Siadenovirus (frogs and fish) (Davison et al., 2003). Adenovirus infecting humans belong to the 
Mastadenovirus group and can be further divided into seven species named A-G. Almost 70 human 
serotypes have been distinguished until today (Ghebremedhin; 2014), with serotype 2 and 5 from 
group C being the most intensively studied and used in gene therapy and vaccination studies. All of 
the serotypes can cause rather mild pathologies, such as cold or diarrhea but in rare cases Ad 
infection can lead to more severe disorders like epidemic keratoconjunctivitis or respiratory 
infections (Monto, 1992). 
2.1.1  Proteins and capsid structure  
Ad capsid, the protein shell enclosing the viral genome, has diameter of ~95 nm and it is 
composed of thirteen structural proteins, identified in sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS–PAGE) (Maizel et al., 1968; Ginsberg et al., 1966).  Various experiments such as 
stoichiometric analysis (van Oostrum and Burnett, 1985) or electron microscopy (Horne et al., 1959; 
Valentine and Pereira, 1965) permitted to look closer at the geometry and architecture of Ad 
particle. The trimeric hexon protein, present in a total copy of 240 units organized in 20 triangular 
facets, is the most abundant element of the icosahedrally shaped capsid. Pentameric penton base in 
non-covalent interaction with protruding trimeric fiber generates a complex called penton, located at 
all 12 vertices of the capsid. Remaining minor components such as proteins IIIa, VI, VIII and IX are 
stabilizing the architecture of the viral particle, acting as a “molecular glue” (figure 2.1).  
The viral capsid encloses a viral core, a tightly packed viral DNA in complex with DNA 
binding viral proteins: core proteins, protein VII, protein X also described as μ, the maturation 
protease AVP and the terminal protein (TP) (Mangel and San Martin, 2014). Protein VII is responsible 
for DNA condensation. Although the exact organization of the viral core is not clear, some studies 
reported that it creates nucleosome-like beads which allow to pack the DNA inside the capsid (Vayda 
et al., 1983). TP protein by fixing the 5’ DNA extremities protects them from degradation (Rekosh et 
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al., 1977). Protein V connects viral core with the capsid by interacting with penton proteins and, 
through IIIA and VI proteins, with hexon proteins. 
Of note, the majority of studies investigating the structure of the Ad capsid focused on viral 
particles of serotype 2 and 5, and thus descriptions of the capsid proteins found in these chapter is 
based on these two serotypes. 
  
 
 
Figure 2.1. General structure of Ad virus particle. The schema shows thirteen structural 
proteins present in Ad viral particle. The capsid organization was based on electron microscopy and 
crystallography studies. The capsid is mainly built from hexon, penton base and fibre proteins. The 
remaining minor capsid proteins, i.e. IIIa, VI, VIII and IX enhance its stability. Inside the capsid, the 
viral core consists of dsDNA genome associated with proteins V, VII, Mu, TP, IVa2 as well as viral 
protease (Russel et al., 2009). 
 
During the last century, advances in technology resulted in a blossom of structural biology 
techniques. Ad hexon was not only the first animal virus protein to be crystallized (Pereira et al., 
1968) but also the longest polypeptide analyzed by X-ray diffraction (Roberts et al., 1986). Thanks to 
protein crystallography the atomic structures of the fiber knob (Xia et al., 1994), fiber shaft (van Raaij 
et al., 1999) as well as penton base (Zubieta et al., 2005) were uncovered. All these efforts gave rise 
to the full, high resolution atomic structure of Ad (Liu et al., 2010; Reddy et al., 2010). 
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In hexon structure we can distinguish the evolutionarily conserved core of the molecule 
which is crucial for the capsid formation and weakly conserved loops exposed at the top of the 
molecule (Figure 2.2). Among these sequences, seven Hyper Variable Regions (HVR) were originally 
described, later reclassified to nine (Rux et al., 2003). They contain serotype-specific residues 
(Crawford-Miksza and Schnurr, 1996), still remaining the most amenable sites for engineered 
modifications).  
 
 
Figure 2.2. Top-down (A and B) and side (C) view of trimeric hexon protein X-ray 
structure.  A and B) Depiction of trimeric hexon structure, with HVRs in the following colours:  
yellow HVR1, green HVR2, light blue HVR3, orange  HVR4, red HVR5, brown HVR6, blue HVR7. C) Side 
view of trimeric hexon, dashed loops represent speculated localization of HVR2 and HVR5 loops 
(Khare et al., 2012). 
 
The trimeric fiber protein can be divided in three domains.  Its conserved base, through the 
N-terminal flexible tail is anchoring the protein to the penton base. A shaft domain contains repeated 
conserved motifs of 15-22aa (Green et al., 1983). Differences in the repetition number dictates the 
fiber length and varies between the serotypes. The KKTK motif found in the fiber shaft allows for the 
interaction with heparan sulfate proteoglycans (HSPG) (Dechecchi et al., 2000). A distal knob 
interacts with coxackie-adenovirus receptor (CAR) and displays flexible loops on its surface (Figure 
2.3). Among them, HI loop was most extensively investigated. Studies report that it is not playing 
a role in intrinsic molecular interactions and thus is a promising site for genetic modifications (Xia et 
al., 1994). 
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Figure 2.3. General structure of trimeric fiber and detailed structure of fiber knob. On 
the left, a fiber model displaying a globular knob domain, a long shaft domain and three N-terminal 
tails. Three subunits are represented by different colors: red, green and blue. On the right, model of 
fiber knob with the positions of C-terminus and various loops represented by different colors: blue HI 
loop, green CD loop, brown DE loop and red FG loop (Liu et al., 2011; Sharma et al., 2013). 
 
The penton base together with the fiber protein creates a penton protein placed in all 
twelve vertices of the viral particle. The penton base is formed by five identical monomers. In the 
structure of each monomer we can distinguish two domains (Figure 2.4). First, the jelly-roll barrel 
domain is conferring stability and site of interaction with the fiber protein (Cusack, 2005). Second, 
the distal domain is an irregular fold, comprising RGD loops and variable loops exposed to the capsid 
surface. RGD loops comprises RGD motifs (arginine-glycine-aspartate) responsible for αv integrin 
binding during cell entry (Zubieta et al., 2005). Variable loops, on the other hand, as the name 
indicates, vary between different serotypes and their function remains to be determined. 
Interestingly, pentons of certain serotypes are able to auto-assemble by twelve units into so-called 
dodecahedrons (Norrby, 1966), structures capable of entering the host cell (Fender et al., 1997).  
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Figure 2.4. Structure of penton base protein. On the left, depiction of the pentameric 
structure of the penton base, with the monomers represented by different colors. On the right, 
ribbon diagram of penton base with the depiction of RGD loop and variable loop localization (Zubieta 
et al., 2005). 
 
2.1.2 Adenovirus life cycle 
2.1.2.1  Interaction with receptors  
Ad cell entry process differs between the various serotypes as they interact with different 
cell-surface molecules. Additionally, some discrepancies can be observed in the cell entry in vitro and 
in vivo. In this part I will describe Ad5 infectivity process which was observed in in vitro studies. For 
the detailed vector biodistribution in vivo, please refer to chapter 2.2.2.  
Ad entrance into the host cell is initiated by interaction of fiber knob with CAR, anchoring 
the viral particle to the cell surface (Bergelson et al., 1997; Freimuth et al., 1999) (Figure 2.5). Loops 
AB, CD, DG and FG from adjacent fiber monomers are involved in CAR binding and one fiber knob can 
interact with three CAR molecules, increasing significantly the affinity of this interaction. More 
precisely, residues Ser408 and Pro409 in the AB loop, Tyr477 in the DG loop and Leu485 in β-strand 
F, have been described as the pivotal fragments involved in CAR interaction (Kirby et al., 2000). CAR 
receptor is predominantly expressed in epithelial cells lining the body cavities and more precisely in 
their tight junctions (Raschperger et al., 2006). It was discovered that the infected cells have 
a tendency to over-produce fiber protein, which upon release from the infected cell binds CAR and 
induces tight junction opening (Walters et al., 2002).  
As Ad attaches to the cell surface through the interaction with CAR, RGD motif in penton 
base is available to bind cell-surface αvβ3 integrins (Wickham et al., 1993). This causes integrin 
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clustering and results in initiation of an “outside-in” signaling (Qin et al., 2004).  Through activation of 
PI3 kinase remodeling of cytoskeleton takes place, resulting in clathrin-dependent Ad5 cell entry. 
Although this entrance pathway is the main mechanism used by Ad5, it has been also shown that this 
virus can access the cell through macropinocytosis (Meier et al., 2002).  
 
 
 
Figure 2.5. Ad5 entry pathway. After initial cell attachment through fiber knob interaction with 
CAR and subsequent integrin binding by RGD motif in penton base (1), Ad enters the cell in a clathrin-
dependent manner (2). This interaction together with the low pH in the early endosome favours 
capsid disassembly (3 and 4). The naked viral particle enters the cytoplasm and thanks to the dynein 
is transported towards the nucleus along the microtubules (5). Viral DNA is transported inside the 
nucleus through the nuclear pore complex (6) (Nemerow et al., 2009). 
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Other important molecules are heparan sulfate proteoglycans (HSPG). These ubiquitously 
expressed molecules are found in increased concentration on hepatocytes. Ad5, presumably through 
a KKTK motif present in the fiber shaft, can use HSPG to more efficiently enter CAR-negative cells 
(Smith et al., 2003). More recent reports entail that Ad5 particle coated with coagulation factor X 
(FX) can be bridged to HSPG and efficiently enter hepatocytes (Waddington et al., 2008), a point that 
will be discussed in chapter 2.2.  
Once internalized into the endosomal pathway, viral particles undergo structure disruption. 
This is initiated through changement of the penton base conformation upon interaction with 
integrins, resulting in loosening of its interaction with hexon protein and in fiber detachment. The 
low pH of endosomal environment is another key factor favoring capsid disassembly as it causes 
exposition of protein VI, implicated in endosome escape (Wiethoff et al., 2005).  
In the cytoplasm, interaction of Ad5 hexon protein with dynein catalyzes the “naked” virus 
movement towards the nucleus (Bremner et al., 2009), using microtubules as a molecular track 
(Warren et al., 2007) (Figure 2.5). Upon reaching microtubule-organizing center (MTOC) the virus 
detaches from microtubules and hexon protein and pIX interact with nuclear pore complex (NPC). 
This leads to complete disruption of the viral particle and ejection of viral DNA into the nucleus 
(Strunze et al., 2011). 
2.1.2.2 Genome 
Ad viral genome reaches the nucleus in the complex with viral protein VII. The role of this 
interaction remains uncertain, but one of the proposed role is the protection of viral DNA from 
degradation by DNA repair mechanisms (Karen and Hearing, 2011). Another possibility is the pVII 
implication in the regulation of viral genome replication and expression (Chen et al., 2007). 
Cellular proteins such as Template activating Factor-Iβ (TAF-Iβ) or members of the TAF-II 
and TAF-III complex have been shown to interact with pVII/DNA complex and influence its 
remodelling (Haruki et al., 2003; Kawase et al., 1996; Okuwaki et al., 2001). More recently it was also 
demonstrated that cellular histones can bind to Ad genome (Komatsu et al., 2011). In addition, 
bridging of H3 histone to Ad DNA through chaperone protein HIRA is influencing the expression level 
(Ross et al., 2011). 
Ad genome in the form of 30-35 kb double stranded DNA is divided in six segments 
comprising early genes (E1a, E1b, E2a, E2b, E3, and E4), two intermediate genes coding for IX and 
IVa2 proteins and five segments encoding late products (L1-L5). Additionally, two genes encoding 
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virus-associated RNAs I and II (VAI and VAII RNAs) are present in Ad genome. They serve as inhibitors 
of host protein synthesis in Ad-infected cells (Figure 2.6).  
 
 
 
Figure 2.6. Organization of Ad genome. The rightward transcription results in expression of 
genes encoding E1A, E1B, IX, L1-5 late proteins, virus associated RNA (VA-RNA) and E3 units. The 
transcription from the complementary strand provides E4, E2A, E2B and IVa2 transcripts. Early 
proteins are marked with black arrows, blue arrows indicate intermediate transcription units while 
late messengers are depicted in green. Virus VA-RNAs I and II are marked as red arrows (Hall et al., 
2010). 
 
Proteins encoded by region E1, E2 and E4 are playing essential roles during virus replication 
and expression of late genes. E1A pushes infected cells into S phase of cell cycle and activates 
transcription of remaining viral genes (Berk, 1986). This early protein modifies the function of key 
regulatory proteins like the chromatin remodeling protein p400 or retinoblastoma (Rb). By 
interacting with p400, E1A protein induces the formation of Myc/p400 complexes on chromatin, 
resulting in activation of Myc-target genes (Chakraborty and Tansey, 2009). In parallel, through its 
interaction with Rb-binding domain CR1 and CR2, E1A leads to the liberation of E2F transcription 
factor and to activation of genes involved in DNA replication and nucleotide metabolism, crucial in 
S phase (Berk, 2005). E1B region encodes proteins E1B-19K and E1B-55K, which display 
anti-apoptotic activities (Berk, 2005). E1B-55K by inhibiting p53 ensures cell entry to G1/S phase 
(Grand et al,. 1999). E1B-19K is able to sequestrate pro-apoptotic proteins BAK and BAX to prevent 
cell death. E2 region codes for viral polymerase, DNA binding protein (DBP) stabilizing the 
single-stranded DNA intermediates and preterminal protein (pTP) fixed on ITRs found on the genome 
extremities.  E3 products exhibit immunomodulatory functions, e.g. E3/19K protein blocks expression 
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of newly synthesized MHC molecules on the cell surface by retaining them in ER (Windheim et al,. 
2004). E4 region contains at least seven open reading frames, which products provide coordination 
of viral RNA metabolism. Some of the E4-encoded proteins, such as E4orf1, E4orf3 or E4orf6, plays a 
role in induction or enhancement of cell transformation. Interestingly, it has been discovered that 
E4orf4 could inhibit lysis of adenovirus infected cells by CTLs (Kaplan et al., 1999). In the following 
steps two proteins of viral capsid are produced, IX and IVa2. Finally, expression of late genes assures 
production of the remaining capsid proteins as well as additional proteins, coordinating and 
facilitating new capsid assembly and maturation. 
2.1.2.3 New virion assembly and release 
Newly produced viral proteins needs to return from the cytoplasm back to the nucleus in 
order to encapsidate replicated copies of viral genome. In case of penton base and fiber this event is 
assured by the presence of nuclear localization sequences (NLS) and after self-assembly which takes 
place in cytoplasm, proteins are entering the nucleus (Fender et al,. 1997). While inside the nucleus, 
these two proteins assemble into a penton protein. Chaperon protein L4-100K participates in hexon 
trimerisation in the cytoplasm and their transport to the nucleus (Hong et al,. 2005). While inside the 
nucleus, all capsid components are able to assemble with the help of L1 52K and 55K proteins  
(Hasson et al,. 1992) and a chaperone protein L4 33K (Fessler et al,. 1999). This structure called 
pro-capsid is then able to encapsidate viral DNA containing Ѱ sequence. Finally, viral protease 
(L3-23K) by cleaving the polypeptides of minor capsid proteins ensures final structure of viral particle. 
Accumulation of new virions in a non-fully elucidated mechanism induces host cell lysis. 
Most probably this step is depending on L3 protein (Chen et al,. 1993) as well as on Ad death protein 
(ADP) (Tollefson et al,. 1996). Ad-induced cell death is of non-apoptotic type, resembling 
programmed necrosis (Abou El Hassan et al,. 2004). Of note, autophagy was also proposed as 
a mechanism of Ad-induced cell death (Jiang al,. 2008). 
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2.2 Adenoviral vectors: their advantages and limits 
Using Ad5, different vectors were obtained. This part of the manuscript will first describe 
the construction of different generations of Ad viral vectors. Subsequently, two main shortcomings of 
their applications will be discussed: in vivo tropism as well as their high immunogenicity.  
2.2.1  Development of adenoviral vectors 
Nowadays, adenoviral vectors are the more frequently used platforms in a vaccination 
studies. This choice is dictated by many advantages they offer, facilitating their construction and 
usage. Firstly, their biology is well investigated. Ad have a transgene capacity of up to 36kbp and are 
able to efficiently transduce the cells regardless of the cell cycle stage. They are non-pathogenic, and 
their episomal nature allows to the insertional mutagenesis. As for the vaccine formulation and 
scale-up production, Ad vectors can be easily produced at high titer (10
11
-10
13
 vp/ml) and their 
non-enveloped nature allows for a formulation of stable lyophilized preparation. 
The first generation of Ad vectors was established by deleting E1 (Ad∆E1) region, thus 
allowing to insert heterologous DNA fragment of 5,5 kb (Bett et al,. 1993) and at the same time 
rendering the vector replication-defective (Danthinne and Imperiale, 2000) (Figure 2.7). As a result, 
production of these vectors could take place only in complementing cell lines providing the missing 
E1 products. Interestingly, low level of viral gene expression from these vectors can also be observed 
in non-replicating cell lines due to partial complementation by host cell factors. This leads to the 
presence of small amounts of viral protein inside the cell and on the cell surface in the form of 
peptides bound to the MHC molecules, resulting in priming ant-Ad cellular responses (Yang et al., 
1994). Moreover, the potential threat of this production technique is the emergence of replication 
competent Ad (rAd) vectors, which have integrated E1 gene in their genome during the production 
process through homologous recombination (Lochmuller et al., 1994). 
In order to additionally expand the cloning capacity, the first generation vectors were also 
deleted in E3 segment (Ad∆E1∆E3), which permitted to increase the cloning capacity up to 7,5 kb 
(Amalfitano et al., 1998) (Figure 2.7). Even though the majority of work with adenoviruses continues 
to use Ad∆E1∆E3 vectors, the need for a bigger transgene insertion gave rise to the next generation 
of Ad vectors deleted additionally in regions E2 and/or E4 and able to accommodate up to 10 kb. 
Similarly to E1, E2 and E4 proteins are also mandatory for the replication process and need to be 
provided in-trans during the vector production (Lusky et al., 1998). Of note, the concomitant deletion 
of E1, E2 and E4 genes reduces the risk of rAd production.  
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Figure 2.7. Different generations of Ad vectors. Genomes of first and second generation Ad 
as well as helper-dependent Ad are depicted under the schema of wild type Ad5 genome. E1–E4 
represents early transcripts and late transcripts are marked as L1–L5. MLP: major late promoter; Ѱ: 
packaging signal (Alba, 2005). 
 
As the last generation vectors, helper-dependent vectors were obtained by deleting all the 
viral genes and by placing the transgene between 5’ and 3’ ITR and encapsidation sequence Ѱ (Figure 
2.7). These “gutless” Ad have a cloning capacity of 36 kb and due to the significantly weaker immune 
system stimulation, resulting from the absence of viral genes, show better stability in various tissues.  
There is a relatively tight restriction on the length of DNA which can be packaged into virions in order 
to preserve vector stability and growth (Bett et al., 1993; Parks et al., 1997). Since inserts are rarely 
reaching 36kbp, additional nucleotide fragments, called stuffer DNA should be introduced in order to 
reach the stability threshold. Coding regions, repetitive sequences or hot spots for recombination 
should be avoided while choosing a stuffer DNA sequence. Gutless Ad vectors are completely derived 
of viral genes, and for the efficient production cells needs to be co-infected with a so-called helper 
virus, providing viral proteins essential for the replication process and new virion production. This 
concomitant infection underlines the need for optimization of the purification process in order to 
avoid contamination by the helper construct (Alba et al., 2005). One of the strategies comprises 
weakening the efficiency of helper vector genome packaging, either by introducing mutations in the 
encapsidation sequence or by increasing the total genome length. Another approach uses helper 
vector with encapsidation sequence flanked with the loxP sites and cell line expressing Cre 
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recombinase (293Cre) (Figure 2.8). After transduction of these cells, the packaging sequence from 
helper vector genome is removed, preventing packaging into newly formed virions.  
 
Figure 2.8. Gutless Ad vector production using the loxP-Cre system. Two constructs are 
needed for the production of gutless vector. The genome of gutless Ad contains transgene, stuffer 
DNA and encapsidation sequence Ѱ placed between its inverted terminal repeats (ITR). Helper Ad 
construct is containing the whole wild-type Ad genome and the encapsidation sequence Ѱ flanked 
with loxP sequences. Upon co-transfection of the Cre/293 cells, both genomes are amplified and viral 
proteins are produced. Cre recombinase removes Ѱ sequence from helper Ad DNA to prevent its 
packaging. This strategy allows to produce gutless vector with the high purity (90-99.9%) (Alba, 
2015). 
 
Regardless of many advantages they provide, Ad vectors are confronted with some hurdles 
that limit their potential. Two main obstacles, their large biodistribution and their strong 
immunogenicity will be discussed in the following sections. 
2.2.2 Tropism and biodistribution of Ad vectors 
Vector dissemination to the non-targeted cells is especially problematic in gene therapy 
and cancer therapy, where specific tissues/cells need to be reached. Non-specific sequestration may 
also limit vector exposure to the immune system, altering the vaccination efficacy. Thus, the efficacy 
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of viral vector depends on its capacity to reach targeted cells or tissues. As the level of expression of 
cell-entry receptors and co-factors usually varies between tissues, we can identify tissues prone to 
virus infection and those who are non-permissive. Based on this, the virus tropism can be defined. 
The biodistribution described in this section is focusing on the studies involving Ad5-derived vectors. 
2.2.2.1 Influence of administration mode 
In vivo Ad5 biodistribution depends on the site of administration. There are several ways 
of administering Ad vectors, among them intravenous (i.v.), intraperitoneal (i.p.) and intramuscular 
(i.m.) are the most frequently used. Upon i.v. injection virus dissemination is rather nonspecific, due 
to the ubiquitous expression of CAR, αvβ3 integrins and HSPGs. Nevertheless, there are certain 
organs which seem to be predominantly targeted by this virus. Results of qPCR report that 90 
minutes after the injection of 5x10
10 
vp via the tail vein of C57BL/6 mice, significantly increased level 
of virus genome was detected in spleen, ovary and especially in liver, with the viral DNA content in 
this organ increased 110 times vs. lung and kidney (Alemany and Curiel, 2001). Transgene expression 
was also evaluated in mice 72h after the i.v. administration of 10
9
–5x10
9
PFU, and revealed virus 
presence in lung, kidney, bladder, heart and urethra with significantly stronger presence in the liver 
(Wood et al., 1999). Another study assessed transgene expression in various tissues seven days after 
injection of 10
8
 PFU through the mouse tail vein, and the results, similarly to the previous analyses 
disclosed strong liver cells transduction (Kosuga et al., 2000). In the case of i.p injection, 48 hours 
after mice were injected with 5x10
10 
vp, Ad vector display a more homogenous virus distribution than 
in the case of i.v. administration. The strongest transgene activity was detected in liver and spleen, 
followed by kidneys and ovaries, and finally the brain, heart and lung (Kanerva et al., 2002). 
Intramuscular injection (i.m.) is another administration method, frequently used in clinics. Rabbits 
injected i.m. with 2x10
10 
vp of Ad vector were exhibiting transgene activity in their liver, lung, testis 
and spleen, and viral DNA was detected in the liver, lungs and spleen (Vajanto et al., 2002). 
2.2.2.2 Liver tropism 
Results of all biodistribution studies point at the liver as the main organ implicated in Ad 
sequestration, with the strongest liver tropism observed upon i.v. injection. The virus preference for 
this organ can be partially explained by its good vascularization. Adenovirus is first captured by 
liver-residing macrophages, called Kupffer Cells (KC), and liver sinusoidal endothelial cells (LSEC) 
lining the hepatic sinusoid. It has been shown that Scavenger Receptors (SR), expressed at high level 
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on the KC surface, are involved in Ad uptake (Xu et al., 2008). It has been suggested that HVR regions 
of Ad hexon might be involved in interaction with SR, since their shielding ablated this binding (Khare 
et al., 2013).  Nevertheless, this is not an exclusive mechanism, since mice with genetic deficiency in 
these cells display similar levels of Ad sequestration. Role of CAR and FX in KC entry was excluded in 
various experiments (Smith et al., 2008; Xu et al., 2008). Mechanism of Ad entry to the LSEC is less 
elucidated, but most probably also relies on SR interaction (Pluddemann et al., 2007). Due to Ad 
entry into the KC and LSEC, hepatocyte transduction in not linearly correlated with the amount of 
administered Ad vector. When administered at low dose, Ad vector is not able to reach hepatocytes 
as it is efficiently uptaken and removed by KC. At a high dose, KC and LSEC cells become saturated 
and the vector is able to transduce hepatocytes.  
2.2.2.3 CAR receptor and integrins 
Transgenic mice with increased expression of CAR receptor are more susceptible for Ad 
infection, especially at the level of tissues which normally are CAR-deficient, as skeletal muscle or 
lymphocytes, suggesting its role in shaping in vivo Ad biodistribution (Nalbantoglu et al., 2001; Hurez 
et al., 2002). However, as shown by numerous studies, single ablation of CAR binding does not limit 
vector infectivity in vivo, indicating that other factors are also playing a role in cell entry (Alemany 
and Curiel, 2001). Similarly, blocking exclusively the integrins binding is not sufficient to reduce Ad 
infectivity, as mice deficient in integrin β5 remains susceptible to Ad (Huang et al., 2000).  Studies 
investigating the outcome of combining both mutations in –CAR and –integrins interaction gave 
variable results. One team showed that after i.v. injection of 10
11
vp of doubly detargeted vector 
levels of virus transgene in liver, lung, spleen and heart were significantly reduced (Einfeld et al., 
2001). Similar results were obtained by the same team while administrating Ad intraperitoneally, 
showing that the doubly mutated vector is less captured by non-targeted tissues and persists longer 
in a blood stream (Akiyama et al., 2004). Contradictory observations were obtained by different 
group, where doubly mutated vector did not show reduced genome accumulation or transgene 
expression in the liver (Martin et al., 2003).  
2.2.2.4 Heparan sulfate proteoglycans 
Another factor influencing strong liver uptake is the increased expression of HSPGs on 
hepatocyte surface, which, as mentioned in 2.1.2.1., are one of primary Ad receptors. Binding of 
KKTK motif present in fiber shaft with HSPGs seems to be dictating Ad liver tropism, as inhibition of 
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this interaction results in a reduction in hepatocyte transduction (Smith et al., 2003). Ad5 vectors 
with fiber from serotype 19 or 37, and thus unable to bind CAR nor HSPGs, showed reduced 
transgene expression in the liver 1 hour and 5 days after the administration (Denby et al., 2004). My 
laboratory reported that pseudotyping Ad5 vector with Ad3 fiber results in reduced transgene 
expression in liver (Vigne et al., 2003). Further analysis showed that this property is mediated by Ad3 
fiber shaft and could be explained by a better KC uptake of this vector (Raddi, in revision). However, 
another study using Ad5 pseudotyped with a shaft from serotypes 31 or 41, also lacking KKTK motif, 
reported unaltered liver sequestration (DiPaolo et al., 2007). A triple mutated vector, where 
alterations of fiber knob and RGD motif in penton base were combined with ablation of KKTK motif 
and HSPGs interaction (through substitution with Ad35 fiber shaft) showed a very significant 
reduction in transgene activity in liver and lung after i.v. injection of 3x10
10
vp
 
(Koizumi et al., 2003). 
The same vector showed similar organ sequestration pattern upon i.p. administration of 10
11
vp 
(Koizumi et al., 2006). These results question the role of HSPG in hepatocyte transduction and 
suggest involvement of other factors. 
2.2.2.5 Blood factors 
Extensive research revealed that host blood factors are heavily influencing Ad transduction 
in liver. It has been shown, using an ex vivo perfusion model that coagulation factor IX (FIX) and 
C4-binding protein belonging to the complement system can interact with Ad fiber knob and mediate 
virus uptake in liver through HSPGs and low-density lipoprotein (LDL) receptor-related protein. 
Interestingly, this hepatocyte uptake is not dependent on CAR interaction (Shayakhmetov et al., 
2005). Another study analyzed a more broaden spectrum of vitamin K–dependent coagulation 
zymogens, including protein C, prothrombin (FII), FVII, FIX FX, FXI, and FXII (Parker et al., 2006). 
Among them, FX appeared to have the biggest impact on hepatic tropism. Indeed, mice depleted in 
coagulation factors were able to restore a full level of transgene expression in liver only in the 
presence of FX. Based on cryo-microscopy results it has been proposed that FX through its GLA 
domain is able to interact with hexon protein. By substituting all HVRs of Ad5 with those from 
serotype 48 it has been shown that these variable domains are involved in interaction with GLA 
domain of FX, suggesting the differences in FX binding between various Ad serotypes (Waddington et 
al., 2008). More precise analyses based on directed mutagenesis revealed that FX binds HVR5 and 
HVR7 of Ad hexon (Vigant et al., 2008; Alba et al., 2009), and single mutation T425A in HVR7 can 
efficiently disrupt Ad-FX interaction (Doronin et al., 2012). While bound to Ad hexon, FX is able to 
interact with HSPGs, however, this interaction is restrained only to HSPG possessing N- and O- linked 
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sulfate group. These are found predominantly on hepatocyte surface which explains Ad5 liver 
tropism despite HSPG ubiquitous expression (Bradshaw et al., 2009). 
The discovery that FX is involved in bridging the Ad to the liver HSPGs through interaction 
with hexon resulted in series of studies investigating the outcomes of this interaction ablation on Ad 
biodistribution. Ad vector mutated in hexon, unable to interact with FX showed markedly decreased 
liver uptake upon i.v. injection of both low (1x10
10 
vp) (Alba et al., 2010) and high dose (1x10
11 
vp) 
(Vigant et al., 2008; Alba et al., 2010). Interestingly, vectors ablated in interaction with FX were still 
efficiently uptaken by KC, and depletion of these cells resulted in high vector accumulation in spleen. 
Thus, for the vaccination studies it might be thus interesting to disable the interaction of Ad with KC 
in order to target spleen more efficiently. At a high dose, this detargeted vector induced strong 
chemokine and cytokine production and more vigorous Th1 responses (Alba et al., 2010). The same 
team evaluated a vector combining ablation in both hexon-FX and penton-integrin interactions 
(Bradshaw et al., 2012). They observed that additional mutation in RGD motif resulted in attenuated 
spleen uptake and reduced inflammatory responses. Contradictory results were obtained in mice 
lacking Ext1, an enzyme required for heparan sulfate biosynthesis, resulting in 8-fold decrease in 
hepatocyte HSPG level. Surprisingly, Ad vector of native tropism as well as Ad vector ablated in 
interaction with CAR were still able to efficiently transduce the liver of these animals, suggesting an 
alternative pathway of hepatocyte entry, not involving HSPGs nor CAR (Zaiss et al., 2016). This sheds 
a new light on molecular mechanisms of in vivo cell entry of Ad vector and underlines the need for 
further examinations in order to fully understand Ad behavior in vivo. 
2.2.3 Immunogenicity of Ad vector 
2.2.3.1 Innate immune responses to Ad vector 
Adenovirus hallmark is the potency to induce robust innate and adaptive immune responses. 
Intrinsic immunogenicity of viral capsid was unveiled by McCoy et al., who showed that innate 
responses induced by Ad vectors were transcription-independent (McCoy et al., 1995). Strong 
production of pro-inflammatory cytokines and chemokines was linked to virus interaction with its 
cellular receptors as well as to its recognition by cytosolic, membranous and secreted PRRs (Figure 
2.9).  
Before entering the cell, virus interactions with CAR and integrins set in motion intracellular 
MAP kinases and PI3 kinase signaling pathways, leading to the production of IL-1, IL-6, IL-12, TNF-α 
and type-I interferons (IFN-I) (Philpott et al., 2004; Tamanini et al., 2006). Additionally, Ad activates 
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cell-surface located TLR2 (Appledorn et al., 2008). More recently, role of FX-coated Ad as a TLR4 
activator has been proposed, as vector ablated in FX binding failed to activate TLR4/TRAF6/NF-κB 
pathway in vivo (Doronin et al., 2012). However, these observations obtained in mice model were 
not confirmed using human mononuclear phagocytes (Echhotz et al., 2015), and thus the role of FX 
remains unclear. C-type lectins receptors (LR), such as cell surface sialic-acid binding 
immunoglobulin-like lectins (Siglecs) and cytosolic galectins have also been shown to recognize Ad 
(Rademacher et al., 2012). LRs directly bind sugars of the Ad capsid and crosstalk between LR and TLR 
signaling has been observed, indicating that LRs enhance the innate immune responses against Ad 
(Kawai and Akira, 2011). Upon internalization into the endosomes, viral particle activates TLR9 
(Appledorn et al., 2008), resulting in IFN-I responses and subsequently, after escape into the 
cytoplasm, becomes recognized by AIM-2 like receptors (ALRs) and NOD-like receptors (NLRs) leading 
to inflammasome formation and pro-IL-1β cleavage (Barlan et al., 2011; Stein and Falck-Pedersen, 
2012). Through cytosolic machineries sensing foreign nucleic acids, viral DNA and virus-associated 
RNAs lead to, respectively, DDX41 /cGAS-dependent (Nociari et al., 2007; Lam et al., 2014) and RIG-I 
dependent (Minalitani, et al., 2011) IRF3 activation and IFN-I production. All these branches of innate 
immunity sensing conjointly lead to the “cytokine storm”, which has been shown to interfere with 
transgene transcription from the viral vector (Sung et al., 2001). 
Extracellular factors are known to influence Ad innate immunity. Defensins, antimicrobial 
peptides secreted mostly by neutrophils are able to bind to Ad and interfere with the exposure of 
lytic protein VI from the capsid (Snijder et al., 2013). As previously mention, Ad coating with FX not 
only was proposed to stimulate TLR4, but also thought to protect virus from the attack of natural Abs 
and the complement (Xu et al., 2013). Ad in complex with Abs is known to activate the classical 
pathway of complement and be captured and cleared by KC more efficiently (Xu et al., 2008). By 
using different strains of immunodeficient mice it has been shown that the presence of natural IgM 
Abs plays a pivotal role in hepatocyte infection by Ad ablated in FX binding. In vitro studies disclosed 
that FX binding to Ad hexon prevents the natural IgM Abs from deposing the complement proteins 
on Ad surface by (Xu et al., 2013). Another interesting mechanism involving Abs is the activation of 
cytosolic Fc receptor TRIM21 by Ad-Abs immune complexes (McEwan et al., 2013). Upon immune 
complex uptake, recognition of Fc part of Ab by TRIM21 triggers a signaling cascade, which 
independently of TLRs and RLRs pathways results in the activation of transcription factors such as NF-
κB, AP-1, IRF3, IRF5 and IRF7 and subsequent production of pro-inflammatory cytokines. 
Interestingly, this was observed for both IgM and IgG, indicating that this mechanism plays a role 
during both primary and secondary Ad infection. This intracellular Ab sensing should be taken under 
account while designing Ad vector for vaccination purposes in pre-immune individuals (McEwan et 
al., 2013). 
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Figure 2.9. Innate immune response induced by Ad. Adenovirus can activate various 
pathways of innate immunity, such as Toll-like receptors (TLRs), AIM2-like receptors (ALRs), NOD-like 
receptors (NLRs) and RIG-I-like receptors (RLRs), lectin receptors LR as well as cGAS/DDX41/STING 
interferon signaling pathway. Additional factors have been described to influence the innate Ad 
sensing, such as coating with FX, intracellular antibodies or defensins. Virus early proteins (in red) as 
well as Virus associated RNA (in yellow) can antagonize induction of innate immunity (Hendrickx et 
al., 2014). 
2.2.3.2 Humoral immune response to Ad vector 
Adenovirus induces strong Ab titers directed against major capsid proteins: hexon, fiber 
and penton (Gahéry-Ségard et al., 1998; Hong et al., 2003). The majority of neutralizing Abs was 
shown to target HVRs of hexon, and substitution of the entire hexon or solely HVRs with those from 
another serotype allowed the chimeric vector to escape the neutralization (Sumida et al., 2005; 
Roberts et al., 2006; Bradley et al., 2012). Nevertheless, a subdominant population of fiber 
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knob-directed Abs was proved to be relevant, as Ad5 vector pseudotyped with both HVRs and fiber 
knob coming from heterologous serotype evaded pre-existing Ad5 immunity more efficiently than 
vector with alteration in HVRs only (Gahéry-Ségard et al., 1998; Bradley et al., 2012). Still, anti-fiber 
Abs on their own are not sufficient for vector neutralization, as sera from mice immunized with Ad7 
failed to neutralize Ad5 vector pseudotyped with Ad7 fiber (Gall et al., 1996). Interestingly, it has 
been observed that while anti-fiber Abs subpopulation is quite modest during the first injection (Gall 
et al., 1996), it is more easily detected after subsequent vector administrations (Gahéry-Ségard et al., 
1998; Sumida et al., 2005). The authors also suggested that anti-fiber Abs might act synergistically 
with those directed against penton (Gahéry-Ségard et al., 1998). 
Neutralizing Abs are targeting regions which vary significantly between the different 
serotypes. As a consequence, induced neutralizing Abs are not cross-reactive. However, non-
neutralizing, cross-reactive Abs induced after repeated Ad-administration can contribute to vector 
elimination by mechanisms like antibody dependent cellular cytotoxicity (ADCC), complement 
activation or opsonisation resulting in better Ad uptake by macrophages (Moffatt et al., 2000; 
Pichla-Gollon et al.,2009). Another aspect of Abs binding to Ad was described in previous section and 
involves activation of pro-infammatory cytokine production through cytosolic Fc receptor, TRIM21. 
2.2.3.3 Cellular immune responses to Ad vector 
Both early and late gene products are targets of CD4
+
 and CD8
+
 T cell responses (Yang et al., 
2003; Onion et al., 2007). Various T cell epitopes have been identified in Ad capsid proteins, with 
hexon being the immunodominant T cell target. The HLA-DP4–restricted, CD4
+
 T cell epitope 
H910-924 was mapped to the C-terminus of hexon sequence and described to be highly conserved 
among various Ad serotypes and recognized by up to 75% of healthy adults (Olive et al. 2002; Tang et 
al., 2004; Onion et al., 2007). Human cytotoxic CD8
+
 T cells are also targeting hexon C-terminus, 
where various cross-reactive class I epitopes have been localized, some of them overlapping H910-
924 epitope mentioned above (Leen et al., 2004, Tang et al., 2006). Cytotoxic responses against fiber 
and penton base were also observed in humans, although turned out to be much less potent and 
prevalent in the healthy individuals (Tang et al., 2006). Taken together these results underpin the 
observation that the most immunogenic entity of Ad is the highly conserved, distal, 100aa long 
sequence of hexon protein. In contrast to human cellular responses, cellular anti-Ad responses in 
mice were less extensively investigated. Nevertheless, in C57BL/6 mice (H-2
b 
haplotype), the 
immunodominant class-I epitope was located in DNA binding protein 43 (Dbp43) (Mc Kelvey et al., 
2004). 
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Cellular branch of pre-existing anti-Ad adaptive immunity in human might be more 
prevalent than the humoral one, as one of the studies showed that while only 28% of analyzed 
individuals displayed anti-Ad Abs, all of them had detectable level of anti-Ad T cell responses 
(Calcedo et al., 2009). These observations were confirmed by another team which in the evaluated 
group detected 64% of individuals possessing anti-Ad T cell responses, while only 55% of them had 
neutralizing anti-Ad Abs (Chirmule et al., 1999). The widely distributed Ad-specific T cells are also 
cross-reactive, as they target conserved regions. Isolated human Ad-specific CD4+ T cells were 
monofunctional, produced IL-2, IFN-γ or TNFα and expressed memory markers. On the contrary, 
CD8+ T cells were polyfunctional and displayed effector memory cell phenotype (Hutnick et al., 
2010). 
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2.3 Ad vectors in vaccination 
Ad5 vectors are the most frequently used vectors. Importantly, their intrincis adjuvant 
features provide valuable innate immune system stimulation, crucial in vaccine design. Nevertheless, 
neutralizing anti-Ad5 Abs are detected in 50-90% of a general population (Holterman et al., 2004) 
which precludes efficient gene transfer upon first vector administration. Additionally, strong humoral 
immunity as well as specific cellular responses (Tatsis et al., 2007; Tatsis et al., 2009) are induced 
after priming with Ad vector, thus impeding effective boosting with a homologous vector. The strong 
anti-vector immune responses elicited by Ad5 hamper expression of the transgene and reduce 
efficacy of this type of vaccination (described herein as classical vaccination) by limiting the quantity 
and duration of antigen availability (Schrimbeck et al., 2008). In order to overcome limitations of 
pre-existing Ad immunity different strategies of Ad-based vaccination were developed. 
2.3.1  Strategies to overcome anti-Ad immunity 
2.3.1.1 Alternative Ad serotypes 
One of the strategies to overcome anti-Ad immunity consists in shifting to different, less 
prevalent human Ad serotypes or non-human Ad. Among the most frequently used is serotype 35, 
evaluated as a vaccine platform against HIV-1 (Keefer et al., 2012) or malaria (Shott et al., 2008; 
Ouedraogo et al., 2011). Another often selected serotypes is Ad26, tested e.g. for a HIV-1 vaccine 
development (Baden et al., 2013), serotype Ad4, also encoding antigen from HIV-1 (Jeff et al., 2013) 
or Ad6 used in HCV vaccination (Chmielewska et al., 2014). Different appealing solutions proposed 
the use of vaccine vectors based on non-human Ad, such as simian, canine, bovine or porcine Ad 
(Bangardi, 2006). A strong interest was drawn to chimpanzee Ad (AdC), among which we distinguish 
9 serotypes with AdC68 being the most extensively used, usually as a HIV-1 vaccine (Fitzgerald et al., 
2003c; Pinto et al., 2003; Reyes-Sandoval et al., 2004). Although efficient upon first injection, these 
vectors are still triggering strong anti-vector immunity that hampers gene transfer upon homologous 
re-administration. 
2.3.1.2 Heterologous prime-boost strategy 
Human non-Ad5 serotypes were also tested for their performance in a heterologous 
prime-boost regimen. Serotypes 11, 35 and 49 were investigated for their ability to induce 
anti-transgene immune responses in an Ad5 pre-immunized background and Ad35-Ad49 regimen 
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turned out to be more potent than rAd35-rAd5 or rAd35-rAd11 regimens (Thorner et al., 2006). The 
combination of serotypes 11 and 35 were also used in a mixed prime-boost schedule to mount 
immune response against SIV (Lemckert et al., 2005). Similarly, Ad26 and Ad35 were tested for their 
combined efficacy in induction of adaptive immune response against SIV (Balandya et al., 2014) and 
Ebola (Geisbert et al., 2011), and in both cases robust anti-transgene cellular responses were 
detected. Heterologous prime-boost vaccination, however, requires construction of multiple vectors 
and assessement of their efficacy and safety, which is not only costly but also time consuming.  
2.3.1.3 Pseudotyping Ad capsid 
As an alternative to the heterologous prime-boost vaccination, Ad5-based vectors with 
geneticaly engeneered capsid were developed. Capitalizing on the knowledge of the Ad capsid 
protein structure, specific capsid alterations were made and by genetic engeneering allowed to 
obtain novel, more optimized vectors. Evaluation of Ad5 chimera bearing the fiber from Ad7 did not 
provide the capacity to escape Ad5 immunity, confirming that the main target of neutralizing Abs is 
hexon (Gall et al., 1996). The high conservation of hexon core allows for it interchanging between 
various Ad serotypes and for engeneering the chimeric viruses. Ad5 pseudotyped with entire Ad6 
hexon have been rescued and showed to be capable of evading anti-Ad5 responses (Youil et al., 
2002). Based on the fact that hexon loops comprising HVRs were shown to contain the main 
serotype-specific epitopes, Roy et al. substituted Ad5 L1-L4 hexon loops with corresponding 
sequences from Ad12. The vectors efficiently escaped pre-existing anti-Ad5 immunity (Roy et al., 
1998). Similarly, introducing L1-L2 loops from Ad2 in Ad5 background also significantly increased 
gene transfer of a chimeric vector in an Ad5-immune background (Gall et al., 1998). Nevertheless, 
these pseudotyped vectors were quite difficult to produce, and so an alternative strategy emerged, 
consisting in substituting exclusively hexon HVRs. Vectors based on Ad5 with all HVRs substituted 
with those from Ad48 efficiently escaped anti-Ad5 immunity, inducing cellular and humoral 
anti-transgene responses (Roberts et al., 2006). One study claimed that removing solely HVR5 is 
enough to induce significantly stronger cell-mediated anti-transgene responses in mice with 
pre-existing anti-Ad immunity (Abe et al., 2009).  
2.3.1.4 Shielding Ad vectors 
Another solution for counteracting pre-existing immunity in the classical vaccination 
approach with Ad vectors is based on biochemical modification of viral capsid (Kreppel and 
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Kochanek, 2008). Among the most popular modifications is PEGylation, consisting in coating viruses 
with PEG polymers which can mask Ad epitopes. Additionaly, PEGylation ablates the native Ad 
tropism and has been shown to reduce transduction of non-target tissues in vivo (O’Riordan and 
Song, 2008). These properties depend strongly on the PEG molecular weight. While small molecules 
may confer immune protection, bigger polymers are required to block CAR and integrin-mediated 
transduction in mice (Hofnerr et al., 2008). Another molecule successfully used for Ad capsid coating 
is poly(N-[2-hydroxypropyl]methacrylamide) (HPMA). HPMA coating on Ad provides protection from 
neutralizing Abs and complement and mediates a prolonged blood persistance of Ad particles in mice 
(Kim et al., 2012). 
2.3.1.5 Administration mode 
The mode of vector administration is another important aspect to consider while trying to 
avoid anti-Ad immunity. One study compared anti-transgene adaptive responses in mice upon 
intramuscular (i.m.), intranasal (i.n.) and oral vector administration (Croyle et al., 2008). While in 
naïve mice i.m. injection was triggering the most potent adaptive responses, the pre-existing Ad 
immunity did not hamper vaccination efficacy only in the case of i.n. administration. The frequency 
of IFN-γ
+
 CD8
+
 T cells was reduced in Ad-immune animals vaccinated i.m. and orally by 80% and by 
15%, respectively. This may be partialy due to the lower levels of anti-Ad Abs in mucosal sites than in 
the systemic circulation (Croyle et al., 2008). Another group also evaluated the performance of oral 
immunization with Ad vector and found that pre-existing anti-Ad immunity did not impair the 
capacity of mounting adaptive responses which displayed mixed Th1-Th2 phenotype (Xiang et al., 
2003).  While sytemic delivery induces mostly systemic immunity, with little or no effect on mucosal 
sites, mucosal administration is capable of eliciting both systemic and mucosal immune responses 
which makes it an appealing mode of vector delivery (Neutra and Kozlowski, 2006). This is especially 
attractive in the vaccination against pathogens having a tropism for mucosal sites, such as those 
spread through aerosols or sexual contact. 
2.3.2  Clinical trials in vaccination with Ad 
Several Ad-based vaccine vectors were evaluated in animal models.  Promising results 
obtained in these studies led to the clinical development of some vaccine candidates, notably against 
HIV, hepatitis C, malaria, H1N1 and H5N1 influenza A or tuberculosis. Ongoing trials are currently in 
different phases of clinical development, with the most advanced stages for HIV and malaria vaccine 
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candidates (figure 2.10 and figure 2.11). As for the end of January 2016, website of the U.S. National 
Institutes of Health (www.ClinicalTrials.gov) shows eighty-four search results with the keywords 
“Adenovirus Vector” and “Vaccination” and thirteen among them are currently recruiting 
participants. Thirty-nine studies are focusing on HIV vaccination, twenty-one are investigating Ebola 
vaccine, thirteen are analyzing anti-malaria immunization and five trials are evaluating HCV vaccine 
candidates.  
 
 
Figure 2.4. Use of viral vectors in clinical trials. The figure shows the number of gene 
therapy and vaccine clinical trials using adenovirus-, retrovirus- or other virus-derrived vectors  for 
the last 2 decades (Appaiahgari & Vrati; 2015). 
 
The most popular clinical trial using Ad vector, called STEP, was investigating the potential 
of replication-defective Ad5 vector expressing various HIV proteins (gag, pol and nef) (Buchbinder et 
al., 2008). At the beginning of 2004, around 3000 volunteers in various countries received the vector 
mixture. Despite repeated intramuscular injections of high virus dose (10
11
 viral particles per 
injection), the formulation was well tolerated. The vaccine proved to be immunogenic, as 75% of 
participants displayed anti-HIV T cell responses as measured by IFN-γ ELISPOT assay. However, the 
observation that vaccinated volunteers displayed higher rates of HIV infection than the 
placebo-receiving group led to the premature termination of the study in 2007. It has been 
underlined that individuals with an increased rate of HIV infection were mostly men having sexual 
intercourse with uncircumcised men and/or those who had elevated titers of pre-existing Abs to Ad. 
One of the possible explanations of this phenomenon indicates that pre-existing anti-Ad Abs 
influenced antigen presentation, causing a shift from Th1 to Th2 type of cellular response and thus led 
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to the reduction of protective anti-HIV CD8
+
 T cells. However, this seems to be unlikely, since Ad 
binding, non-neutralizing, cross-reactive Abs were detected in all the participants of the study, and 
there is no reason to assume that only neutralizing Abs influence the antigen presentation (Haut and 
Erlt, 2009). Hence, it remains ambiguous whether anti-Ad Abs indeed played a role in increased HIV 
infection rate and if so, what was the exact mechanism of this interrelationship.  
Another possible mechanism of the observed enhanced HIV infection is the vector-
mediated activation of Ad5-specific CD4
+
 T cells that became ideal targets for HIV infection 
(Buchbinder et al., 2008). This theory was also proposed in other studies, where administration of a 
pneumococcal-based vaccine or an influenza virus-based vaccine in HIV-1-infected patients showed 
that vaccination can lead to a temporary increase in viral load (Brichacek et al., 1996; Staprans et al., 
1995). However, other clinical trials using different vaccine platforms, also inducing CD4
+
 T cells such 
as poxvirus vector, did not increase susceptibility to HIV-1 infection. Interestingly, effectors T cells 
induced by these vaccines rapidly contract to form central memory cells while Ad, due to its 
persistence, stimulates a prolonged effector phase. This protracted presence of effector cells was 
proposed to be a possible explanation for the increase in HIV-1 acquisition rates observed in the STEP 
trial. 
 
 
Figure 2.5. Clinical development of Ad-based vectors. Pie chart indicates the number of 
clinical trials of different stages using Ad vectors. (Appaiahgari & Vrati; 2015). 
 
Another study developing HIV vaccine with Ad vectors, called HVTN, reached phase-II of 
clinical development. It consisted of priming with six DNA sequences encoding different HIV proteins 
(Gag, Pol, Nef and Env proteins), followed by an i.m. administration of 10
10
vp of Ad5 vectors 
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expressing the same HIV proteins. The study was suspended in 2013 due to the lack of efficacy in 
reducing the HIV infection rate or in alleviating the HIV infections (Hammer et al., 2013). 
Ad vectors based on less prevalent serotypes and xenotypes are used in a phase-I trial in 
the development of a HCV vaccine. HAd6- and ChAd3-based vaccine candidates encoding viral NS3 
protein were administrated i.m. in a dose varying from 5x10
8
 to 7.5x10
10
vp in different prime-boost 
combinations. Induction of strong, long-lasting and polyfunctional anti-HCV CD4
+
 and CD8
+ 
T cells 
responses was reported. Induced T cells were both of central and effector memory type and retained 
polyfunctionality and proliferative capacity (Barnes et al., 2012). Malaria is another pathogen 
targeted with the use of Ad vectors. Phase-IIa of Controlled Human Malaria Infection trial evaluated 
ChAd63 vectors expressing various Plasmodium malariae proteins, administered i.m. at a dose of 
5x10
10 
vp. Unfortunately, this study reported that the induced humoral and cellular responses failed 
to confer any protection (Sheehy et al., 2012). Another example of successful Ad application in 
vaccination field comes from the development of tuberculosis vaccine. An Ad35 vector expressing an 
antigen of Mycobacterium tuberculosis (AERAS-402), reached a phase-I study, where healthy 
volunteers, immunized with BCG in their infancy were given one i.m. injection (3.2 × 10
9
 vp). The 
vaccine was found to be safe, well tolerated in all the participants and capable of inducing adaptive 
immune responses. Interestingly, the vaccine was able to boost CD4
+ 
and CD8
+
 cellular responses in 
the group previously immunized with BCG. Of note, Ad5 pre-existing immunity did not affect the 
vaccination efficacy (Abel et al., 2010). 
Overall, despite STEP study, Ad vectors are consider to be relatively safe. In spite of some 
significant discoveries highlighting their vaccination potential, further improvements needs to be 
introduced to additionally increase their vaccination performance, especially in patients displaying 
pre-existing anti-Ad Abs. Among these various strategies allowing to circumvent anti-Ad5 immunity, 
Epitope Display approach seems to be taking the lead, and will be described in the Chapter 3. 
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3.1 Abstract 
Adenoviruses (Ad), originally vectorised for the purposes of gene therapy are becoming a 
very popular tool in the field of vaccination studies. Their highly immunogenic properties constitute 
a serious drawback to their application as gene delivery vehicles, due to the rapid elimination of 
transduced cells by host humoral and cellular responses. In far contrast, this ability to stimulate 
strong innate and adaptive immunity makes them an appealing platform for vaccination 
development. High level of transgene expression, capacity to infect dividing and non-dividing cells, 
lack of viral DNA integration into the host genome, relatively safe profile and ease of manipulation, 
these are only a few of the Ad features favoring their choice as a suitable immunization vehicles. 
Furthermore, their capacity to infect dendritic cells (DC) and to induce pro-inflammatory cytokine 
production results in eliciting a potent adaptive immunity and justifies why Ad are so heavily used in 
the vaccination field.  
Unfortunately, the presence of pre-existing anti-Ad serotype 5 (Ad5) immunity in a majority 
of population (50-90%) is hampering Ad5-mediated gene transfer. A few strategies have been 
proposed in order to overcome this limitation, such as virus capsid pseudotyping, replacing Ad5 with 
less prevalent serotypes or choosing non-human vectors.  
More recently, another strategy was developed, consisting in genetically inserting epitopes 
of interest into the proteins of Ad capsid. This review will present the state-of-art and current 
perspectives of this vaccination approach, called “epitope display”. First, simple modification in the 
capsid proteins, hexon, fiber, pIX or penton base will be described. Then, studies using vectors 
combining both epitope display and transgene-encoded antigen will be analyzed. We will finish by 
general conclusions of Ad epitope display vaccination performance and outline the remaining 
unanswered questions and the future perspectives.  
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3.2 Introduction 
3.2.1 Adenovirus 
Ad are non-enveloped, double stranded DNA viruses isolated for the first time 50 years ago 
from the human adenoid cells (Rowe, 1953). Since their discovery more than 55 serotypes have been 
distinguished, with serotype 2 and 5 being the most intensively studied and used in gene therapy and 
vaccination studies. Advances in structural biology techniques gave rise to the full, high resolution 
atomic structure of Ad (Liu et al., 2010; Reddy et al., 2010). The first generation of Ad vectors was 
established by deleting early gene E1 (Ad∆E1) and thus rendering them replication-defective 
(Danthinne and Imperiale, 2000). In order to expand the capacity of transgene accommodation these 
vectors were additionally deleted in E3 segment (Ad∆E1∆E3) which permitted to increase the cloning 
capacity up to 7,5 kb (Amalfitano et al., 1998).  Ad∆E1∆E3 are remaining the most frequently used Ad 
vectors in vaccination studies. 
3.2.2 Adenovirus immunogenicity 
Adenovirus hallmark is the potency to induce robust innate and adaptive immune 
responses. Intrinsic immunogenicity of viral capsid was unveiled by McCoy et al., who showed that 
innate responses induced by Ad vectors were transcription-independent (McCoy et al., 1995). Strong 
production of pro-inflammatory cytokines and chemokines was linked to virus interaction with its 
cellular receptors, as well as recognition by cytosol, membranous and secreted Pattern Recognition 
Receptors (PRRs). All this branches of innate immunity sensing lead conjointly to the “cytokine 
storm”, which has been shown to interfere with transgene transcription from the viral vector (Sung 
et al., 2001) and thus to limit the Ad efficiency in the classical vaccination strategy.  
Both early and late gene products are targets of adaptive immunity, which includes B cell, 
CD4
+
 and CD8
+
 T cell responses (Yang et al., 2003; Onion et al., 2007). Neutralizing Abs were shown to 
target principally HVRs of hexon (Sumida et al., 2005; Roberts et al., 2006; Bradley et al., 2012). 
Nevertheless, subdominant population of fiber knob-directed Abs was also detected (Gahéry-Ségard 
et al., 1998; Bradley et al., 2012). Various T cell epitopes, both for CD4
+
 and CD8
+
 lymphocytes have 
been identified in the Ad capsid proteins, with hexon being the immunodominant T cell target. (Leen 
et al., 2004 ; Olive et al. 2002; Onion et al., 2007 ; Tang et al., 2004; Tang et al., 2006). Cytotoxic 
responses against fiber and penton base were also observed, although turned out to be much less 
potent and prevalent in the healthy individuals (Tang et al., 2006).  
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3.2.3 Overcoming pre-existing Ad immunity 
Strong immunogenic properties of Ad are hampering expression of vector-encoded 
transgene and reducing efficacy of this type of vaccination (described here as the classical 
vaccination) by limiting the quantity and duration of antigen availability (Schrimbeck et al., 2008). 
Nevertheless, its natural adjuvant features provide valuable innate immune system stimulation, 
crucial in vaccine design. In order to overcome limitations of pre-existing Ad immunity and turn its 
properties in our favor, new strategies of Ad-based vaccination were developed. One of them 
comprises in shifting to different, less prevalent human Ad serotypes or non-human Ad (Keefer et al., 
2012; Shott et al., 2008; Ouedraogo et al., 2011; Baden et al., 2013; Alexander et al., 2013; 
Chmielewska et al., 2014). Different appealing solutions propose vaccine delivery vectors based on 
non-human Ad, such as simian, canine, bovine or porcine serotypes (Bangari, 2006), with the biggest 
interest drawn to chimpanzee Ad (Fitzgerald et al., 2003; Pinto et al., 2003; Reyes-Sandoval et al., 
2004). The human non-Ad5 serotypes were also tested for their performance in a heterologous 
prime-boost injections (Thorner et al., 2006; Lemckert et al., 2005; Balandya et al., 2014; Geisbert et 
al., 2011). This strategy, however, requires construction of multiple vectors and verification of their 
efficacy and safety, which is not only costly but also time consuming. Thus, as a simpler alternative, 
Ad5-based vectors with altered capsid proteins begun to be developed. The availability of its detailed 
structure enabled precise alterations and allowed to engineer novel, more optimized Ad5 vectors 
with immunodominant fragments deleted or replaced by those from less prevalent serotypes. 
Exchange of whole hexon protein resulted in generation of chimeric viruses (Youil et al., 2002) and 
Ad5 with alterations in hexon loops escaped pre-existing anti Ad5 immunity (Roy et al., 1998; Gall et 
al., 1998; Abe et al., 2009).  
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3.3 Epitope display 
Limited performance of classical vaccination strategy and availability of precise capsid 
protein alteration techniques led to the development of another solution for escaping neutralizing 
anti-Ad5 Abs “Epitope display” vaccination approach allows to bypass the gene-transfer stage of the 
antigen delivery by genetically inserting epitope of interest into the Ad capsid protein. Thus, epitope 
is available to the immune system as early as at the time of vector injection and pro-inflammatory 
ambiance provided by Ad5 ensures the stimulation of innate immunity and strong cytokine 
production. Moreover, the presence of various CD4
+ 
T cell epitopes in Ad capsid proteins could 
enhance the induction of adaptive immune response against the epitope, in agreement with the co-
called “carrier-hapten theory”.  
First application of this vaccination strategy dates to 1994, when insertion of an epitope 
coming from poliovirus VP1 capsid protein into the loop 1 of Ad2 hexon upon mice immunization 
resulted in serum able to recognize the VP1 (Crompton et al., 1994). Since this first experiment many 
other studies chose hexon as an insertion site, tempted by its great abundance and well 
characterized structure of highly variable and flexible loops. Progressively, other major proteins, such 
as fiber or penton base along with the minor pIX protein also gained focus.   
3.3.1 Hexon display 
Trimeric hexon protein, present in a total copy of 240 units organized in 20 triangular facets 
is the most abundant element of the icosahedrally shaped virion. In its structure we can distinguish 
the evolutionarily conserved core of the molecule, crucial for the capsid formation and weakly 
conserved loops exposed at the top of the molecule. Among these sequences seven Hyper Variable 
Regions (HVR) were originally described, later reclassified to nine (Crawford-Miksza and Schnurr, 
1996, Rux et al., 2004). They contain serotype-specific residues (Crawford-Miksza and Schnurr, 1995), 
remaining until today the most amenable sites for engineered modifications. More recently, HVR5 
and HVR7 has been shown to participate in bridging Ad5 to the heparan sulfate proteoglycans 
through interaction with blood coagulation factor X (FX) (Vigant et al., 2008; Alba et al., 2008). 
Comparative studies have been performed in order to detect the most accessible fragment 
in the hexon sequence of Ad5. One of them consisted in inserting his6 peptide into HVR2, 3, 5, 6, or 
HVR7. Epitope was shown to be well exposed on the native virion only when incorporated into HVR2 
and HVR5, weakly accessible in the context of HVR7 and not exposed in HVR3 and HVR6 (Wu et al., 
2005). Ad5 HVR2 and HVR5 were also evaluated in a different study for their flexibility in 
accommodating size-increasing peptides, ranging from 45 to 95aa (Matthews et al., 2008). HVR5 
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turned out to be more permissive and able to accommodate up to 65aa without losing virus viability, 
while HVR2 tolerated only 45aa peptide. Insert was accessible on the non-denaturated virion for all 
rescued viruses and induced humoral responses in C57BL/6J mice, with higher IgG titer for HVR5 
display. McConnell et al. in their study, using increasing size of epitope coming from Bacillus 
anthracis (B. anthracis) propose 36aa as a limiting size of Ad5 HVR5 insert in order to retain 
accessibility and ability to induce humoral responses in BALB/c mice. Attempts to detect cellular 
responses failed, which was justified by non-confirmed presence of T cell epitope within the selected 
antigen sequence (McConnell et al., 2006).  
Many studies used Ad5 HVR2 or HVR5 as an epitope insertion site for the vaccination 
purposes. Worgall and colleagues placed 14aa epitope of Pseudomonas aeruginosa (P. aeruginosa) 
outer membrane protein in the HVR5 of the hexon and upon mice vaccination detected humoral and 
cellular responses. High IgG titers and specific IFN-γ–positive CD4
+
 and CD8
+
 T cells conferred 
protection against pathogen challenge and could be boosted by second administration of the vector. 
Additionally, Abs titers significantly surpassed the outcome of vaccination with a homologous 
purified peptide immersed in Freud’s adjuvant (Worgall et al., 2005). Interestingly, differences in 
induced humoral responses were observed between three mice strains tested in this study, C57BL/6, 
BALB/c, and CBA. Titers of particular IgG subclasses varied significantly, shedding a light on the 
influence of MHC molecule allele on the induced immunity. HVR5 of Ad5 was also evaluated by our 
team and insertion of ovalbumin (Ova) epitope resulted in good peptide accessibility and strong 
humoral responses in C57BL/6 mice (Lanzi et al., 2010). Abs titers could not be significantly increased 
with repeated vector administration, because of the induced anti-Ad Abs masking displayed epitope. 
Palma and his group chose to investigate vaccination potential of HVR1-displayed epitope. 
To this end epitope from Plasmodium falciparum circumsporozoite protein was inserted into Ad5 
hexon and after confirming its accessibility, injected into C57BL/6 mice. Strong humoral responses 
were detected and the induced Abs were capable of recognizing P. falciparum sporozoites in vitro 
(Palma et al., 2011). Another study evaluating Ad5 HVR1 focused on vaccinating against 
Trypanosoma cruzi. Similarly, obtained results were promising, as humoral response induced in 
BALB/C or C57BL/6 mice after priming could be boosted in homologous injection and conferred 
protection in pathogen challenge test (Farrow et al., 2014).  
The permissiveness of HVR7-9 to peptide insertion was evaluated with the use of 
neutralizing B cell epitope of porcine reproductive and respiratory syndrome virus (PRRSV) GP5 
protein (Hansra et al., 2015). Vectors with an epitope placed in HVR8 and HVR9 could not be rescued, 
suggesting to us that Ad5 is unable to tolerate insertions in these sites. As for the HVR7 display, virus 
was viable, grew well in cell culture and the epitope was detected in vitro on the virion surface. No in 
vivo tests have been performed in this study. 
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Table 3.1. Vaccination studies using hexon display strategy. 
Vector Insertion site Type of 
modification  
Source of 
epitope 
Evaluated 
insert size 
Reference 
Ad5 HVR1 substitution 
or insertion 
P.falciparum 20 or 24aa Palma et al., 2011 
Ad5 HVR1 substitution  T.cruzi 24aa Farrow et al., 2014 
Ad5 HVR2 insertion HIV 39aa Matthews et al., 2010* 
Ad5 HVR2, 3, 5, 6 
or 7 
substitution 
or insertion 
His6 12aa Wu et al., 2005 
Ad5 HVR2 or HVR5 insertion RGD-his6 45 to 95aa Matthews et al., 2008 
Ad5 HVR1 or HVR5 substitution 
or insertion 
P. yoelii 18aa Shiratsuchi et al., 2010* 
Ad5 HVR5 insertion Influenza A 9aa Krause et al., 2006* 
Ad5 HVR5 substitution B.anthracis 16 to 245aa McConnell et al., 2006 
Ad5 HVR5 insertion P. aeruginosa 14aa Worgall et al., 2005 
Ad5 HVR5 insertion P. aeruginosa 14aa Worgall et al., 2007* 
Ad5 HVR5 substitution Ovalbumin 17 or 22aa Lanzi et al., 2010 
Ad5 HVR7, 8 or 9 insertion PRRSV 15aa Hansra et al., 2015 
replicative 
Ad5 
HVR1 inserion P.falciparum 24aa Karen et al., 2014* 
AdC68 HVR1 or HVR4 substitution 
or insertion 
 
Influenza 39aa Zhou et al., 2013 
Ad3 HVR1 substitution flag, flaghis6 or 
flaglgshis6 
 
8 to 19aa Zhong et al., 2012 
Ad3 HVR1 + HVR2 substitution EV71 15aa Xue et al., 2013 
Ad5 HVR1+ HVR2 
HVR1 + HVR5 
substitution HIV-1 and his6 6 or 7aa Gu et al., 2013 
* for detailed description see paragraphs 3.3.5. & 3.3.6. 
 
Zhou and colleagues compared vaccination performance of non-human vector, AdC68, 
displaying influenza virus epitope in HVR1 or HVR4 (Zhou et al., 2013). In vitro analysis revealed 
significantly reduced accessibility of influenza epitope in HVR4. These results were confirmed by 
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assessing IgG titers upon C57BL/6 and ICR mice immunization, which were much more modest in 
case of the vector displaying peptide in HVR4.  
Interesting approach was investigated by Zhong and co-workers. In their vaccination design 
multiple epitope peptide was placed into HVR1 of Ad3. Insert corresponded to flag, flaghis6 or 
flaglgshis6 sequence. Surprisingly, humoral response in BALB/C mice was raised against a new 
epitope, generated by adjacent sequences of flag, lgs and his6. As a result, Abs produced upon mice 
immunization with vectors displaying flaghis6 or flaglgshis6 sequences were not able to recognize 
GST-his6 and GST-flag fusion proteins in vitro (Zhong et al., 2012). This experiment underlines the 
necessity of incorporating the epitopes separately into different regions rather than simultaneously 
into one hexon site.  
In the following study the same team constructed and investigated multivalent Ad3 vector, 
barring two different epitopes of enterovirus type 71 (EV71) in HVR1 and HVR2 (Xue et al., 2013). 
In vitro as well as in vivo experiments indicated, that both epitopes were equally accessible and 
capable of inducing comparable humoral responses. Additionally, sera from BALB/C mice immunized 
by this bivalent vector neutralized EV71 more efficiently than sera of animals vaccinated with vectors 
displaying only one epitope. This suggests that accumulation of various epitopes on one viral particle 
could be a new promising vaccination strategy. 
Different conclusions, however, can be drawn from similar study performed by Gu and his 
team (Gu et al., 2013). HIV-1 epitope was placed in Ad5 HVR1 and, in parallel, His6 was introduced 
into HVR2 or HVR5. In vitro tests showed that all the epitopes are equally exposed on the virus 
surfaces. Nevertheless, upon BALB/C mice immunization significant differences were observed. Both 
viruses efficiently induced production of anti-HIV Abs, however His6 humoral response was detected 
only for the virus displaying this peptide in HVR5. These results suggest, that HVR2 in the context of 
another epitope placed in HVR1 may not be a suitable insertion site, as this combination could be 
detrimental to the in vivo presentation of the antigen, resulting in lack of antibody response. 
Whether the discrepancy between these two studies is a result of the difference in chosen epitopes 
or vector serotypes, remains uncertain. 
Taken together, the studies discussed above are signaling that the most promising site for 
epitope insertion in hexon is HVR5. It seems to tolerate the longest inserts without jeopardizing the 
virus viability or stability and induced humoral responses are strong and protective.  Other 
convenient sites for peptide display are HVR1, 2 and to much lesser extend 4 and 7. Tests evaluating 
HVR 3, 6, 8 and 9 permissiveness failed in producing the viable vectors, indicating that these regions 
may contribute to capsid formation and/or stability. As for the size of the displayed peptide, 
depending on the HVR, 45-66 aa seems to be the limiting length. The longer the inserts become, the 
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less infectious the rescued viruses are. One has to also be prudent while trying to insert epitopes in 
multiple HVRs, as this may result in their unequal accessibility. 
3.3.2 Fiber display 
Fiber protein in a non-covalent interactions with penton base protein generates a complex 
called penton, located in all 12 vertices or Ad capsid. It is a trimeric protein, protruding from the 
capsid surface, with three distinguishable structure domains. Conserved base is anchoring fiber to 
the penton base (Zubieta et al., 2005). The prolonged shaft with the repeating conserved KKTK motif 
plays a role in interactions with heparan sulfates proteoglycans (Dechecchi et al., 2000). Finally, distal 
knob is interacting with coxackie-adenovirus receptor (CAR) and displaying a flexible loops on its 
surface (Freimuth et al., 1999). Among them, HI loop was first chosen to be modified as is not 
involved in CAR interactions (Xia et al., 1994). 
The differences in the selected epitopes across the performed studies disabled the direct 
correlation between epitope insertion site and vaccination potential of recombinant vector until an 
elegant analysis performed by Krause. By introducing identical peptide coming from influenza A virus 
hemagglutinin sequence into HVR5 of hexon, C terminus of pIX, HI loop in fiber protein or the RGD 
motif in penton base, she concluded, that the most promising target for epitope insertion is the fiber 
protein (Krause et al., 2006). Despite in vitro analysis, indicating that all insertion sites resulted in 
almost equal epitope accessibility (with slightly higher Abs binding to hexon), upon in vivo 
immunization of three different strains of mice, C57BL/6, BALB/c, and CBA, fiber display elicited the 
highest IgG antibody titer. It was also the most potent in inducing IgM production in CBA mice. These 
results were obtained upon injecting the same amount of viral particles in each BALB/c experimental 
group but also when number of injected viral vehicles was adjusted in order to obtain equal epitope 
copy number for each group.  Evaluation of anti-hemagglutinin CD4
+
 T cell responses in CBA mice by 
ELISPOT assay also privileged fiber display as the most immunogenic. This observation was suprising 
taking into account the fact that this protein has 20 fold lower total copy number in one viral particle 
than the hexon protein.  
Our team also demonstrated the exceptional potential of fiber display in inducing strong 
humoral responses in C57BL/6 mice (Lanzi et al., 2010). By inserting Ova B cell epitope into the HI 
loop of this capsid protein we showed that after priming epitope placed in fiber is less immunogenic 
than hexon HVR5 display. However, upon second administration, fiber display induced higher anti-
epitope IgG titers, boosted more than 300 fold in comparison to the first injection, while no increase 
was observed for virus with epitope inserted into hexon. In order to understand the mechanism of 
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remarkable boosting potential of fiber display, splenocytes, CD4
+
 T cells, CD8
+
 T cells or serum from 
naïve or Ad-immunized mice were adoptively transferred into naïve recipient mice. Subsequent 
vector administration unmasked crucial role of anti-Ad Abs, as epitope placed in fiber elicited in this 
background stronger anti-Ova humoral responses than in naïve set-up. On the contrary, in the 
presence of anti-Ad sera, hexon display vector presented significant reduction of efficacy. We 
observe discrepancy between our and Krause’s studies. Contrasting observations of vectors 
vaccination potential upon one injection could result from different antigen choice, mode of 
modification (insertion vs substitution) or way of immunization (i.p vs. i.m.). 
 
Table 3.2. Vaccination studies using fiber display strategy. 
Vector Insertion site Type of 
modification  
Source of epitope Size of 
insert 
Reference 
Ad5 HI loop insertion Influenza A 9aa Krause et al., 
2006 
Ad5 HI loop substitution Ovalbumin 17 or 22aa Lanzi et al., 
2010 
Ad5 HI loop insertion P. yoelii 18aa Shiratsuchi et 
al., 2010* 
Ad5 CD, DE, FG or HI 
loop, C-terminus 
insertion P.aeruginosa 14aa Sharma et al., 
2013 
* for detailed description see paragraph 3.3.5. 
 
Various sites of fiber protein were evaluated for their peptide insertion permissiveness and 
vaccination potential. To this end, different vectors were constructed with epitope from 
P.aeruginosa OprF protein placed in loops CD, DE, FG, HI, fiber C-terminus and in hexon HVR5 
(Sharma et al., 2013). In vitro analysis showed that all fiber alterations resulted in decreased 
CAR-dependent infectivity, with the least reduction observed for FG and HI insertion. These two 
vectors also gave the most promising results during assessment of epitope accessibility on the intact 
virion, bypassing the hexon HVR5 display.  Subsequent in vivo studies in BALB/c mice confirmed the 
vaccination capacities of FG and HI display, which elicited IgM mucosal immunity and high IgG titers, 
overcoming after 3 injections those induced by Ad5 vector encoding OprF protein as a transgene. 
Cellular CD4
+
 and CD8
+
 IFN-γ responses induced by this vaccine vehicles were detectable, although 
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more modest than those found in mice vaccinated with transgene-encoding vector. Both branches of 
adaptive responses induced by epitope placed in FG and HI conferred protection against pathogen 
challenge. 
Studies using fiber as a site of epitope display are less numerous than those involving 
hexon. This may be caused by 36 fold lower abundance of this protein, misleadingly suggesting 
weaker stimulation of immune system. However, studies evaluating vectors with heterologous 
epitopes placed in this capsomer highlight its remarkable vaccination potential. In all three papers 
quoted in this section, immune responses induced upon several injections are more potent and 
stronger than for hexon display. In addition, in Ad-immunized background fiber-modified vectors 
seem to escape pre-existing immunity more efficiently, making them a very promising tool in Ad5 
vector vaccination. In all studies HI loop was successfully used as an epitope insertion site. However, 
FG loop turned out to be equally accessible and potent, creating an exciting possibility of inserting 
many epitopes in different fiber sites. 
3.3.3 pIX display 
Protein pIX is a minor components of capsid and it is stabilizing the architecture of the viral 
particle, acting as a “molecular glue” (Liu et al., 2010). It interacts with hexon-formed structures, 
called Group Of Nine (GON), which are forming each of the capsid faces. Thus, 240 copies of pIX can 
be found in one viral particle. Three domains have been identified in pIX structure:  conserved 
amino-terminal, central alanine-rich (found only in the human Ad serotypes), and conserved 
carboxy-terminal. In fully formed Ad structure amino-termini remain embedded in the GON while 
carboxy-termini is exposed on the surface, which makes it a promising locus for antigen insertion 
(Rosa-Calatrava et al., 2001). 
One of the first incorporation of heterologous peptide into pIX was described by Dimitriev, 
where carboxy-terminal Flag epitope introduced in pIX ectodomain did not alter virus infectivity and 
was shown to be accessible in vitro (Dmitriev et al., 2002). Subsequent experiments by fusing with 
pIX introduced into the Ad capsid the whole proteins, such as GFP (Meulenbroek et al., 2004), Herpes 
Simplex Virus Type 1 Thymidine Kinase (Li et al., 2005; Matthews et al., 2006), metallothionein (Liu et 
al., 2014) and single-chain or single-domain antibody fragment (Vellinga et al., 2007; Poulin et al., 
2010). These studies were aiming at analyzing vector biodistribution or altering its tropism. Another 
interesting study inserted complement-regulatory peptide in pIX in order to reduce the Ad-related 
pro-inflammatory cytokine and chemokine production, which could be especially advantageous in 
the field of gene therapy (Seregin et al., 2010). An insertion of single-chain T cell receptor directed 
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against the CT antigen melanoma-associated antigen (MAGE)-A1 in complex with the HLA class I 
molecule of haplotype HLA-A1 is a promising discovery with regard to Ad-based cancer therapy (de 
Vrij et al., 2008).  
As for the vaccination field, in the previously quoted study 9aa epitope of influenza was 
inserted into pIX. In vitro evaluation reported relatively weak peptide accessibility, completely 
abolished CAR-dependent virus infectivity and significantly reduced integrin-dependent cell entry 
(Krause et al., 2006). IgG titers induced upon vaccination didn’t reach the limit of detection. First 
successful experiment using pIX in vaccination field was perform by fusing Yersinia pestis V or F1 
antigen to its C-terminus (Boyer et al., 2010). For both antigens humoral responses were detected 
upon first injection into BALB/c mice and conferred protection in a pathogen challenge test. Second 
vector administration additionally ameliorated the efficacy of vaccination by increasing the 
anti-antigen Abs titers and protecting more mice from intranasal exposure to Yersinia pestis. Efficacy 
of epitope display strategy was also compared to the subunit vaccine performance, where molar 
equivalent of purified V or F1 proteins were administered with Alhydrogen adjuvant (aluminium 
hydroxide wet gel suspension). Much better results were obtained for antigen exposed on pIX, both 
on the level of Ig titers and pathogen challenge assay. This is in agreement with the study performed 
by Worgall et al., in 2005, where superiority of Ad over classical Freund’s adjuvant was 
demonstrated. 
Another study fused Friend murine leukemia virus (FMLV) gp70 protein to pIX (Bayer et al., 
2010).  As the vaccination regimens performed in this study comprised simultaneous vaccination with 
two different vectors, encoding or displaying various FMLV antigens, it is difficult to assess the exact 
contribution of each antigen form to the immunization outcome. Nevertheless, vaccination regimen 
including vector displaying antigen in pIX induced high binding antibody titers. The neutralizing titers, 
on the other hand, were markedly lower and CD4
+
 T cell responses were only weakly induced. The 
pIX antigen displaying vector needed additionally a transgene antigen form in its genome to trigger 
efficient response, which is described in more details in section 1.5.  
Prospect of inserting the whole protein in the Ad capsid ensures a few encouraging 
features. One of them is possibility of administering several relevant epitopes that could broader the 
induced immunity. Another advantage of this approach is the fact that B cell epitope in the context 
of the original protein will more likely acquire proper conformation. Despite these features pIX 
remains less frequently selected for this vaccination strategy than hexon or fiber. Big insertion 
capacity (up to 65 kDa by Matthews et al., 2006) of this minor Ad protein is favoring its application in 
gene therapy studies, where it gained more spotlight than in the context of vaccination. 
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Table 3.3. Vaccination studies using pIX or penton base display strategy.  
Vector Insertion site Type of 
modification  
Source of 
epitope 
Size of 
insert 
Reference 
 
pIX display 
Ad5 C-terminus insertion Influenza A 9aa Krause et al., 
2006 
Ad5 C-terminus terminal fusion Ovalbumin 
FMLV 
45kDa or 
70kDa  
Bayer et al., 
2010 
Ad5 C-terminus terminal fusion Yersinia pestis 37kDa or 
15 kDa 
Boyer et al., 
2010 
Ad5 C-terminus terminal fusion Ovalbumin 45kDa  Johrden et al., 
2013* 
 
penton base display 
Ad5 RGD loop insertion Influenza A 9aa Krause et al., 
2006 
Ad3 
dodecahedron 
RGD loop or N-
terlminus 
substitution Influenza A 18aa Szurgot et al., 
2013 
* for detailed description see paragraph  3.3.6. 
3.3.4 Penton base 
 Pentameric penton base is located in all 12 vertices or Ad capsid, resulting in total number of 
60 copies in one viral particle. The monomeric penton base shows high similarity to hexon in its 
topology with a jelly-roll barrel domain located at the base, responsible for fiber binding and two 
loops formed at the distal end, containing conserved RGD motif implicated in interaction with αv 
integrins (Zubieta et al., 2005). 
Studies using penton base as a platform are much less frequent than for previously 
described capsomers. Penton base permissiveness for epitope insertion was first evaluated by Krause 
 86
et al., in 2006. Epitope from influenza was placed in RGD loop, which resulted in good accessibility 
and Ab recognition in vitro. However, infectivity test showed that both CAR- and integrin-dependent 
pathway of infection was notably diminished. ELISA test failed to detect the induction of humoral 
response upon C57BL/6 or BALB/C mice vaccination. Interestingly, when using different mice strain, 
CBA, a weak signal was detected, suggesting small production of Abs. To our knowledge, after this 
first study there was no trial that successfully introduced heterologous epitopes into the penton base 
of the Ad viral particle for vaccination purposes. However, Ad3 dodecahedrons (Dds) were evaluated 
for their vaccination potential. Dds are VLP structures lacking viral genome, formed solely by penton 
base and recognized for their extraordinary capacity to enter the cells (Fender et al., 1997). T cell 
epitope from Influenza M1 protein was selected and placed in variable loop or at the N-termini of 
penton base (Szurgot et al., 2013). In vitro tests confirmed efficient uptake and cross-presentation of 
inserted antigen. After chicken immunization, Influenza-specific CD4
+
 and CD8
+
 cellular responses 
were induced. Addition of Freud’s adjuvant did not result in reinforcement of induced response, 
emphasizing the dodecahedron adjuvant potential.  
It would be interesting to compare vaccination performance of epitope display on 
dodecahedron and full Ad particle in one study in order to elucidate if efficient dodecahedron uptake 
could balance impoverished number of Ad-associated CD4
+
 T cell epitope number. 
3.3.5 Combining epitope display strategy with classical vaccination 
The encouraging results of epitope display strategy led to the idea of combining this new 
immunization approach with the classical vaccination design. One of the first experiments 
investigating this idea was study performed with Ad5 vector AdOprF.RGD.Epi8, displaying 
P.aeruginosa B cell epitope coming from OprF protein (Epi8) in hexon HVR5 and encoding the whole 
OprF protein in the form of transgene (Worgall et al., 2007). Additionally, RGD motif was introduced 
into fiber knob to enhance DCs transduction in an integrin-dependent manner. Its vaccination 
potential was compared to Ad vector encoding OprF only. Two and four weeks after mice 
immunization no difference between IgG titers was observed between the groups. Analysis of Th2 
cellular responses showed similar level of Il-4 production. On the contrary, detection of IFN-γ 
demonstrated stronger CD4
+
 Th1 and CD8
+
 cellular response in mice immunized with vector 
combining epitope and transgene. This enhancement resulted also in better mice survival in 
P.aeruginosa pulmonary challenge test. Advantage of combining two vaccination strategies in one 
vector was also underpinned by results of boosting the immune response in a homologous injection. 
Antibody titers were increased only in the presence of OprF epitope in the capsid and this led to 
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better mice protection in pulmonary infection with P. aeruginosa. Nevertheless, it has to be 
underlined that differences in in vivo performance can also be related to better DCs infectivity by 
AdOprF.RGD.Epi8 due to the presence of RGD motif. 
Another study evaluated immune responses induced upon vaccination by Ad5 vectors 
encoding Friend murine leukemia virus glycoprotein g70 and/or displaying whole Env protein in pIX 
(Bayer et al., 2010). Boost injections for all groups of FV-susceptible CB6F1 mice were performed 
with the use of homologous vectors, having its Ad5 fiber pseudotyped with knob and shaft from 
serotype 35. After two injections vector displaying antigen in its capsid (without transgene) showed 
diminished viral load control, lower neutralizing Abs titers and lack of detectable CD4
+
 T cell 
responses. On the contrary, vaccination with the vector combining antigen in the form of transgene 
and a pIX display led to more efficient humoral and cellular responses. It is worth noticing that titers 
of total binding IgG Abs were similar for both transgene/display and display-only vectors. Differences 
in the neutralizing Abs concentration between those groups could result from much weaker 
CD4
+
 T cell response upon immunization with vector displaying the g70, causing the lack of Abs 
affinity maturation. This underlines the beneficial effect of the presence of CD4
+
 T cell epitope in the 
antigen sequence. Analogous vectors using Ova protein model were used to evaluate CD8
+
 T cell 
proliferations. Results of adoptive transfer with CFSE-stained, Ova-specific CD8
+
 lymphocytes, 
analyzing kinetics of the response, again privileged vector combining two vaccination strategies 
(Ad5.pIXova) over classical vaccination vector (Ad5.ova). Production of IFN-γ, Il-2 and TNFα by 
CD8
+
 T cells, contrarily, was similar for both groups. Vector carrying antigen in pIX but not in the form 
of transgene was not tested in this part of study.  
Matthews and colleagues proposed combining hexon HVR2 display of B cell epitope from 
HIV Env protein, MPER, with HIV Gag protein provided in the form of transgene (Matthews et al., 
2010). In this design the displayed epitope is not additionally present in the sequence of encoded 
protein and combining this two different antigens in one viral particle serves rather as a “vaccine 
cocktail”, stimulating simultaneously anti-Env humoral response and anti-Gag cellular immunity. 
Control vector were also constructed, encoding Env or Gag only, as well as vector carrying B cell 
epitope in HVR2 without transgene. After confirming in vitro transgene expression and epitope 
accessibility on the capsid surface mice were immunized twice in a homologous injection design. 
Vectors displaying MPER epitope elicited specific, strong humoral responses and were able to boost 
it upon second administration. Surprisingly, no anti-MPER Abs were detected in group vaccinated 
with Ad encoding whole Env protein. This was explained by the fact that Env, as a precursor protein, 
is cleaved into g41, comprising MPER epitope, and g120. Production of the latter could mask the Ab 
recognition of gp41. Additional presence of Gag transgene, providing CD4
+
 T cell epitopes did not 
enhanced anti-MPER Ab titers. Evaluation of Gag-specific cellular response revealed no significant 
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difference between epitope display/transgene and transgene-only groups. On the contrary, upon 
boosting, vector encoding Gag and carrying MPER in HVR2 was able to reinforce anti-Gag CD8
+
 T cell 
response. These results could be limited by weaker anti-Ad immune response triggered by vector 
with alteration in hexon.  
Interesting study combining transgene expression with fiber and hexon display in one viral 
particle was performed by Shiratsuchi and his team (Shiratsuchi et al., 2010). In a Plasmodium yoelii 
circumsporozite (CS) protein model different recombinant Ad were constructed. All of them were 
encoding whole CS protein in their genome (WT/CS-GFP) and additionally some of the vectors were 
displaying CS B cell epitope in one of the following sites: hexon HVR1 (B-HVR1/CS-GFP), hexon HVR5 
(B-HVR5/CS-GFP), fiber HI loop (B-Fib/CS-GFP)  or simultaneously in hexon HVR1 and fiber HI loop 
(B-HVR1/B-Fib/CS-GFP). Interestingly, CS peptide placed in fiber was recognized in vitro to the similar 
extend as during its incorporation into hexon, although total copy number differs 20 fold.  While 
after single vector administration no difference was observed among the groups, upon three 
injections of increasing virus doses into mice, Ab titers recognizing the displayed epitope were 
significantly higher for all capsid modified vectors while compared to WT/CS-GFP. Sera from mice 
injected with B-HVR1/CS-GFP and B-HVR1/B-Fib/CS-GFP were the most potent in Plasmodium yoelii 
CS neutralization test in vitro, proving their ability to recognize not only synthetic peptide but also 
native epitope. Adding additional epitope copy in fiber does not seem to increase the efficacy of 
HVR1-display immunization. Cellular responses, on the contrary, were weaker for all the groups 
having epitope placed in capsid proteins, resulting probably from altered infectivity of this vectors as 
shown in vivo. However, in mice with pre-existing anti Ad5 immunity only HVR1/CS-GFP and 
B-HVR1/B-Fib/CS-GFP could elicit CD8
+
 T cell immunity, hinting about the presence of Ad5 
neutralizing epitope in HVR1. Pathogen challenge assay showed that injections with HVR1/CS-GFP 
protected mice better than immunization with WT/CS-GFP. 
Non-human Ad was also assessed for the potential of mounting potent adaptive immune 
responses in this vaccination strategy. Chimpanzee-derived AdC68 vectors were generated, 
displaying B cell epitope from influenza M2 protein ectodomain in hexon HVR1 or HVR4. Additional 
vectors were produced by introducing the sequence encoding NP-M2e fusion protein into the 
genome of wild-type or M2e-modified hexon (Zhou et al., 2013). All vectors induced detectable 
anti-M2e responses in mice, however, both Ad vectors with epitope in HVR1 triggered markedly 
higher anti-M2e Abs titers. Double injection with these constructs resulted in stronger humoral 
responses than in a group undergoing heterologous injection of AdC68 and AdC6 vectors, both 
encoding NP-M2e. What is worthy of note, is that additional presence of antigen in a form of 
transgene did not enhance the strong vaccination performance of epitope displaying vectors as the 
titers were not increased. Nevertheless, Abs avidity was strengthened by concomitant NP-M2e 
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expression, suggesting that protracted display of transgene products over time droves maturation of 
B cells. Weaker efficiency of HVR4 display upon prime and boost could be explained by reduced Abs 
accessibility of this site observed in vitro. After priming NP-specific CD8
+
 T cells were detected for 
both hexon modified vectors encoding NP-M2e but their frequencies were not increased by boost 
injection. Induction of potent humoral and cellular responses by hexon modified vectors expressing 
NP-M2e conferred higher protection in a pathogen challenge assay than in case of epitope display 
only vector.  
The strategy to combine classical vaccination with new epitope display approach offers an 
interesting features. Transgene form ensures strong Abs production upon priming and peptide 
present in the capsid allows for efficient boosting of induced humoral response. By providing 
supplementary stimulation to the B cells, encoded antigen drives Abs affinity maturation and serves 
also as a target for cellular responses. 
3.3.6 Epitope display strategy in alternative context of vaccination 
Johrden with his group compared immunization potential of virus displaying Ova in pIX 
protein (Ad5.pIXova) with those of coated polystyrene particles loaded with recombinant Ova. 
UV-inactivated Ad5.pIXova (UV-Ad5
pIXova
) was also included in the study to evaluate the influence of 
in vivo viral genome expression (Johrden et al., 2013). Upon two injections, Ad5.pIXova induced the 
most significant IgG1 and IgG2c anti-Ova Ab titers, surmounting humoral response triggered by 
UV-Ad5
pIXova 
or polystyrene-Ova particles. Similar patterns could be observed in the analysis of 
cellular CD8
+
 and CD4
+
 T cell responses, highlighting the importance of in vivo transgene expression. 
Ad vectors adjuvant properties were emphasized in in vitro DC activation assay, where Ad5.pIXova 
and UV-Ad5
pIXova 
induced IFN-α and IFN-β production comparable to LPS stimulation. 
Recently performed study evaluated in monkeys the vaccination potential of the replicative 
Ad vector, bearing B cell epitope from the circumsporozoite protein (CSP) of Plasmodium falciparum 
in the hexon HVR1 (Karen et al., 2014). Four Aotus nancymaae monkeys were used in this study. In 
order to confirm the virus ability to replicate, Ad vectors encoding GFP protein were first orally 
administered to 2 animals. Due to the problems with GFP detection following immunization schedule 
was based on direct delivery into the trachea by percutaneous puncture (IT), which resulted in 
efficient transgene expression. Interestingly, monkeys that first received orally GFP-encoding control 
virus responded differently to subsequent IT administration of epitope-display vector. These two 
animals developed high-level of anti-CSP responses as soon as after the first or the second 
intratracheal immunization. Monkeys which had not received oral immunization with control vector 
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displayed weak anti-CSP titers after the first exposure. The anti-CSP Ab titer gradually increased with 
the second and third virus administration, to finally reach the titer of orally pre-immunized mice. This 
highlights the very potent priming of oral virus administration and role of anti-Ad immunity in 
inducing the adaptive responses against displayed peptide. Produced anti-CSP Abs recognized 
full-length CSP expressed normally on the sporozoite surface. Result of sporozite neutralization 
in vitro varied significantly between the four tested animals. This could be the result of slight genetic 
differences of this outbreed monkeys. It would be interesting to compare in parallel the outcome of 
vaccination with the homologous, non-replicative vector. This could shed a light on the relevance of 
the presence of newly synthetized virus proteins and DNA on the vector immunogenicity. 
The importance of Ad proteins expressions in the context of efficient vaccination is still 
a burning question. The interesting conclusions could be drawn from the study where empty capsid 
or UV-inactivated vector were compared to non-replicative and replicative vector in a homologous 
setting. 
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3.4 Conclusions and perspectives 
Epitope display strategy is a promising approach to vaccinate against the infectious diseases 
and cancer. Genetic insertion of heterologous epitope of interest into the Ad capsid offers many 
advantages. One of them is contribution of invaluable adjuvant properties of Ad viral particles to the 
magnitude of anti-insert adaptive responses. Indeed, some studies discussed in this review compared 
that the same purified peptide, administered with a standard adjuvant such as Freund’s complete 
adjuvant, gives weaker immune responses than the same epitope in the context of Ad capsid 
insertion. This is due to the efficient stimulation of innate immunity by Ad but also, supposedly, could 
result from better access to APC and good peptide exposure on the capsid surface. It has been also 
suggested that repetitive display of the epitope on the capsid surface can lead to cross-linking of 
BCRs upon the peptide recognition. This can in turn activate B cells and reinforce humoral response.  
Techniques to enhance stability of the B cell epitopes conformations are also being developed and 
include use of special scaffolds, flanking the epitope by small sequences having propensity for folding 
into α-helix or adding the linkers to improve presentation. As for T cell epitopes, a few studies 
showed that flanking the selected peptide by 2-5aa long fragments coming from the natural protein 
sequence may enhance the epitope MHC presentation. 
Little is known about the molecular basics of the epitope display immunogenicity. Results of 
various studies show efficient induction of immune responses even in presence of preexisting Ad 
Abs, hinting that gene transfer is not necessary in order to mount efficient immune responses against 
the displayed epitope. Dodecahedrons particles, deprived of viral DNA, were still able to trigger 
strong cellular responses against inserted influenza T cell epitope. This suggests that stimulation of 
TLR9 or cytosolic DDX41 /cGAS, the innate sensors for Ad DNA, is not a crucial step in the induction 
of adaptive responses against the heterologous peptide. Results obtained with UV inactivated Ad, 
however, suggest that DNA cross-linking diminishes the vector performance. It would be interesting 
to compare in parallel the immunogenicity of dodecahedron particles, Ad viral particles deprived of 
viral genome, so-called Ad empty capsids and fully formed Ad particles.  One would assume that due 
to the lack of many additional Ad CD4
+ 
epitopes present in the hexon protein, dodecahedrons would 
display the weakest immunogenic potential. Also, role of another Ad associated PAMPs, such as TLR2 
or TLR4 remains to be elucidated. 
Another factor having an impact on the vaccination outcome is MHC molecules allele 
variability. Evaluation of humoral responses in different strains of mice disclosed that T cell epitope 
comprised in the sequence of displayed peptide plays a big role in the total IgG production and 
influences percentage of particular IgG subclasses contribution to the final titer. This genetic 
restriction of vaccination performance suggests that vectors displaying B cell epitope with 
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intrinsically embedded T cell epitope can induce different humoral responses in immunogenetically 
heterogeneous population, depending on the avidity of peptide anchoring to MHC molecule as well 
as on the strength of interaction with TCR.  
The importance of T cell epitope presence was confirmed in studies combining B cell 
epitope display with the whole antigen protein encoded as a transgene. Even though the total Abs 
amount was not altered by the additional presence of transgene antigen, the neutralizing Abs titer 
and the avidity was significantly enhanced. Helper T lymphocytes induced against the supplementary 
epitopes provided by encoded heterologous protein along with protracted display of the transgene 
contributed to additional B cell activation and maturation of humoral response. On the level of 
cellular responses, there are strong evidences favoring antigen administration in the form of 
transgene as both CD4
+
 and CD8
+ 
are stronger and confer better protection against pathogen. 
Nevertheless, as far as humoral response is concerned, transgene form of antigen on its own, 
although capable of inducing high antibody titers, was unable to further increase the Ig production 
after second administration. On the contrary, epitope display, especially in fiber protein, upon 
several administrations triggered as potent humoral immunity as transgenic form of antigen or even 
surpassed it. Hence, the interest of combining this two vaccination strategies in one viral particle 
would assume strong induction of both cellular and humoral responses by transgene antigen upon 
priming and contribution of capsid-displayed epitope to further increase in Abs titers upon boosting. 
Discovery of various sites in the Ad capsid, permissive for epitope insertion, created an 
opportunity of placing more than one copy of epitope, or what’s more, inserting two different 
peptides in one viral particle. Simultaneous display of identical peptide in hexon and fiber protein 
revealed that additional epitope copy in fiber did not further enhanced good immunization 
performance of hexon display. Studies evaluating the vaccination with two different epitopes in 
various hexon HVRs shown that concomitant display may result in unequal vaccination potency, 
presumably due to the sterical hindrance and uneven access to the epitopes. This results, however, 
vary depending on the size of inserted epitope or the distance between insertion sides in the final 
confomation of hexon protein. So far, no study has evaluated the immunization abilities of vector 
with alteration in two distinct sites of fiber. In regard to its remarkable boosting potential this could 
generate very promising tool in vaccination field.  Exploiting multiple insertion sites in the Ad 
capsomers is a very appealing strategy, especially since it has been shown that placing multiple 
epitopes in one single site results in humoral responses targeting new epitopes generated by 
adjacent peptide sequences. 
Another limit is the insert size that particular capsomer is able to tolerate. Hexon has been 
evaluated for their insertion capacity and depending on the HVR, peptide of up to 30-40aa seems to 
be the limiting size. Even though viruses with longer epitopes have been obtained, their infectivity 
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and stability was decreased. As for fiber loops, 22aa is the longest insert successfully introduced into 
its structure. No study so far investigated the ability of this capsomer to accommodate increasing 
peptide fragments. Protein pIX, on the other hand, possess a remarkable ability to display not only 
the selected peptides but also the entire heterologous proteins. This is of big interest not only in the 
vaccination field but also in gene therapy where the entire therapeutic protein needs to be provided 
to counteract the pathology. 
Except T cell epitope from influenza A placed on Ad3 dodecahedron surface, no other study 
so far evaluated the outcome of vaccination with Ad displaying CD8
+
 T cell epitope. Whether this 
strategy would repeat the success of B cell epitope display, remains to be elucidated. In case of 
obtaining sufficient cellular response stimulation, combining T cell and B cell epitope display on one 
viral particle could be an interesting perspective. 
Finally, another viruses were also used as a vaccine platform in this approach. A study using 
Influenza virus, Vaccinia virus or Rabies virus vectors displaying B.anthracis epitope showed that only 
heterologous injection consisting in priming with Influenza vector resulted in production of 
neutralizing Abs (Langley et al., 2010). This is a drawback in comparison to Ad efficiency, where the 
same vector can be re-injected in order to reinforce potent adaptive responses.  Rabies virus 
pseudotyped with SIV-1 glycoprotein, however, triggered production of neutralizing Abs and cellular 
responses controlling viremia in rhesus macaques (McKenna et al., 2004). Adeno-associated virus 
(AAV) was also tested and B cell epitope form Ova placed in its surface protein induced humoral 
responses (Manzano-Szalai et al., 2014). Still, for each vector administration an additional adjuvant 
was included, masking the natural adjuvantic properties of AAV. 
All things considered, in spite of certain limitations Ad vectors remain one of the most 
promising platform in vaccination field. Epitope display vaccination strategy, reviewed in this paper, 
proved its efficacy in a various vaccination designs. Nevertheless, a few questions still remain to be 
answered and further investigation of molecular mechanisms of this relatively new immunization 
approach could result in a very potent vaccination tools. 
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4 Hepatitis C virus  
Hepatitis C virus (HCV), identified in 1989, is a major human pathogen causing chronic 
hepatitis and related liver pathologies. Infection often goes unnoticed for a long time as virus 
manifests itself very slowly, initially displaying only flu-like symptoms. Being able to persist and 
replicate undetected for many years, HCV slowly and gradually attacks the liver, where it can cause 
cirrhosis or cancer. Around 180–200 million people are now predicted to be infected worldwide and 
the virus continues to spread in developing countries. It is estimated that more than 350,000 people 
worldwide die from HCV-related liver disease every year. The current treatment is expensive, 
generates heavy side effects and its efficacy depends on the HCV genotype. All these constraints 
underline a need for a successful HCV vaccine, which so far is not available.  
4.1 Molecular virology of HCV  
HCV belongs to the Flaviviridae family of viruses, which share some specific molecular 
characteristics of capsid structure and genome organisation. Among members of this family we can 
find dengue fever virus, yellow fever virus, tick-borne encephalitis virus or Japanese encephalitis 
virus.  
 
 
Figure 4.1. Genetic organization and polyprotein processing of HCV. Hepatitis C virus 
genome is flanked with 5’ and 3’ non-coding regions (NCR). Following IRES-mediated translation, one 
polyprotein is generated which upon cleavage by viral and cellular proteases give rise to 10 proteins. 
Structural proteins C, E1 and E2 form viral capsid, while non-structural proteins p7, NS2, NS3, NS4A, 
NS4B, NS5A and NS5B perform various functions during virus life cycle (Moradpour et al., 2007). 
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4.1.1 Genome 
HCV genome in the form of positive single stranded RNA is divided in three regions: a 5′UTR 
or noncoding region, a 9000 nucleotides long open reading frame (ORF) and a short 3′UTR (Figure 
4.1). The 341 base long 5’UTR contains the internal ribosomal entry site (IRES) which after binding to 
the 40S ribosomal subunit forms a translation pre-initiation complex (Thurner et al., 2004). This 
region is the most conserved one in the whole HCV genome. The 3’UTR plays a role in minus-strand 
priming during HCV replication (Thurner et al., 2004). In the ORF, the structural proteins are encoded 
by the N-terminal part while the remaining part codes for the non-structural proteins. 
4.1.2 Proteins and capsid structure 
HCV genome encodes one polyprotein, which after cleavage by viral and cellular proteases 
generates 10 proteins, roughly divided into structural and non-structural proteins (Figure 4.1).  
4.1.2.1 Structural proteins 
One of the three non-structural proteins is the nucleocapsid-forming core protein. This 
RNA-binding protein has been reported to interfere with numerous cell mechanisms by interacting 
with a variety of cellular proteins (Ray& Ray, 2001). It has anti- and pro-apoptotic functions (Meyer et 
al., 2005) and is involved in carcinogenesis as well as in lipid metabolism (Moriya et al., 1998; Moriya 
et al., 1997). 
Two remaining proteins forming the viral particle are glycoproteins E1 and E2, embedded in 
a host cell-derived lipid bilayer surrounding the capsid. These type-I transmembrane proteins 
assemble in a non-covalent heterodimer (Deleersnyder et al., 1997). Both proteins are heavily 
glycosylated, and some glycans were described to participate in proper protein folding as well as in 
interaction with cell receptors (Goffard et al., 2005). For that reason they are good targets for 
anti-HCV Abs. Indeed, in infected individuals the majority of circulating anti-HCV Absrecognizes 
epitopes present in E1 and E2 sequence (Keck et al., 2008; Meunier et al., 2008; Perotti et al., 2008). 
In the E2 protein sequence we distinguish fragments of very modest variability which are 
described as Hyper Conserved Regions (HCR). They are involved in binding to HCV putative receptor 
CD81. In these regions a few neutralizing epitopes were identified, such as 412–419aa epitope 
located in HCR1 (Zhang et al., 2007). In the sequence of E1 and E2 we can also distinguish areas with 
significantly increased mutation rate, and their variability is most probably driven by the pressure to 
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escape the immune system. They are described as Hyper Variable Regions (HVRs), and so far three of 
them were discovered. HVR1 maps to the first 27aa in the E2 ectodomain (residues 384–410) (Kato 
et al., 1992) and is recognized as the main HCV neutralizing epitope. Despite its big sequence 
variability, the overall conformation and positively charged amino acid residues at certain positions 
are conserved, in order to preserve the role of this region in virus attachment (Penin et al., 2001). 
Downstream of HVR1, 9 residues are forming HVR2 (residues 474–482) (Kato et al., 1992), a region 
involved in heterodimer formation, receptor binding and virus entry (McCaffrey et al., 2011). Finally, 
HVR3 (residues 431–466) was more recently identified and also seems to be involved in the cell entry 
process (Troesch et al., 2006).   
4.1.2.2 Non-structural proteins 
Seven remaining proteins obtained after the polyprotein cleavage are performing various 
functions during virus genome replication and formation of new virions.  
The p7 polypeptide is found on the junction between structural and non-structural 
proteins. This small membrane protein is involved in assembly and release of infectious virions 
(Steinmann et al., 2007). NS2 protein exerts protease activity and after self-cleavage from NS3 is 
degraded in the proteasome (Franck et al., 2005). NS3 is a multifunctional protein with serine-type 
protease domain in N-terminal end and a RNA helicase/NTPase domain in the C-terminus. Together 
with NS4A which is a cofactor for its protease activity, this protein is essential for the HCV life cycle.  
It catalyzes cleavage at the NS3/NS4A, NS4A/NS4B, NS4B/NS5A and NS5A/NS5B junctions, crucial for 
the generation of the viral RNA replication complex components. Consequently, NS3-NS4A protease 
is nowadays one of the most popular targets for directly acting antivirals (DAAs) in HCV treatment. 
NS4B is responsible for intracellular membrane alterations, serving as a mechanical support for the 
RNA replicating complex (Egger et al., 2002). NS5A regulates HCV replication, although its exact 
mechanism of action is not clear (Elazar et al., 2003). Finally, NS5B has activity of RNA-dependent 
RNA polymerase and is responsible for the synthesis of new copies of genomic RNAs (Ago et al., 
1999). Because of its nondispensable function in HCV life cycle, NS5B constitutes another major 
target for antiviral therapy (Scheel & Rice, 2013). NS5B lacks proof-reading function and it is one of 
the main reasons why HCV genotypes as well as quasispecies emerge so quickly. 
Non-structural proteins, and most importantly NS3 and NS5B are the main targets for 
cellular responses raised against HCV. Numerous class I-restricted epitopes were found in the NS3 
sequence (Cerny et al., 1995; Kurokohchi et al., 1996; He et al., 1999). Moreover, it has been 
described that patients responding to IFN-α therapy develop cytotoxic T lymphocytes specific for one 
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of these epitopes (Vertuani et al., 2002). These reports makes NS3 a promising vaccine candidate in 
the perspective of inducting a protective T cell-mediated immunity. 
4.1.2.3  Capsid structure 
First analysis of the virus morphology revealed a 30-60nm particles (He et al., 1987; Yuasa 
et al., 1991). Subsequent tests involving detergent treatment of infectious sera disclosed 30-40 nm 
icosahedron-shaped particles containing both core protein and RNA (Takahashi et al., 1992). Similarly 
to the other members of Flaviviridae family, this nucleocapsid built-up from core protein 
ensapsidating the viral genome is enveloped by a host-cell derived lipid bilayer. E1 and E2 viral 
glycoproteins are embedded as heterodimers into the viral envelope (Figure 4.2). 
 
 
Figure 4.2. HCV viral particle structure. Viral genome is enclosed in a capsid formed by a core 
protein. Viral capsid is enveloped by a bilipid layer originating from host cell membranes into which 
glycoproteins E1 an E2 are embedded (Sharma, 2010). 
 
The circulating HCV particles can be present in various forms. In the sera of infected 
individuals two distinct virus populations were found. One of them comprised infectious virus 
particles in interaction with low-density lipoproteins (LDL) and very-low-density lipoproteins (VLDL) 
(Andre et al., 2005). In parallel, immune complexes of HCV particles associated with 
immunoglobulins are also present, and considered to be less infectious (Andre et al., 2002; Hijikata et 
al., 1993; Thomssen et al., 1992). Interestingly, proportions between these two subpopulations 
reflect the stage of liver disease and fluctuate over the course of infection (Kanto et al., 1994; Petit et 
al., 2003). Non-enveloped nucleocapsids were also found in the sera of infected patients. Recent 
findings suggest that they can enter immune cells, such as B- or T cells. Once inside CD4
+
 T cells, they 
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are capable of activating production of IL-2, IL-10, and IFN-γ, which in turn can lead to partial T cell 
exhaustion and Treg expansion (Doumba et al., 2013). 
4.1.3 HCV live cycle 
HCV has a very restricted host range as it infects only humans and chimpanzees. This pathogen 
displays strong liver tropism, albeit infection of DCs, B cells and other cell types has also been 
reported.  
4.1.3.1 Cell attachment and entrance 
Circulating HCV gains access to the liver through liver sinusoidal endothelial cells (LSECs) and 
Kupffer cells (KC). These cells, respectively, express on their surface liver/lymph-node-specific 
intercellular adhesion molecule 3-grabbing integrin (L-SIGN) and dendritic-cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin (DC-SIGN). Both molecules are able to bind E2 
glycoprotein with high affinity, and presumably to transfer virus to hepatocytes (Figure 4.3). 
 The first stage of HCV life cycle is the attachment to its receptors on the hepatocytes. The 
most important role in HCV cell entry is played by CD81, class B type I scavenger receptor (SR-BI), LDL 
receptor (LDLR) and two proteins found in tight junctions, occludine-1 (Ploss et al., 2009) and 
claudin-1 (CLDN1). 
CD81 and SR-BI are considered as main HCV entry receptors (Pileri et al., 1998; Scarselli et al., 
2002). CD81 is a tetraspanin found on many cell types. SR-BI is a fatty acylated protein found in lipid 
raft domains, highly expressed on hepatocytes (Babitt et al., 1997). Both CD81 and SR-BI interact 
with E2 glycoprotein, however, amino acid residues in E2 sequence involved in this binding remain to 
be identified. E2 region 502-520aa is a possible candidate, as mutations in this region influence HCV 
usage of SR-B1 and CD81 receptors (Harman et al., 2014). CD81 and SR-BI are both crucial, but not 
sufficient factors for HCV cell entry, as non-hepatocyte cells expressing these two molecules remain 
not permissive for the infection (Bartosch et al., 2003).  
LDLR is an endocytic receptor, involved in lipoprotein transport into the cells through 
receptor-mediated endocytosis (Chung and Wasan, 2004). It is implicated in the HCV infection 
process due to virus interactions with LDL and VLDL, and most probably serves as an initial anchoring 
molecule (Wunschmann et al., 2000). Other molecules involved in HCV cell entry are 
glycosaminoglycans (GAG), ubiquitously expressed on various cell types. HVR-1 of E2 has been shown 
to bind HSPG with a strong affinity, and this interaction, along with binding to LDLR, is docking HCV 
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particle to the host cell surface. While attached to the cell, HCV particle can subsequently interact 
with main entry receptors, CD81 and SR-BI. Claudin-1, a tight junction component, was more recently 
identified as another entry receptor (Evans et al., 2007).  
 
.  
 
Figure 4.3. HCV entry. HCV initial attachement to cell surface involves low density lipoprotein 
receptor (LDLR) and glycosaminoglycans (GAG) and allows for subsequent interaction with class B 
type-I scavenger receptor (SR-BI), CD81 tetraspanin and claudin-1 (CLDN1). Upon clathrin-dependent 
internalization, in acidified endosome, viral envelope bilayer fuses with endosome membrane 
releasing viral capsid into the cytoplasm (Moradpour et al., 2007). 
 
HCV enters the cell in a clathrin-dependent manner and entering particles are associated 
with CD81 and CLDN1 (Blanchard et al., 2006; Coller et al., 2009). Once internalized, the virion is 
transported to early endosomes where, in a presumably pH-dependent manner, fusion between viral 
and host membranes takes place. Then, the nucleocapsid gains access to the cytosol, where viral RNA 
is translated to viral polyprotein and initiates viral replication. 
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4.1.3.2 Translation 
The internal ribosome entry site (IRES) element, present in the 5′-UTR of the viral RNA is 
able to directly bind ribosomal subunit 40S. This interaction allows for the recruitment of the 
translation complex to the viral genome and helps to overcome the need for the capping process. In 
order to initiate the translation of its proteins, HCV needs host cellular factors, such as eukaryotic 
initiation factors (eIF)-2 and -3 (Ji et al., 2004; Otto and Puglisi, 2004). Upon translation of one ORF, 
the long polyprotein is generated and subsequently cleaved by host and viral proteases, as indicated 
in section 4.1.2.2. 
4.1.3.3 Replication 
HCV genome replication is a semi-conservative and asymmetric process. In the first turn 
negative-strand intermediate is synthesized using positive-strand genome RNA as a template. This 
RNA of negative polarity serves as a template to produce numerous copies of positive strand 
genome, which will subsequently serve in the process of polyprotein translation, synthesis of new 
replication intermediates or will be encapsidated in new virus particles (Bartenschlager et al., 2004). 
The replication of HCV genome takes place in special alterations of ER membranes induced 
by NS4B, called membranous web. This solution offers a few important advantages, such as local 
concentration of viral products, physical support and arrangement of replication complex and 
stabilisation of viral RNA during unwinding. Additionally, this organization provides protection from 
the host defence mechanisms or RNA interference and facilitates access to lipid factors, crucial for 
the replication (Penin et al., 2004). Pivotal role in replication process is played by NS3, NS4B, NS5A 
and NS5B viral proteins as well as cellular proteins, such as phosphatidyl-inositol-4-kinase-III (PI4KIII) 
(Reiss et al., 2011), ARFGAP1 (Li et al., 2014) or vesicle-associated membrane protein-associated 
protein A (VAP-A) and VAP-B (Paul et al., 2013). Lipid droplets are also found in the membranous web 
and most probably are playing an important part in viral RNA synthesis and new virion 
morphogenesis (Miheyanari et al., 2007). 
4.1.3.4 New virions formation and release  
The process of HCV assembly and release appears to be closely linked to lipid metabolism. 
Newly produced homodimerized core proteins are transferred to cytosolic lipid droplets (Barba et al., 
1997), which seems to be an essential step for the recruitment of remaining viral proteins implicated 
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in virion assembly. Indeed, mutations blocking interaction between core and lipid droplets 
dramatically alter assembly of new virus particles (Boulant et al., 2007). The newly produced viral 
genome copies are directed to the assembly sites thanks to the NS3/4A or NS5A protein. In parallel, 
glycoproteins E1 and E2 mature in ER, undergoing glycosylation and forming a heterodimer 
(Dubuisson et al., 1994). Then, thanks to the interactions between E1 and NS2 as well as E2 and p7, 
E1E2 complex approaches lipid droplets where virion assembly takes place (Ma et al., 2011). 
Subsequent steps of virions assembly are tightly related to VLDL secretion pathway, as virion is 
associated with lipids resembling in their composition VLDL and LDL (Huang et al., 2007). Thus, 
apolipoproteins such as apoE or apoB associate with new virion and are also considered essential for 
the final assembly. Finally, after budding from the ER, HCV particles are transported through the 
secretory pathway to the cell surface where they are released (Figure 4.4). 
 
 
 
Figure 4.4. HCV replication and new virions assembly.  Upon polyprotein cleavage, the 
non-structural proteins associate with cellular factors to form double-membrane vesicles known as 
membranous web where replication takes place. Core protein is then loaded onto lipid droplets (LDs) 
which interact with the ER-embedded replication-complex to create the virion assembly site. 
Replicated viral genomes, through the interaction with NS3/4A or NS5A, are transferred to the 
assembling virions. Glycoproteins are brought to the assembly site via NS2 and p7. Subsequent 
events of HCV virion morphogenesis are tightly related to the VLDL assembly metabolism, albeit this 
process is poorly understood (Dubuisson & Cosset, 2014). 
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Interestingly, direct cell-to-cell transmission is observed in cell culture (Brimacombe et al., 
2011) and in the patient’s liver (Wieland et al., 2014). This process could explain ability of this virus to 
remain ignored by the immune system and thus persist in the organism. The detailed mechanism of 
this process remains unknown, however CD81, occludin and CLDN-I were shown to be crucial in this 
event (Brimacombe et al., 2011). 
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4.2 HCV infection, pathogenicity and treatment 
High mutation rate of HCV sequence, due to the high error rate of viral RNA-dependent 
RNA polymerase and the host immune system pressure, has led to the evolution of 11 different virus 
genotypes, differing in their nucleotide sequence by as much as 30%-50% (Wang et al., 2013). This 
sequence divergence causes significant discrepancies in virus responsiveness to the treatment. 
Moreover, after infection, virus gradually mutates inside the host, leading to the generation of 
so-called quasispecies, corresponding to closely related viral variants. This ability to quickly mutate 
allows the pathogen not only to evade the immune system and persist in the organism for decades, 
but also to acquire resistance to the applied treatment. Understanding both of these mechanism is 
crucial in order to more efficiently counteract HCV epidemic. For a long time possibilities to analyze 
this pathogen were very limited due to the lack of suitable infection model. Development of the HCV 
replicon strategy as well as establishment of adequate animal models allowed a better 
understanding of the virus life cycle (Uprichard et al., 2006). 
4.2.1  Interplay with the immune system 
Due to its vast arsenal of escape strategies allowing to hide from immune system HCV is 
a special challenge as a vaccine target. The virus is known to interfere and cause perturbation in the 
amount and functionality of various cells playing role in both innate and adaptive immune responses.  
Defects in the populations of Natural Killer cells, DCs, macrophages or T cells have been reported in 
chronically infected patients.  
4.2.1.1 Innate immunity 
Natural Killer Cell (NK) are one of the cells affected by HCV infection. This cell subset is 
involved in direct killing of endangered and pathological cells without MHC restriction. In acute phase 
of HCV infection NK display “active state” with enhanced cytotoxicity. In chronic infection, however, 
they become crippled in their cytotoxic performance and have a tendency to produce IL-10 and 
TGF-β. This impairs their capacity to activate DCs and favors the skewing of T cells into a Th2 T cells 
profile, more permissive for HCV (De Maria et al., 2007; Jinushi et al., 2004). 
DCs are both decreased in their number and impaired in functionality during chronic HCV 
infection. They do not display fully mature profile (Auffermann-Gretzinger et al., 2001) and secrete 
IL-10, thus generating immunosuppressive environment (Averill et al., 2007) and favoring 
proliferation of Treg subpopulation (Dolganiuc et al., 2008). Additionally, increased expression of 
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programmed death molecule ligand (PD-L1), having an inhibitory effect on T cells, was observed 
(Dolganiuc et al., 2008). 
Kupffer cells, liver-resident macrophages are also aberrant in HCV chronic infection. 
Similarly to DCs, they display PD-L1, along with another inhibitory molecule, galectine-9, also 
important in suppressing T cell responses (Mengshol et al., 2010). In parallel, HCV can activate 
secretion of IL-10 and TGF-β through the stimulation of TLR2/MyD88 pathway of signalization 
(Dolganiuc et al., 2004). 
All these alterations conjointly lead to insufficient and defective adaptive responses, that 
are described in the following paragraphs. 
4.2.1.2 Humoral response 
In viral infections, neutralizing Abs (nAbs) usually play a critical role. They help to control 
viremia and protect from re-infection. The majority on Abs generated during HCV infection is 
directed against glycoproteins E1 and E2. Their implication in controlling HCV pathogenesis remains 
a controversial issue. Studies in chimpanzees showed that administration of hyperimmune sera, 
targeting mostly HVR1 sequence, conferred protection against homologous HCV challenge (Farci et 
al., 1996). This was confirmed by the observation that induction of nAbs during the early stage of 
infection allows for HCV control (Pestka et al., 2007). On the contrary, the reports that the virus can 
be controlled in patients suffering from hypogammaglobulinemia suggests that Abs are not required 
for HCV eradication (Semmo et al., 2006). It is now believed that in the context of chronic infection 
delayed antibody response allows for development of viral mutants with escape mutations at Ab 
epitopes (Zeisel et al., 2008). In parallel, an interesting mechanism allowing HCV to escape the 
humoral response was described. It involves the induction of interfering Abs, non-neutralizing 
immunoglobulins directed against HCV. Upon binding to the virus they are masking the neutralizing 
epitopes and thus allow HCV to avoid neutralization (Zhang et al., 2007; Zhang et al., 2009). 
Additionally, lipoproteins associated with the virus could shield the viral surface glycoproteins and 
influence the induction of humoral responses (Tao et al., 2009). Similarly, glycans presented on E1 
and E2 by covering the neutralizing epitopes assure protection from neutralization (Helle et al., 
2011). Finally, ability to move between cells without entering the extracellular environment, also 
known as cell-to-cell spread, limits HCV arecognition by the humoral arm of the immune system. 
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4.2.1.3 Cellular response 
HCV-specific T cells can be detected in the organism around 4-8 weeks after the initial 
infection (Cox et al., 2005). During acute infection, induction of sustained, robust, and multi-specific 
CD4
+
 T cell responses correlates with the rate of spontaneous HCV clearance in both experimental 
models and infected patients (Lechner et al., 2000; Thimme et al., 2002). More precisely, 
Th1 CD4
+
 cells provide protection and ensures HCV control, while Th2 CD4
+
 cells lead to the 
development of chronic HCV infection (Tsai et al., 1997). HCV-specific CD4
+ 
lymphocytes play a key 
role in viral clearance by producing antiviral cytokines such as IFN-γ and by boosting the performance 
of antiviral B cells and CD8
+
 T cells. This contribution is underlined by a reduction of this population in 
the stage of chronic infection (Urbani et al., 2006).  Moreover, a strong correlation is found between 
the recurrent viremia and loss of CD4
+ 
T cell responses after initial viral clearance (Gerlach et al., 
1999), highlighting additionally the importance of these cells. 
Virus-specific CD4
+
 and CD8
+
 T cells found in chronically infected patients showed reduced 
proliferative response and impaired effector functions. Their specific cytotoxicity is hampered and 
IFN-γ production decreased (Gruener et al., 2001; Wedemeyer et al., 2002). Even though they are 
found in the liver with 30-fold greater frequency in comparison to peripheral blood (He et al. 1999), 
most of the time the phenotype of these T cells shows incomplete differentiation (Appay et al., 
2002). This disabled adaptive response is a result of many impairments in immune system 
functionality induced by HCV (Figure 4.5). 
Failure of T-lymphocyte responses in HCV chronic infection is primarily caused by 
exhaustion of these cells. Exhausted T cells are characterized by their inability to proliferate or 
secrete antiviral cytokines. One of the hallmark of this state is an upregulation of inhibitory 
receptors, such as PD-1, CTLA-4 or TIM-3 and low expression of CD127 (Radziewicz et al., 2007; 
Nakamoto et al., 2009; McMahan et al., 2010). Additionally, some studies reported that intrahepatic 
HCV-specific CD8
+
 T cells expressing high levels of PD-1 are likely to undergo apoptosis (Radziewicz et 
al., 2007). The presence of inhibitory cytokines is also influencing T cell exhaustion and in parallel 
favors development of Treg subpopulation. Production of IL-10 and TGF-β at high levels by innate 
immunity cells, such as DCs, macrophages or NK and by CD4
+
 T cells plays a pivotal role in this 
process. Additionally, insufficient DC maturation and reduced number of CD4
+
 T cells result in lack of 
adequate stimulation. HCV infection alters also liver chemokine profile and an increased CCL17 and 
CCL22 expression in this organ favors recruitment of Th2 and Treg, resulting in HCV persistence 
(Riezu-Boj et al., 2011). 
Another very important mechanism allowing to avoid cellular responses is the selection of 
escaping quasispecies dictated by the pressure of the immune system. High proliferation rate and 
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polymerase lacking proofreading function allow to rapidly adapt to the immune pressure through 
selection of escape, beneficial mutations. In the context of cellular responses, mutations were shown 
to influence epitope processing (Seifert et al., 2004), MHC binding (Chang et al., 1997) and TCR 
stimulation (Chang et al., 1997). In order to induce effective T cell responses against HCV, 
a conserved epitope needs to be selected that will not tolerate the mutations due to the high fitness 
cost (Uebelhoer et al., 2008). Among the suitable candidates, NS3 and NS5B proteins seem to be the 
most promising ones due to their critical role in HCV life cycle. 
 
 
Figure 4.5. Factors resulting in T cell exhaustion. The main factors contributing to the 
development of HCV-specific T cell exhaustion are i) inhibitory cytokines (IL-10 and TGF-β), ii) 
inhibitory T cell receptors (PD-1, 2B4, CD160, CTLA-4, KLRG1 and TIM-3), iii) Impaired allostimulatory 
capacity of DCs, iv) loss of CD4
+
 T cell help and v) inhibition by Treg cells (Brenndorfer & Sallberg; 
2012). 
4.2.2 HCV pathogenicity 
HCV spreads mainly through blood contact while sexual transmission accounts only for 
a minority of cases. Depending on the transmitted viral load, virus RNA can be detected in the blood 
between 1-3 weeks after infection (Farci et al., 1991). Along with the increase of viral genome yield, 
the concentration of serum alanine aminotransferase (ALT) also rises, indicating hepatic injury. Still, 
first stages of HCV acute infection usually pass unnoticed, as clinical symptoms are unspecific: 
fatigue, nausea, abdominal pain, loss of appetite or mild fever. Liver-related jaundice appears in 
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50-84% of individuals (Loomba et al., 2011). In some patients HCV infection can be self-limiting, and 
level of HCV RNA decreases below the threshold of detection in 3-4 months after the onset of acute 
infection (Santantonio et al., 2008). However, in 54-86% of cases, patients fail to clear the virus and 
chronic infection is established, defined by viral RNA persistence 6 months after the initial infection 
(Seeff & Hoofnagle; 2002). The factors influencing HCV eradication are not fully explored, but age 
(Vogt et al., 1999), sex (Bakr et al., 2006), or single nucleotide polymorphism in IL-28B locus (Ge et 
al., 2009) seem to be implicated.  
During the chronic infection, various extrahepatic manifestations (EHM) of the virus can be 
detected. Among the most relevant is mixed cryoglobulinemia, defined by the presence of Abs 
precipitating at a temperature lower than 37 °C. HCV infection influences insulin metabolism, and the 
prevalence of insulin resistance and type-2 diabetes is increased in chronically infected patients 
(White et al., 2008). Many others associated pathologies can be observed in e.g. neural system, skin, 
or eyes. Prolonged infection is linked to the development of liver cirrhosis. Viral proteins can 
interfere with various cell signaling pathways and mechanisms. These interactions lead to the 
deregulation of cytokine production and subsequently to the excess in synthesis and deposition of 
extracellular matrix (ECM). The matrix metalloproteinases (MMPs) are unable to remove all the ECM 
excess, and thus the balance between fibrogenesis and fibrolysis is disturbed. TGF-β is the most 
potent pro-fibrogenic cytokine released during inflammation. It is produced at high levels by 
deregulated cells of the immune system, described in previous sections, thus favoring cirrhosis 
developement.  
Ultimately, chronic HCV infection can lead to the hepatocellular carcinoma (HCC). It is 
estimated that HCV infection in responsible for approximately 25% of HCC cases (Tanaka et al., 
2006).  As in fibrosis process, the main reason for HCC development is the interaction of viral 
proteins with host cell proteome. Various proteins, such as core protein, NS3, NS5A and NS5B display 
an oncogenic potential, mostly by deregulating the cell cycle control or apoptosis (Table 4.1). It has 
been described that core protein is a sufficient factor to induce HCC in transgenic mice (Moriya et al., 
1998). This protein is implicated in the apoptosis, cell proliferation and formation of reactive oxygen 
species (Kang et al., 2009). NS3 was shown to interact with p53 and inhibit activity of p21 (He et al., 
2003). Besides its interaction with p53 (Lan et al., 2002), NS5A induces also chromosome instability 
(Wu et al., 2008). Finally, NS5B is promoting cellular proliferation by downregulation of Rb protein 
(Munakata et al., 2007).  
Additional stimulation in the process of HCC development is provided by the chronic 
inflammation established in the liver, most probably resulting from the cell cycle deregulation. This 
state is presumably involved in the increase of mutation rate, and thus HCC development and 
progression (Fabregat et al., 2009). Nevertheless, the exact molecular mechanism of this process are 
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not fully understood. It is estimated that establishment of this pathology can take around 10-30 
years after the initial HCV encounter. Until today, HCC treatment is very limited. There is no effective 
chemotherapy available and patients with small and slow-growing tumors usually undergo liver 
transplantation. The benefit of this operation is hampered by the frequent recurrence of HCC in the 
graft. It is thus crucial to limit the viremia at earlier stages of HCV pathology to prevent HCC 
developement. The arsenal of available compounds counteracting chronic HCV infection is described 
in the next section. 
 
 
Table 4.1. Interactions of HCV proteins with cellular proteins favoring oncogenesis (Ming et al., 
2015). 
 
4.2.3 Treatment of HCV chronic infection  
For a long time the “golden standard” of anti-HCV therapy was a combination of IFN-α and 
ribavirin. Both compounds were limiting HCV infection in an unspecific manner. IFN-α is boosting the 
immune system and inducing anti-viral state in uninfected cells. Its efficacy in infected individuals 
was proven even before the identification of HCV as a causative agent. Nevertheless, monotherapy 
was long and had limited success (Di Bisceglie et al., 2002). Addition of ribavirin significantly 
improved the therapy outcome, raising the sustained virologic response (SVR) rate to 35-40% 
(McHutchison & Poynard, 1999). Ribavirin is a guanosine analogue and can prematurely block virus 
RNA replication (Maag et al., 2001). In another proposed mode of action, the molecule is causing an 
“error catastrophe” by increasing the mutagenesis rate in HCV genome, especially in NS5A region 
(Contreras et al., 2002).  
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Further improvement in the regimen performance was achieved by covalently attaching the 
polyethylene glycol (PEG) molecule to recombinant IFN-α. It resulted in longer drug half-life and thus 
better pharmacokinetic performance. This ameliorated combination of (PEG)-IFN-α and ribavirin 
raised the treatment efficacy to 54-56% (Manns et al., 2001). Depending on the genotype, therapy 
lasted 24 or 48 weeks and was associated with various severe side effects, such as anemia, flu-like 
symptoms, irritability, depression, anxiety or fatigue. Interestingly, the therapy outcome was strictly 
linked to HCV genotype, with the worst predictions for genotype 1, being also the most prevalent in 
US and Europe (Hézode et al., 2014). 
 
Figure 4.6. Currently evaluated DAAs inhibiting HCV viral replication. In order to 
counteract virus replication, different proteins crucial for this process are targeted by directly acting 
antivirals (DAAs). Among them the most promising targets are NS3/4A, NS5A and NS5B and their 
inhibitors are already FDA approved or still evaluated in clinical trials (Lam et al., 2015). 
 
A new era in HCV treatment began with the discovery of the first generation of directly 
acting antivirals (DAAs). Initially, the attention was drawn to NS3 protease inhibitors, and the first 
molecules of this type, boceprevir and telaprevir, became available in 2011.  They were included in 
the standard (PEG)-IFN-α/ribavirin treatment of patients infected by HCV genotype 1, rising SVR to 
70%. Notwithstanding, even though new drugs proved themselves efficacious in fighting the virus, 
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they added additional layer of side effects. Another burden was a necessity of high dose 
administration, resulting in the intake of as much as three pills per day (Hézode et al., 2014). 
Subsequently, treatment focus expanded to other non-structural proteins involved in virus 
replication: NS5A and NS5B. Many molecules are already approved by US Food and Drug 
Administration (FDA) or are currently being evaluated in clinical trials (Figure 4.6). Among the most 
intensively discussed molecules is Sofosbuvir. It is a uridine nucleotide pro-drug, whose active 
metabolite is incorporated into virus RNA by NS5B, resulting in chain termination. It was first 
approved by FDA in December 2013 and released by Gilead under the market name Sovaldi®. This 
drug is used in clinics in combination with ribavirine or (PEG)-IFN-α/ ribavirin, in patients infected 
with virus genotype. In late 2014, the same company obtained FDA approval to introduce to the 
market single tablet regimen (Harvoni®) for the treatment of genotype 1 chronic HCV infection. It is 
a combination of Sofosbuvir and Ledipasvir, an NS5A replication complex inhibitor. In 12 week 
treatment this (PEG)-IFN-α/ribavirin-free regimen leads to the SVR in around 97-99% of individuals. 
Another combination of drugs involving Sofosbuvir was accepted in late 2014 for the treatment of 
genotype 1 patients. Janssen Therapeutics supplemented the Gilead’s Sofosbuvir with their drug 
named Olysio®, containing NS3/4A inhibitor, Simeprevir. Combinations of Sofosbuvir with different 
molecules e.g. Daclatasvir, are also being tested (Hézode and Bronowicki, 2016).  
Various cocktails of DDAs are currently being used in patients. Ribavirin, due to its low price 
and good tolerability in IFN-free regimen still remains a useful tool. It can improve the results of anti-
HCV regimens and allows to reduce the treatment duration. The final combination of DDAs +/-
ribavirin is tailored to each patient, depending on the HCV genotype, previous HCV treatment history 
and outcome as well as the eventual presence of liver cirrhosis (Hézode and Bronowicki, 2016). 
Unfortunately, the majority of current DAAs does not have a pan-genotypic efficacy. Also, new DAAs-
based therapies are very expensive and associated with secondary effects. Altogether, this still makes 
a discovery of an effective cross-reactive anti-HCV vaccine a high priority, not only to prevent the 
initial infection but also to counteract re-infection after successful cure with costly DAAs (Walker and 
Grakoui, 2015). 
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4.3 Vaccination against HCV  
Vigorous humoral and cellular responses are associated with better resolution rate of HCV 
infection. Furthermore, individuals who managed to spontaneously clear the virus have significantly 
increased chances to prevent the virus persistence upon the second encounter. This advocate the 
demand for the development of a successful vaccine. Since the discovery of the virus as a causative 
agent of hepatitis C, many vaccination strategies were evaluated. Until today, a few vaccine 
candidates based recombinant proteins, synthetic peptides, DNA plasmids or recombinant viruses 
have been tested in non-human primates and humans (Ghasemi, 2015).  
4.3.1 Peptide vaccines 
Peptide vaccine IC41 developed by Intercell (Austria) consisted of five peptides derived 
from core, NS3, and NS4 proteins of HCV (genotypes 1 and 2) and was adjuvanted with 
poly-L-arginine. The results of a phase-I study in 128 HLA-A2
+
 healthy volunteers showed that IC41 is 
safe, well-tolerated and capable of inducing dose-dependent T cell reponses (Firbas et al., 2006). The 
same formulation was tested in 60 HLA-A2
+
 chronic HCV patients. Up to 67% of enrolled patients 
displayed T cell proliferation while IFN-γ responses were detected in almost 42% of individuals. 
Another team evaluated vaccination potential of peptide vaccine with synthetic peptides from E1, E2, 
NS3 and NS5A proteins immersed in incomplete Freund’s adjuvant. Results from 12 individuals 
showed induction of HCV-specific cellular responses in all patients and 3 of them showed reduction 
in HCV RNA levels (Yutani et al., 2007). 
4.3.2 Recombinant protein vaccines 
The first HCV vaccine based on recombinant protein tested in human was a truncated E1 
protein immersed in aluminum hydroxide adjuvant (T2S-918/InnoVac-C). The formulation showed 
induction of anti-E1 Abs in healthy individuals (Leroux-Roels et al., 2004). Another recombinant 
protein vaccine, based on E1E2 heterodimer with MF59C adjuvant, proposed by Chiron, was 
evaluated in 60 healthy individuals. It not only induced Ab production, but also provided stimulation 
for CD4
+
 lymphocytes, important in the control of acute hepatitis. This combination allows to 
neutralize virus infectivity but to also prevent persistence. The vaccine development was allegedly 
hampered by the problems with E1E2 manufacturing (Frey et al., 2010; Law et al., 2013). As another 
strategy Innogenetics NV (Belgium) proposed InnoVAC-C, a therapeutic vaccine candidate containing 
E1 protein in aluminum hydroxide adjuvant. Study in 122 chronically infected HCV subjects showed 
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an increase in anti-E1 Ab titers and presence of HCV-specific cellular responses but these responses 
did not stop the progression of liver disease and thus no further studies were performed 
(Wedemeyer et al., 2008).  
Core protein with ISCOMATRIX™ adjuvant was another vaccine candidate evaluated in 
a phase-I study enrolling 30 healthy individuals. Anti-core Abs were induced in 29 subjects, but 
anti-HCV T cell responses were detected in only two subjects (Drane et al., 2009). Another 
therapeutic vaccine candidate formulated with core and NS3 proteins was GI-5005. Results of phase-I 
clinical trial confirmed its immunogenicity in chronically infected patients. Subsequent evaluation of 
GI-5005 in combination with the (PEG)-IFN-α/ribavirin in phase-II study involving more than 250 
chronic HCV-1 individuals resulted in increase in their SVR (Habersetzer et al., 2009). 
4.3.3 DNA vaccines 
As for the DNA vaccination, CIGB-230 was the first vaccine candidate to reach clinical trial. It 
contained a mix of plasmids expressing Core/E1/E2 proteins and the core protein itself. The results of 
phase-I showed a production of neutralizing Abs and induction of core-specific T cell responses in the 
majority of individuals with half of them presenting an improvement in liver histology and fibrosis 
reduction (Castellanos et al., 2010). ChronVac-C proposed by the Tripep Company (Sweden) was the 
second DNA HCV vaccine to reach a human trial. This formulation, based on the conserved HCV 
regions (NS3/NS4A) was administrated to 12 chronic HCV individuals i.m. through electroporation 
(Sallberg et al., 2009). The results were promising, indicating the reduction of HCV RNA in 2/3 of the 
patients, and thus ChronVac-C is currently further investigated in a combination with standard 
IFN-based therapy in phase-II clinical trial (ClinicalTrials.gov Identifier: NCT01335711).  
4.3.4 Viral vector-based vaccines 
Viral vectors are another potent formulation in HCV vaccination and Ad vectors appears to 
be the most potent vaccine design for T cell priming in both non-human primates and humans 
(Casimiro et al., 2003). One vaccine candidate based on Ad was designed by Okairos (Italy). Initially, 
the vaccination schedule was based on a heterologous prime-boost regimen. Ad6 and AdC63 vectors 
encoding the entire genotype 1b NS3-NS5B region were constructed and induced both CD8
+ 
and CD4
+ 
cellular
 
responses in chimpanzees (Folgori et al., 2006). In later stages, these constructs were 
evaluated in 36 human volunteers having low risk of HCV exposure. The results were encouraging, as 
the induced T cell responses were multifunctional and cross-reactive (Barnes et al., 2012). Then, 
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a regimen modification was introduced, consisting in priming with chAd63 and boosting with 
modified vaccinia Ankara virus (MVA) (Swadling et al., 2014). This provided an increase in CD8
+
 and 
CD4
+ 
T cell frequencies and also ensured higher percentage of cells displaying central or effector 
memory cell phenotype. The currently recruiting phase-I/II study in high-risk individuals will provide 
us will important informations on the efficacy of this vaccine (ClinicalTrials.gov Identifier: 
NCT01296451). 
Another study evaluated MVA vector encoding HCV core, E1, E2 and NS3 genes in 
a heterologous prime-boost regimen with DNA vaccination in chimpanzees (Transgene). Upon 
immunization, strong anti-HCV CD4
+ 
and CD8
+
 T cell responses were observed. However, three out of 
four animals developed chronic infection upon pathogen challenge (Rollier et al., 2007).  
A MVA vector encoding NS3, NS4, and NS5B proteins has shown to be effective in HLA-A2.1 
and HLA-B7.2 transgenic mice, as it induced strong and long-lasting, cross-reactive, anti-HCV CD4
+ 
and CD8
+
 T cells. Moreover, 6 months later a boosting injection was able to recall these responses, 
indicating the induction of memory T cells by this construct (Fournillier et al., 2007). The same 
formulation (TG4040) was then assessed for its efficacy in 15 chronically infected HCV individuals. 
The induction of vigorous CD8
+
 T cell responses allowed for HCV viral load reduction in six of them 
(Habersetzer et al., 2009). After acceptable safety profile demonstrated in phase-I, TG4040 entered 
the phase-II of clinical trials in combination with (PEG)-IFN-α/ribavirin therapy (ClinicalTrials.gov 
Identifier: NCT01055821). A total of 153 individuals received the standard-of-care treatement either 
alone or in combination with 6 or 13 injections of TG4040. The results indicate that addition of 
TG4040 vaccine to (PEG)-IFN/Ribavirin treatement increases SVR rate. 
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Several advantages such as their ability to transduce different cell types, the high level of 
transgene expression as well as the ease of their manipulation and production makes Ad5 
a promising platform for vaccine development. Nevertheless, the efficacy of immunization with these 
transgene-encoding vectors is hampered by anti-Ad Abs, highly prevalent in the human population. A 
few strategies were proposed to overcome Ad immunity, among them epitope display vaccination 
approach, consisting in genetic insertion of selected epitopes into the viral capsid. Few teams, 
including ours, evaluated the immunization efficacy of Ad5 vectors carrying B-cell epitopes. We 
previously showed that B-cell epitopes (Ova323-339) derived from ovalbumin (Ova) model antigen, 
when inserted into Ad5 capsid, were capable to trigger anti-Ova humoral responses in both naïve and 
Ad5-immune mice. Moreover, a remarkable boosting potential was observed with an Ad displaying 
Ova epitope inserted into capsid fiber protein (Lanzi et al., 2011).  
The present studies seek to go further in our understanding of epitope display strategy of 
vaccination.  More precisely, the objectives of my thesis aims at i) understanding the parameters 
controlling the efficacy of Ad displaying B cell epitopes in fiber protein, ii) characterizing the capacity 
of Ad displaying T-cell epitopes to trigger cellular responses and iii) evaluating the potential of Ad 
displaying epitopes to elicit humoral and cellular responses against HCV.  
 
I) First objective: this part of my work was conducted to determine molecular bases controlling the 
induction of humoral responses by Ad displaying B-cell epitopes. For this, we took advantage of 
previous results of our laboratory showing the key role of Ad interactions with cellular receptors and 
factors in shaping Ad tropism and inflammatory profile. More precisely, mutations in hexon (HVR5 
deletion) and in penton base (RGD deletion) ablated Ad5 interaction with FX and integrins, 
respectively (Vigant et al., 2008; Vigne et al., 2003). Additionally, the modification of Ad5 fiber with 
Ad3 shaft was shown to reduce blood toxicity, cytokine production (Raddi et al., 2016) and liver 
uptake (Raddi, in revision). Based on these previous data, we introduced different capsid 
mutations/modifications in an Ad displaying Ova323-339 B cell epitope in the fiber protein in order to 
evaluate the influence of cell entry on vector vaccination potential. In parallel, we also pursued 
studies in mice deficient in innate immune pathways in order to understand their contribution to the 
establishment of humoral responses elicited by Ad displaying Ova323-339 in the fiber protein.  
 
ii) Second objective: previous unpublished data of our laboratory investigated the capacity of Ad 
displaying T cell epitopes inserted into hexon or fiber protein to induce anti-Ova cellular responses. 
Ad displaying Ova257-264 immunodominant T cell epitope were constructed and produced and 
preliminary results have confirmed their ability to trigger anti-Ova cellular responses (thesis 
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Anastasia Lanzi). To go further in the characterization of these vectors, we monitored the 
phenotypes and kinetics of anti-Ova cellular responses. In particular, these immune responses were 
assessed in both Ad-naive and Ad-immune mice in order to analyze the influence of pre-exiting Ad 
immunity on the efficacy of Ad displaying T cell epitopes. 
 
iii) Third objective: In this last part of my thesis, I applied the epitope display strategy of vaccination 
to a therapeutic target, HCV. To this end, HLA-A2-restricted, class-I epitopes from non-structural 
protein NS3 were inserted into Ad hexon or fiber protein. In parallel, Ad5 vectors displaying B cell 
epitopes from structural E2 protein were inserted into Ad hexon or fiber protein.  Ad displaying NS3- 
or E2-derived epitopes were produced, characterized and we assessed their ability to trigger cellular 
or humoral responses, respectively.  
 
For each of these objectives, the data obtained are presented as manuscripts in preparation in 
separate chapters of the results section.  
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PART 1 
 
Molecular bases controlling the 
efficacy of epitope display strategy 
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ARTICLE I 
TLR/MyD88 pathway but not the process of Ad infection shapes the humoral responses elicited by 
adenovirus displaying epitopes on their capsid. 
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Abstract 
 
Performance of adenoviral (Ad) vectors in vaccination studies is heavily limited due to the strong 
prevalence of anti-Ad antibodies, hampering vector transgene expression.  As an alternative 
approach, epitope display strategy was developed, bypassing the need for a gene transfer. To better 
understand the molecular mechanisms of this new vaccination approach, various virus- and 
host-related factors were evaluated. Vectors ablated in the interaction with their receptors were still 
able to induce potent anti-epitope humoral responses.  Vaccination studies in MyD88
-/-
 MAVS
-/-
 mice 
unraveled that TLR and RLR stimulation is not a crucial element in this immunization strategy. 
Altogether, our data shed a new light on the molecular mechanisms involved in the induction of 
humoral responses against the heterologous epitopes presented on Ad capsid.  
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1. Introduction 
 
Adenoviruses (Ad) belong to a family of non-enveloped DNA viruses containing a linear 
double-strand DNA genome. The accumulation of knowledge regarding their biology led more than 
20 years ago to the development of Ad-derived vectors [1]. The ease of Ad manipulation, their 
production at high titers as well as the strong level of gene expression achieved by these vectors 
make them attractive tools for gene therapy but also for vaccination. Indeed, Ad-mediated gene 
transfer of DNA fragments encoding heterologous proteins was shown to elicit strong humoral and 
cellular responses towards transgene-encoded proteins [2]. The efficacy of this approach of 
vaccination (hereafter referred to as classical approach) stems in Ad’s ability to transduce in vivo 
a large set of cells and in the intrinsic immunogenic properties of this vector [3]. 
Several studies investigated Ad capsid proteins and cell receptors controlling Ad infection. 
Thus, in the case of the well-characterized serotype 5 Ad (Ad5), interaction of fiber protein, and more 
precisely its knob, with Coxsackie and Ad receptor (CAR) was shown to be responsible for initial virus 
attachment. Then, subsequent binding of a penton base-located RGD motif to cellular integrins 
allows virus endocytosis through a clathrin-dependent pathway [3]. The role of integrins and CAR in 
controlling Ad distribution in vivo was for a long time a matter of debate. CAR was shown to play only 
a minor role in the transduction of different tissues, including liver and spleen [4][5]. Integrin-ablated 
Ad led to a reduced transgene expression in spleen and lung [6]. Of note, ablation of both CAR and 
integrin binding was unable to reduce liver gene transfer [5][7](and for a review see [3]). Besides CAR 
and integrins, different studies demonstrated a role for Ad shaft in controlling liver but also spleen 
transduction [8, 9][4]. More recently, different Ad serotypes were shown to bind to plasma proteins 
such as vitamin K-dependent coagulation factors, leading to liver transduction [10]. Among 
numerous coagulation factors, factor X (FX) plays a key role in liver transduction by bridging Ad 
capsid to liver heparan sulfate proteoglycans (HSPG). More precisely, mutations of Ad capsid helped 
to identify Ad hexon protein as the capsomer directly involved in FX binding [11-13].  
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Besides their role in cell transduction followed by transgene expression, Ad receptors 
contribute to the intrinsic immunogenic properties of this vector. For example, interaction with CAR 
and integrins were at the origin of pro-inflammatory cytokines and chemokines production in 
epithelial cells and macrophages (for a review see [3]). Innate immune responses to Ad are also 
triggered through the stimulation of pathogen recognition receptors (PRR). Several studies reported 
a role of membrane-anchored sensors such as TLR9 and more surprisingly TLR2 in controlling 
cytokine production [14][15]. In addition, mice deficient in MyD88, an adaptor protein common to 
different TLR signalling pathways, displayed reduced levels of serum pro-inflammatory cytokines and 
chemokines [14]. After endosome escape, one can anticipate that Ad stimulate cytosolic sensors. 
Indeed, following Ad infection, synthesis of viral associated (VA) RNA elicits type I interferon (IFN) 
through RIG-I mediated pathway [16]. Finally, comparison of the transcriptome in the spleen after 
administration of wild-type and FX-ablated Ad unmasked an unanticipated key role of FX in activating 
NFκB pathway leading to pro-inflammatory cytokine production [17].  
Despite their efficacy in transducing cells in vivo and their strong adjuvant properties, the use 
of Ad in the classical vaccination approach is hampered by the highly prevalent anti-Ad5 immunity. 
Moreover, Ad vector immunogenicity impairs the efficiency of homologous prime-boost 
administrations. Several strategies were developed to overcome these limitations (for a review see 
[2]), among them epitope display relying on genetic insertion of relevant epitopes into Ad capsid. 
This approach was successful at inducing antibody responses against P. Aeruginosa [18], B. anthracis 
[19] or Plasmodium [20]. Using a B cell epitope derived from Ova model antigen, we previously 
uncovered that Ad pre-existing antibodies (Abs) strongly increased antibody response elicited by Ad 
displaying the epitope into the fiber protein [21]. The present results seek to go further in our 
understanding of this strategy of vaccination by defining the role of Ad interaction with its receptors, 
as well as the influence of innate immune pathways.  
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2. Material and methods 
2.1. Mice 
Seven-week-old mice C57BL/6 female mice were purchased from Harlan (Gannat, France). 
MyD88- (MyD88
-/-
) and MAVS- (MAVS
-/-
)-deficient mice were bred in animal facilities of TAAM-UPS44 
(Orléans) or UMR0892 (VIM, Jouy-en-Josas), respectively. All mice were conditioned for at least one 
week in the animal facilities before beginning of the experiments. All animal experiments were 
conducted in accordance with the institutional guidelines of Gustave Roussy Institutional Animal Care 
and Use Committee. 
 
2.2. Virus construction and production 
AdWT (described as AE18 in ref. [22]) is based on Ad5 and possess deletions in E1 and E3 
regions. The expression cassette cloned instead of the E1 region contains the promoter/enhancer 
from the immediate early gene of human cytomegalovirus (CMV), the Escherichia coli lacZ gene with 
a nuclear localization signal, and the SV40 late polyA signal (SV40pA). AdH-3OVA2 and AdF-3OVA2 
derived from AdWT and displaying OVA320-341 (3OVA2) respectively in hexon or fiber protein were 
described previously [21]. AdP*F-3OVA2, AdH*F-3OVA2, AdH*P*F-3OVA2 and AdS*F3-OVA2, 
disabled in Ad interactions with its natural receptors, were derived from AdF-3OVA2 (Table 1). More 
precisely, AdP*F-3OVA2 was derived from AE74 [9] bearing a deletion of penton base RGD motif, 
impairing interaction with integrins. AdH*F-3OVA2 was derived from AdH[GA]24 [12] bearing 
a deletion of hypervariable region 5 of hexon protein, impairing FX binding. AdH*P*F-3OVA2 
contains both deletions. Finally, AdS*F-3OVA2 was obtained from AdWT by replacing the fiber shaft 
with the shaft from Ad serotype 3 [23]. All capsid-modified viruses (Table 1) were constructed by 
recombinational cloning in E. coli [24]. 
Ad-OVA (provided by Dr D. Descamps, INRA, Jouy-en-Josas) has a wild-type capsid and 
encodes the full ovalbumin protein. Ad control encoding no transgene was described previously [25]. 
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All viruses were obtained using previously described procedures [5], stored at -80°C in 
PBS-7% glycerol, and titrated by spectrophotometry (1 OD260 = 1.1×10
12
 viral particle [vp]/ml). 
 
2.3. Cell lines 
The 293A human embryonic kidney cell line (R705-07, Invitrogen) was maintained in modified 
Eagle medium (MEM) supplemented with 10% FBS and 1% of non-essential amino acids (NEAA). 
CHO-k1-hCAR and CHO-k1-pCDNA were kindly provided by J.M. Bergelson (School of Medecine, 
University of Pennsylvania). L929 murine fibrosarcoma cells were kindly provided by Dr U. Greber 
(Institute of Molecular Biology, Zurich, Switzerland) and maintained in DMEM supplemented with 
10% FBS. 
 
2.4. SDS-PAGE 
Purified viruses (10
10
 vp) were resuspended in Laemmli lysis buffer, boiled for 10 min, and 
loaded onto a 10% NuPage gel (Novex, Invitrogen, CA). After electrophoresis, the gel was stained 
with a silver staining kit (Invitrogen, Carlsbad, CA). 
 
2.5. In vitro cell transduction 
In order to evaluate virus infectivity, cells were plated out in 12-well plates at 1 x 10
5 
cells 
/well 48 h prior to infection. On the day of infection, cells were counted and infected with different 
multiplicity of infection (MOI) of different Ad in 400µl of serum-free medium. After 24 h, 
βgalactosidase (βgal) activity was measured using a chemiluminescent assay (BD Biosciences, 
Clontech, CA) and protein concentration was determined using the Bio-Rad Protein Assay (Bio-Rad 
Laboratories, Hercules, Marnes-la-Coquette, France). Results were presented as relative light units 
(RLU) per microgram of proteins. 
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In order to evaluate FX-dependent cell transduction, viruses were incubated with or 
without human FX (1 U/ml, Cryopep) for 1h in order to ensure efficient Ad coating. Then, virus-FX 
solution was added to CHO-k1-pCDNA cells and cells were incubated for 24h at 37°C. βgal activity 
was measured as described above. 
 
2.6. Epitope detection on virions 
To confirm the presence and accessibility of the epitopes on the capsid surface, denatured 
or native viral particles were coated on 96-well plates (Nunc, Roskilde, Denmark). Viruses were 
inactivated by incubation at 56 °C for 30 min, followed by addition of 0.1% SDS. Spectrophotometric 
measurements at 215 and 225nm allowed to determine viral protein concentrations, and 
subsequently 100ng was coated on 96-well plates. To analyse epitope presence and accessibility on 
native virions, non-denaturated viruses (100ng) were coated on the plates. After overnight 
incubation at 4°C, non-specific sites were blocked with 5% milk PBS-Tween for 2 h, then plates were 
washed and incubated for 1 h with an anti-ovalbumin rabbit polyclonal antibody (AB1225, Millipore, 
MA). Upon washing, an anti-rabbit IgG peroxidase-linked Ab (NA934, Amersham Biosciences, Saclay, 
France) was added for 1 h and peroxidase activity was revealed by incubation with the substrate 
O phenylenediamine dihydrochloride (Sigma–Aldrich, Lyon, France) for 30 min. The reaction was 
stopped by addition of 3N HCl and spectrophotometric readings were performed at 490 nm. 
 
2.7. In vivo experiments 
Capsid-modified viruses (10
10 
vp) in PBS (200µL) were injected intraperitoneally. Repeated 
injections were performed at 2 weeks intervals with a total number of injections ranging between 
2 and 3. Blood samples were collected from the submandibular vein, before virus injection and at 
different time points thereafter. Mice sera were prepared and analyzed for the presence of 
anti-ovalbumin, anti-βgal and anti-Ad Abs by ELISA as described below.  
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In some experiments, mice were depleted of coagulation factors by subcutaneous injection 
of 133µg of warfarin in 100µl of PBS at day 3 and 1 prior to virus administration. Ad naïve or 
Ad-immune mice were obtained after injection of PBS or AdWT (10
10
 vp). 
 
2.8.  Measurement of specific antibodies 
Sera were analysed for the presence of specific Abs by ELISA. After coating of 96-well plates 
(Nunc) with 1µg of ovalbumin (Sigma), 100ng of βgal (Sigma) or 100ng of denaturated AdWT viral 
particles, serial dilutions of the sera in 5% milk PBS-Tween were added. Bound Abs were detected 
with peroxidase-conjugated anti-mouse IgG, IgG1, IgG2a, or IgG2b isotype goat Abs (Southern 
Biotechnology Associates, Birmingham, AL). The peroxidase activity was revealed by incubation with 
the substrate O-phenylenediamine dihydrochloride (Sigma–Aldrich) for 30 min. The reaction was 
stopped by addition of 3N HCl and spectrophotometric readings were performed at 490 nm. Titers 
were defined as the reciprocal of the highest dilution giving an OD490 2-fold above background 
values. 
 
2.9. Statistical analysis 
A Mann–Whitney test, recommended for groups fewer than 30 mice, was conducted. Differences 
were considered significant when P < 0.05. All graphs and statistical tests were obtained with the use 
of GraphPad Prism software. 
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3. Results 
Antibody responses elicited by Ad displaying epitopes does not require gene transfer  
Our previous results have shown that pre-existence of anti-Ad Abs strongly enhances 
anti-ovalbumin (Ova) antibody responses elicited by AdF-3OVA2 bearing OVA320-341 B cell epitope 
[21], suggesting that cell transduction is dispensable for the efficacy of this vector. To address 
specifically this question, we compared the ability of capsid-modified AdF-3OVA2 and AdH-3OVA2 
(Table 1) to elicit anti-Ova antibody responses relative to AdOVA, encoding the whole Ova protein as 
a transgene, in both naïve and immune mice. C57BL/6 mice were injected with PBS or with an Ad 
bearing a wild-type capsid (AdWT, 10
10 
viral particle) and two weeks later received one 
intraperitoneal injection of AdH-3OVA2, AdF-3OVA2 or AdOVA (10
10 
vp). In Ad-naïve mice, AdOVA 
induced high levels of anti-Ova antibodies from day 14 p.i. up to 210 days p.i. In accordance with our 
previous study [21], AdH-3OVA2 led to a significantly higher anti-ovalbumin Ab responses compared 
to AdF-3OVA2 (Figure 1, upper panel). However, this response remains lower that the one observed 
in AdOVA-injected mice. In Ad-immune mice, AdF-3OVA2 triggered strong anti-ovalbumin antibody 
responses compared to AdH-3OVA2 as described previously [21] while AdOVA was unable to trigger 
any antibody response (figure 1, lower panel). Interestingly, the immune response elicited by 
AdF-3OVA2 was long lasting with strong Ab titers detectable up to 7 months after the immunization. 
While strong anti-βgalactosidase (βgal) Ab responses were elicited by AdF-3OVA2 and AdH-3OVA2 in 
Ad-naïve mice, none of them triggered significant anti-βgal Ab responses in Ad-immune mice 
(Supplementary Figure 1). 
Altogether, our data indicate that, in contrast to AdOVA, AdF-3OVA2 was able to trigger Ab 
responses in both naïve and immune mice, suggesting that virus transduction is not mandatory for 
the efficacy of this vector.  
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Production and characterization of Ad displaying ovalbumin epitope in the fiber and ablated in 
their native receptor interaction 
To examine more precisely whether virus transduction plays any role in controlling the 
efficacy of AdF-3OVA2, different vectors were produced displaying both 3OVA2 epitope inserted into 
the fiber protein and capsid modifications impairing the binding to specific receptors. AdP*F-3OVA2 
presents a deletion of the RGD motif in penton base protein in order to ablate interaction with 
integrins [9]. AdH*F3-OVA2 contains a mutation in HVR5 hexon impairing binding to FX [12]. 
AdH*P*F-3OVA2 possesses both hexon and penton base mutations. Finally, AdS*F-3OVA2 contains 
an Ad3 fiber shaft instead of Ad5 shaft [9] impairing binding to CAR receptor. All vectors were 
produced at titers comparable to AdF-3OVA2 (Table 1). SDS-PAGE analyses showed no difference in 
virus composition between the different Ad. As expected, all viruses but AdS*F-3OVA2 displayed 
a similar migration pattern for the modified fiber. For AdS*F-3OVA2, the migration pattern of the 
fiber protein is consistent with its reduced size (Figure 2A). Additionally, 3OVA2 epitope was 
detected on native virions by ELISA (Figure 2B) using a polyclonal Ova antibody. With the exception 
of AdS*F-3OVA2, all vectors possess the same capacity to transduce CHO-k1-hCAR cells, a cell line 
overexpressing the Ad primary receptor. AdS*F-3OVA2 led to a reduced cell transduction (Figure 3A) 
consistent with previous results of our laboratory (Raddi et al. in revision). Next, we examined 
transduction efficiency using specific cell lines allowing to monitor the detargeting from native Ad 
receptors. AdP*F-3OVA2 and AdH*P*F-3OVA2 were tested on CAR-negative integrin-positive L929 
cells. Both vectors led to a reduced βgal activity compared to AdF-3OVA2, confirming their reduced 
ability to bind integrins (Figure 3B). AdP*H*F-3OVA2 was used to transduce CAR-negative 
CHO-pcDNA cells in the presence or absence of FX (Figure 3C). The results showed vector displayed 
reduced ability to use FX in accordance with the role of hexon protein in FX binding (Figure 3C and 
3D, right part).  
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Humoral responses elicited by Ad displaying ovalbumin epitope in the fiber and ablated in their 
native receptor interactions 
After the characterization of the different vectors, we examined their capacity to mount 
anti-Ova humoral responses. C57BL/6 mice were twicely intraperitoneally injected with 10
10
vp. Sera 
were collected two weeks after each administration and anti-OVA, anti-βgal and anti-Ad Abs were 
quantified by ELISA. Remarkably, no difference in their ability to trigger anti-ovalbumin Abs was 
observed between detargeted vectors (AdH*F-3OVA2, AdP*F-3OVA2, AdP*H*F-3OVA2 and 
AdS*F-3OVA2) and AdF-3OVA2 neither after priming nor after boosting (Figure 4A). In contrast, 
anti βgal antibody titers were significantly reduced after priming in AdH*P*F-3OVA2- and 
AdS*F 3OVA2 injected mice (Figure 4B, P < 0.05) compared to AdF-3OVA2-injected mice. After 
boosting, all detargeted vectors were significantly impaired in their ability to trigger anti-βgal Ab 
(Figure 4B). Of note, all vectors induced comparable anti-Ad Ab responses at all time points (data not 
shown). Altogether, these results underline that while detargeting Ad for its natural receptors reduce 
its ability to trigger humoral responses against the transgene, it has no impact on its ability to trigger 
humoral responses against an epitope displayed on the capsid. 
Besides FX-detargeting through hexon modification, we also used a pharmacological 
approach based on administration of warfarin, a drug able to deplete all vitamin K-dependent blood 
factors. To do so, mice were pre-treated with warfarin or PBS before each AdF-3OVA2 
administration. Blood factor depletion was confirmed by the measurement of FX activity in mice sera 
harvested prior to virus delivery (data not shown). Measurement of anti-Ova titers showed no 
significant difference between warfarin- and PBS-pre-treated mice neither after priming nor after 
bosting (Supplementary Figure 2). Additionally, levels of anti-βgal and anti-AdAbs also remained 
unmodified in warfarin-pretreated mice (Supplementary figure 2). Thus, both genetic and 
pharmacological approaches used to detarget Ad from FX were unable to decrease humoral 
responses towards 3OVA2 epitope. 
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Collectively, these results underline that in contrast to humoral responses against βgal 
transgene, the humoral responses against 3OVA2 epitope displayed on fiber protein do not rely on 
Ad interaction with their cellular receptors. 
 
Role of innate immune pathways in humoral responses elicited by Ad displaying ovalbumin 
epitope inserted into the fiber protein 
To get further insights into molecular bases controlling the efficacy of vaccination with Ad 
displaying epitopes, we investigated the role innate immune pathways. First, since TLRs and Myd88 
were shown to participate in Ad innate immunity, we examined their role in shaping humoral 
responses by using MyD88-deficient mice. No significant difference was found in anti-Ova humoral 
responses in wild-type and MyD88-deficient mice, neither after priming nor after boosting (Figure 
5A). In addition, both strains elicited comparable levels of anti-βgal (Figure 5B) and anti-Ad Abs 
(Figure 5C). Interestingly, compared to AdF3-OVA2-injected wild-type mice, AdF3-OVA2-injected 
MyD88-deficient mice displayed a strong increase in IgG1 anti-Ova Abs and a trend to a reduced level 
of IgG2b anti-Ova Abs without any difference in IgG2a (Figure 5D, p <0.05). In contrast, MyD88
-/-
 
mice displayed very low titers of anti-βgal IgG1 and IgG2b and a strong reduction in IgG2a (Figure 5D, 
p < 0.01). No difference in anti-Ad isotypes were found between MyD88
-/-
 and wild-type mice (Figure 
5E). Then, we examined the role of RIG-I-induced innate immune pathway using MAVS-deficient 
mice. The levels of total anti-Ova IgG Abs (Figure 6A) as well as IgG1, IgG2a and IgG2b Abs (Figure 6B) 
were comparable in wild-type and in MAVS-deficient mice, ruling out a major role of RIG-I/MAVS 
pathway in induction of anti-epitope humoral responses. 
Altogether, these results underline that TLR/MyD88 and RIG-I/MAVS pathways are both 
dispensable in mounting antibody responses against 3OVA2 epitope. However, they also reveal that 
TLR/MyD88 pathway influences the isotype nature of antibody responses against the displayed 
epitope.
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4. Discussion 
Vectors derived from Ad were used in different preclinical studies as well as in clinical trials for 
purpose of vaccination. The high seroprevalence of neutralizing Abs as well as the induction of strong 
anti-vector immunity after first administration led to the development of different strategies to 
overcome these limits [2]. Among them are the use of other Ad serotypes or even xenotypes but also 
epitope display on Ad capsid. This latter approach relies on insertion of peptides within a capsid protein 
(most of the time hexon protein). Generally, those peptides were B cell epitopes and they were found to 
successfully elicit antibody responses against model antigens [21] but also against several pathogens 
such as influenza virus [18], B. anthracis [19] or Plasmodium yoelii [20]. While several studies 
investigated the role of the site of epitope insertion and thus the number of motifs per capsid [21][27] 
or the size of the peptides [19], no study investigated molecular mechanisms controlling the efficacy of 
Ad displaying epitopes.  
In a previous study, we discovered a key role of anti-Ad Abs in increasing antibody responses 
induced by Ad displaying Ova-derived epitopes in the fiber protein. At the same time, anti-Ad Ab were 
impeding the efficacy of Ad displaying epitopes into the hexon protein [21]. These previous results 
suggested that when anti-Ad Abs were able to neutralize the particle, Ad displaying epitopes were still 
able to trigger antibody responses. Two observations of the present paper confirmed that Ad infectious 
process is not mandatory to allow AdF-3OVA2 to elicit antibody responses. First, lacZ recombinant 
AdH-3OVA2 failed to trigger significant anti-βgal antibody responses in Ad-immune mice while being 
more efficient in inducing anti-Ova Ab responses than in Ad-naïve mice (Figure 1). Second, detargeting 
AdF-3OVA2 from its native receptors reduced its ability to elicit antibody responses against βgal 
transgene without significant impairment of Ab production against 3OVA2 epitope (Figure 4A). 
Altogether, these results indicate that epitope display strategy of vaccination does not rely on gene 
delivery in contrast to the classical Ad vaccine approach that requires transgene expression. 
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Detargeting Ad from integrin receptor or from FX did not impact Ad’s capacity to induce 
humoral responses toward βgal transgene. However, ablation of both integrin and FX binding or 
modification of Ad5 shaft translated into a significant reduction of anti-βgal antibody titers (Figure 4B). 
These results may stem in the reduced ability of Ad impaired in hexon:FX and penton:integrin binding to 
transduce the spleen and to induce cytokine production [28]. AdS*F-3OVA2 also led to the decrease in 
anti βgal responses. This behaviour could be related to the reduced ability of shaft-mutated Ad to 
transduce different cells and tissues in vivo (Raddi et al. in revision) but may also be linked to their 
reduced ability to trigger pro-inflammatory cytokine and chemokine production [23].  
Innate immune responses are key factors for the establishment of adaptive immune responses. 
Among the different innate immune pathways, Ad were shown to activate TLR/Myd88 signalling. At all 
analysed time points, no significant modification of total anti-IgG Abs against Ad, βgal or 3OVA2 epitope 
was found in MyD88
-/-
 mice compared to their wild-type counterparts (Figure 5A). These data suggest 
that TLR/MyD88 pathway is dispensable to mount efficient humoral responses or, alternatively, that 
other innate immune pathways could compensate the lack of MyD88. However, it should be noticed 
that Hartman et al. reported previously a reduction in anti-Ad IgG Ab in MyD88
-/-
 mice compared to 
heterozygous MyD88
+/-
 mice [29]. The discrepancies between their study and our study could be linked 
to differences in mouse strains, virus dose and mode of administration.  
Increase of anti-epitope IgG1 Abs (Figure 5B) unravelled a role of MyD88 in shaping Ig isotype 
switching. Interestingly, MyD88 was not mandatory for the production of different anti-Ad IgG isotypes 
(Figure 5F) but was required for the production of anti-βgal IgG2a Abs (Figure 5D). The difference in 
requirement of MyD88 for the production of Abs against the inserted epitope, the vector or the 
transgene product could be linked to their intrinsic nature (soluble protein or particle, monomeric or 
multimeric protein). The precise TLR involved in MyD88 activation was not investigated in this study. 
However, previous studies have unravelled Ad’s capacity to trigger different TLRs such as TLR2 [30], 
TLR4 [17] and TLR9 [14] [30].  
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Modification of IgG isotype balance in MyD88
-/-
 mice compared to their wild-type counterparts 
was also reported for other non-enveloped DNA viruses ([31][32][33]) but also for enveloped RNA 
viruses ([34][35]). The role of MyD88 may be linked to its ability to trigger type-I IFN production by 
dendritic cells. This cytokine was shown to promote IgG2b and IgG2c production while reducing IgG1 
level [36][37]. MyD88 expressed by B cell could also directly promote isotype switching and affinity 
maturation as described by [32][38]. 
 Several studies have previously shown that Ad triggers RIG-I pathway [16]. Our study revealed 
that mice deficient in MAVS, a protein downstream of RIG-I, did not show modification in total IgG 
production nor specific IgG isotype production against the epitope displayed into the capsid (Figure 6). 
This suggests that MAVS/RIG-I pathway did not play any significant role in modifying humoral responses 
against the epitope nor against the transgene product. Alternatively, other innate immune sensor 
pathways such as TLR/MyD88 may compensate the absence of functional RIG-I/MAVS pathway. 
 To summarize, our results shows that the efficacy of epitope display does not depend on Ad 
infection process nor on Ad interaction with its natural receptors. Interestingly, whereas mice deficient 
in TLR/MyD88 or RIG-I/MAVS pathways mount IgG antibody responses comparable to control mice, we 
unmasked a key role of MyD88/MAVS pathway in shaping antibody isotype production not only against 
the epitope but also against the transgene product. Thus, the present study improved our 
understanding of molecular bases controlling the efficacy of Ad displaying epitopes on their capsid. The 
results pave the way for the development of vaccines based on epitope display on Ad capsid.  
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Tables and figures 
 
Table 1. Characteristics of Ad displaying ovabumin epitopes. 
a
 Mean ± SD 
Virus Transgene 
Ovalbumin 
323-339
 epitope 
(3OVA2) 
Additional alterations 
Titer 
a
 
(×10
12 
vp/ml) Modified 
protein 
Inserted 
sequence 
Modified protein Alteration 
AdWT βgal - - - -  4.4 ± 0.8 
AdOVA Ovalbumin - - - -   7.3 ± 2.1 
AdH-3OVA2 βgal Hexon + - -  4.5 ± 2.9 
AdF-3OVA2 βgal Fiber + - -  4.6 ± 1.9 
AdP*F-3OVA2 βgal Fiber + Penton base RGD deletion   2.3 ± 1.0 
AdH*F-3OVA2 βgal Fiber + Hexon HVR5 deletion  2.1 ± 0.6 
AdP*H*F-3OVA2 βgal Fiber + 
Penton base 
Hexon 
RGD deletion 
HVR5 deletion 
 2.5 ± 1.2 
AdS*F-3OVA2 βgal Fiber + Fiber Ad3 shaft  1.7 ± 0.6 
 
 
Figure 1 Kinetics of anti-OVA humor
C57Bl/6 mice were immunized intraperitoneally with 10
AdH-3OVA2) or with an Ad vector encoding 
determined by ELISA at different time points after injection. 
results of individual mice (n = 5
Right part, means + SEM for each group. 
  
al response. Naïve (upper panel) or Ad immune (lower panel) 
10 
vp of capsid-modified 
Ova as a transgene (AdOVA). Anti
Left part, circles 
-6) and means, respectively. Titers below 100 were plotted as 50. 
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Ad (AdF-3OVA2 or 
-Ova IgG titers were 
and bars represent 
 
 
Figure 2 Epitope detection on capsid
vp of either a control Ad (AdWT) or a capsid
AdH*P*F-3OVA2 and AdS*F-3OVA2) were separated on a 10% polyacrylamide gel. M
are indicated with white arrows while hexon, penton base, polypeptide IIIa (pIIa) and native fiber 
proteins are labelled with black ones. (
coated with 100 ng of native viruses and in
protein. The binding was detected with HRP
experiments is shown, means ± SD of four replicates.
-modified vectors. (A) Silver staining of capsid modified Ad. 10
-modified Ad (AdF-3OVA2, AdH*F-3OVA2, AdP*F
B) Detection of OVA epitopes on virions. ELISA plates were 
cubated with a rabbit polyclonal antibody against the 
-conjugated secondary antibody. One of two 
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Figure 3 In vitro infectivity of capsid modified vectors.
mock-infected (NI) or infected with different MOI of capsid
AdP*F-3OVA2, AdH*P*F-3OVA2 and AdS*F
infected (NI) or infected with different MOI of capsid
AdH*P*F-3OVA2). (C and D) Transduction of CHO
infected with different MOI of capsid modified Ad (AdH*F
without FX coagulation factor. (
24 h post-infection and expressed as relative light unit (RLU) per µg of protein. (
βgal activity 24 hours after CHO
of FX in comparison with βgal activity 
experiments are shown. 
 
 (A) Transduction of CHO
-modifed Ad (AdF-3OVA2, AdH*F
-3OVA2). (B) Trasduction of L929 cells. Cells were mock
-modifed Ad (AdP*F
-k1-pCDNA. Cells were mock infected (NI) or 
-3OVA2 and AdH*P*F
A-C) For each panel, βgal activity was measured in cells harvested 
-k1-pCDNA infection in the presence of physiological le
in the absence of FX. The representative results of at least 2 
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-k1-hCAR. Cells were 
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-
-3OVA2 and 
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D) Fold-inductions of 
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Figure 4 Humoral responses elicited by Ad displaying Ova epitopes and ablated in their native 
receptor interaction. C57BL/6 mice were immunized intraperitoneally with 10
10
 vp of capsid-modified 
AdF-3OVA2, AdH*F-3OVA2, AdP*F-3OVA2, AdH*P*F-3OVA2 and AdS*F-3OVA2. Anti-ovalbumin (A) 
and anti-βgal (B) IgG titers were determined by ELISA at day 14 after first (priming) and second 
(boosting) administration. Titers below 100 were plotted as 50. One of two experiments is shown, 
dots and bars represent results form individual mice (n = 5-6 mice) and means, respectively. 
*, p < 0.05 versus AdF-3OVA2; ns, non significant. 
 
Figure 5 Influence of MyD88 on hum
immunized intraperitoneally with 10
(E) IgG were measured by ELISA at day 14 after first (priming) and second (boosting) administration.
Dots and bars represent results from individual mice 
(B), anti-βgal (D) and anti-Ad (F) 
day 42 after the first administration. Titers below 100 were plotted as 50. *, 
versus wild-type mice. 
oral responses elicited by Ad displaying Ova epitope
10 
vp of AdF-3OVA2. Total anti-Ova (A), anti
(n = 6-7 mice) and means, respectively. Anti
antibody isotypes IgG1, IgG2a and IgG2b were measured by ELISA at 
P < 0.05 
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Figure 6 Influence of RIG-I/MAVS pathway on humor
epitope. Mice were immunized intraperitoneally with 10
isotypes (B) specific for Ova were determined by ELIS
(boosting) administration or (B) at day 42 post
as 50. Circles represent individual mice and bars reflect means.
  
al responses elicited by Ad displaying 
10 
vp of AdF-3OVA2. Total IgG (
A  (A) at day 14 after first (priming) and second 
 the first administration. Titers below 100 were plotted 
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Supplementary figures 
Supplementary Figure 1 Kinetics of anti
(lower panel) C57Bl/6 mice were immunized intraperitoneally with 10
(AdF-3OVA2 or AdH-3OVA2) or with an 
IgG titers were determined by ELISA at differen
shown. Left part, dots and bars represent
Titers below 100 were plotted as 50. 
  
-βgal humoral response. Naïve (upper panel) or Ad immune 
10 
vp of 
Ad vector encoding Ova as a transgene 
t time points after injection. One experiment of two is 
 results of individual mice (n = 5-6) and means
Right part, means + SEM for each group. 
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Supplementary Figure 2 Influence of coagulation factor FX on humoral responses elicited by Ad 
displaying Ova epitopes. Mice were immunized intraperitoneally with 10
10
 vp of capsid-modified 
AdF-3OVA2. Before each injection, mice were pre-treated with PBS or warfarin. Anti-Ova (A), 
anti-βgal (B) and anti-Ad (C) IgG titers were determined by ELISA at day 14 after first (priming) and 
second (boosting) administration. Titers below 100 were plotted as 50. One of two experiments is 
shown, dots and bars represent results form individual mice (n = 5-6 mice) and means, respectively. 
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Abstract 
 
Although the capacity of Ad vectors displaying heterologous epitopes to induce humoral responses 
was previously demonstrated for various epitopes, their potential do induce CD8
+
 cellular responses 
upon class-I T cell epitope display remains an open question. We thus constructed Ad vectors with 
ovalbumin epitope SIINFEKL inserted into hexon or fiber proteins. The displayed epitopes were 
efficiently uptaken and processed by dendritic cells in vitro. Vaccination studies in naïve and immune 
mice confirmed the capacity of vector displaying epitope in hexon to induce robust cellular 
responses. Analysis of kinetics and phenotype of ovalbumin-specific CD8
+
 T cells suggests that this 
vector induces potent effector memory differenciation.  
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1. Introduction  
Vaccine development has been one of the most impactful contributions to the mortality 
reduction in the medicine history. During decades, conventional vaccines were based on attenuated 
or inactivated whole pathogens, and have contributed to the eradication or regression of diseases 
like smallpox or poliomyelitis [10]. However, this traditional approach does not answer the new 
needs of vaccinology, and especially its safety concerns. Increased knowledge in the field of 
immunology and molecular biology has allowed for the emergence of new subunit vaccines, based 
on selected fragments of the pathogen, injected as recombinant protein, DNA vaccine or expressed 
by recombinant vector [1]. Thus, the current goal of vaccinology is to present to the immune system 
only antigens of interest. The most precise and minimal targets recognized by the immune system 
are epitopes and thus a new class of vaccine, consisting in epitope presentation, has emerged.  
Epitope-based vaccines allow to direct immune responses toward selected epitopes of the 
pathogen [14]. Thus, by controlling the type of pathogen fragment which will be presented, the 
epitope-based vaccine safety is surpassing traditional vaccines. In consequence, potentially harmful 
regions of the pathogen which could lead to auto-immune or oncogenic reactions are no longer 
included during vaccine preparation. Other advantage of this new vaccine type is the possibility to 
combine different peptides in one vaccine formulation and to select epitopes which are presented by 
highly prevalent allels of HLA molecules. 
Therefore, the main challenges of this vaccination strategy consist in identifying suitable 
epitopes and presenting them correctly to the immune system. A safe, practical and efficient delivery 
system is needed to expose the epitope and to activate immune responses. Numerous studies have 
focused on this subject and evaluated carriers like lipopeptide [9] MAP [8] or viral pseudo-particles 
[13]. In this work, we proposed the adenovirus (Ad)-derived vectors as a promising epitope delivery 
system. Indeed, Ad from serotype 5 are safe, easy to manipulate and produce, and they activate 
efficiently both innate and adaptive responses [16]. 
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Recombinant Ad vectors have been extensively used in a classical vaccination strategy [11]. 
However, the vector gene transfer is heavily limited by the presence of anti-Ad neutralizing 
antibodies (Abs) in 50 to 90% of human population [15]. To circumvent this problem, another use of 
Ad has emerged, based on epitope insertion into adenoviral capsid protein. Different regions of 
capsid proteins have been identified for their capacity to accommodate modifications without 
affecting capsid self-assembly, enabling genetic insertion of heterologous epitopes in these regions 
[3]. 
The efficacy of epitope display strategy with the use of Ad capsid as a platform has already 
been demonstrated by other groups [4, 9, 19]. Worgall et al. have inserted a neutralizing epitope 
from P.aeruginosa into hexon protein, which has led to protection of immunized mice against a lethal 
infection by the pathogen [18]. In the same manner, we have previously demonstrated that insertion 
of a model B epitope from the ovalbumin (Ova) protein into hexon or fiber protein results in efficient 
humoral anti-epitope responses that are boosted after re-administrations of the vector. Interestingly, 
we highlighted the fact that anti-Ad Abs control the efficacy of the anti-epitope responses, 
depending on the insertion site. Nonetheless, the studies evaluating this strategy have concentrated 
exclusively on B cell epitope insertion. Therefore, we have decided to pursue the study of this vaccine 
approach by inserting a class I-restricted T cell epitope from Ova, OVA257-264, into hexon and fiber 
proteins. The aim of this work is to compare the vaccination efficiency depending on the insertion 
site and the epitope number. We have investigated the role of flanking sequences, by inserting the 
epitope either alone or with additional residues from the Ova sequence, since these flanking residues 
could potentially modulate the processing efficiency of the epitope [12]. The immunization potential 
of these Ad vectors was assessed in both presence and absence of anti-Ad immune responses and 
the kinetics and phenotype of the induced cellular responses were analyzed. 
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2. Materials and methods 
 
2.1. Cells 
The RF33.70 T cell hybridoma was generously provided by Dr. K.L. Rock (Dana Farber Cancer 
Institute, Boston, MA, USA), and was grown in RPMI  supplemented with 10% SVF, 1% non-essentials 
amino acids, 1% glutamine and 1% hepes. 
 
2.2. Mice 
7-week-old C57BL/6 female mice were purchased from Janvier (Le Gesnest Saint Isle, France) 
or Harlan (Gannat, France). They were conditioned for at least one week in the animal facilities 
before beginning the experiments. All animal experiments were approved by Gustave Roussy 
Institutional Animal Care and Use Committee. 
 
2.3. FLDC preparation 
FLDC (Flt3 ligand-dependent dendritic cells) were generated from bone marrow precursors. 
Bone marrow cells were harvested from tibia and femurs of C57Bl/6 mice by flushing with   complete 
RPMI medium (RPMI supplemented with 5% SVF, 1% non-essentials amino acids, 1% glutamine, 1% 
pyruvate and 5.10
-5
 M β-mercaptoethanol), and filtered through a 100 µm cell strainer.  After 
removal of blood cells by ACK Lysing Buffer (Invitrogen, Cergy-Pontoise, France), the cells were 
resuspended and the concentration was adjusted to 2x10
6
 cells/mL. Cells were plated in MW6 plates, 
and recombinant human Flt3 ligand was added at 250 ng/mL. Cultures were fed with fresh Flt3 
complemented RPMI medium every 2-3 days. At day 10, FLDCs were harvested from the cultures by 
vigorously pipetting. Cells were labelled with Pacific blue anti CD11b (eBioscience, CA, USA), FITC anti 
I-A
b
, PE anti CD24, PE-Cy
TM
7 anti CD11b and PerCP anti CD45R/B220 (BD Bioscience, CA, USA) Abs. 
The diverse phenotypic characteristics of FLDC were confirmed using a FACSscan (BD Biosciences).   
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2.4. Adenoviral vectors 
LacZ-recombinant control AdWT (AE18 in ref. [17]) was derived from Ad5 with E1 and E3 
regions deleted. The expression cassette cloned instead of the E1 region contains the 
promoter/enhancer from the immediate early gene of human cytomegalovirus (CMV), the E. coli 
β-galactosidase gene with a nuclear localization signal, and the SV40 late polyA signal. AdH-SL, 
AdH-3SL2 and AdH-5SL2, derived from AdWT, contain respectively a short (OVA257-264: SIINFEKL, 
referred in the text as SL peptide), medium (OVA254-266: QLESIINFEKLTE, referred in the text as 3SL2 
peptide), or a long (OVA252-266: LEQLESIINFEKLTE, referred in the text as 5SL2 peptide) peptide derived 
from Ova (Table 1). These peptides were inserted into the hexon protein in place of 
269TTEAAAGNGDNLT281 of hypervariable region 5. AdF-SL, AdF-3SL2 and AdF-5SL2 contain respectively 
SL, 3SL2 or 5SL2 peptide inserted in place of T539QETGDTTPS548 into the HI loop of the fiber protein. 
All modified viruses (Table 1) were constructed using recombinational cloning in E. coli [14].  
All viruses were obtained using standard procedures as described [6],
 
stored at −80 °C in 
PBS-7% glycerol and titrated by spectrophotometry (1 OD260 = 1.1 × 10
12
 viral particle (vp)/ml).  
 
2.5. SDS-PAGE and silver stain analysis 
Purified viruses (10
10
 vp) were resuspended in Laemmli lysis buffer, boiled for 10 min and 
loaded onto a 10% NuPage gel (Novex, Invitrogen, CA). After electrophoresis, the gel was stained 
with a silver staining kit (Invitrogen, Carlsbad, CA). 
 
2.6. Detection of SL, 3SL2 and 5SL2-epitopes on virions   
Viruses were inactivated at 56°C during 30 minutes and 0.1% SDS was added. 
Spectrophotometric reading was performed at 215 and 225 nm to determine virus concentrations 
and 100 ng were coated on 96-well plates (Nunc, Roskilde, Denmark). After overnight incubation at 
4°C, non-specific sites were blocked with 5% milk PBS-Tween, then plates were washed and 
incubated with a rabbit polyclonal antibody against the Ova protein (AB1225, Millipore, MA) for 1 
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hour. After washing, an anti-rabbit IgG peroxydase-linked Ab (NA934, Amersham Biosciences, Saclay, 
France) was added for 1 hour and peroxidase activity was revealed by incubation with the substrate 
o-Phenylenediamine dihydrochloride (Sigma-Aldrich, Lyon, France) for 30 min. The reaction was 
stopped by addition of 3N HCl and spectrophotometric reading was performed at 490 nm. 
 
2.7. Antigen presentation assay 
FLDC were seeded on a 96-well culture plate at a density of 10
5
 cells/well. Cells were 
incubated with control or capsid-modified Ads for 2 hours at 10
4 
or 10
5
 vp/cell in a final volume of 
100 µL of complete RPMI medium. Controls included untreated FLDC, FLDC pulsed for 2 hours with 
Ova protein (2mg/mL), or SIINFEKL peptide (10µg/mL). Then, RF33.70 cells (10
5
 cells/well in 100 µL) 
were added and cells were co-cultured during 2 days at 37°C. The response of stimulated RF33.70 
cells was assessed by determining the amount of IL-2 released into supernatants using a murine IL-2 
ELISA Kit (BD Bioscience). 
 
2.8. In vivo experiments  
Control or capsid-modified viruses (10
10
 vp) in PBS (200 µL) were injected intraperitoneally 
in C57Bl/6 mice. Repeated injections were performed at intervals of 2 weeks. Spleens were collected 
at different time points after the second injection. 
 
2.9. Epitope-specific cellular responses 
Spleen from naïve or immunized mice were crushed in complete RPMI medium, and filtered 
through a 100 µm cell strainer. After removal of blood cells by ACK Lysing Buffer (Invitrogen, 
Cergy-Pontoise, France), the cells were resuspended and the concentration was adjusted at 2.5 × 10
6
 
cells/mL. Splenocytes were then directly used for tetramer staining assay, IFN-γ ELISPOT assay or 
were restimulated in vitro. 
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To assess specific cellular responses splenocytes were seeded on a 24-well plate (5 x 10
6
 
cells in 2mL) and restimulated in different conditions in triplicates: RPMI medium, Ova SIINFEKL 
peptide (5µg/mL), Ad peptide FALSNAEDL (5µg/mL) or βgal peptide ICPMYARV (5µg/mL). As 
a positive control a mix of ionomycine (1µM) and PMA (0.1µM) was used. Cells were incubated for 72 
hours at 37°C. Then, supernatant was collected and assayed for the presence of IFN-γ using a murine 
IFN-γ kit (eBioscience). 
For ELISPOT assay restimulants were prepared and added in triplicates to the ELISPOT 
plates (Eurobio) in 100µl/well: RPMI medium as a negative control, Ova SIINFEKL peptide (5 µg/mL), 
Ad peptide FALSNAEDL (5µg/mL), βgal peptide ICPMYARV (5µg/mL), Ova protein (236,5µg/ml) and 
mix of ionomycine (1µM) and PMA (0.1µM) as a positive control. Cells were then added to the wells 
(100µl) and incubated 22 hours at 37°C. Plates were revelated with supplied reagents and spots were 
counted with the ImmunoSpot® S6 FluoroSpot Line Plate Reader (CTL). For tetramer staining assay, 
splenocyte suspension was stained with a phycoerythrin (PE)-coupled major histocompatibility 
complex (MHC) class I pentamer, containing H-2K
b
 restricted SIINFEKL epitope (CliniScience) and with 
monoclonal antibodies anti : CD90.2 (clone:53-2.1) eFluor® 450-coupled; CD45R (B220) 
(clone:RA3-6B2) APC-eFluor® 780 coupled; CD8a (clone:53-6.7) FITC-coupled; CD44 (clone:IM7) 
PE-Cyanine5 or PerCP-Cyanine5.5 coupled; CD197 (CCR7) (clone:4B12) APC-coupled; CD127 
(clone:A7R34) Alexa Flour® 700-coupled; CD62L (clone:MEL-14) PE-Cyanine7-coupled and KLRG1 
(clone:2F1) PE-eFluor® 610-coupled (eBionscience). Cells were analyzed by MoFlo® Astrios™ Flow 
cytometer and cell sorter (Beckman Coulter) and software Summit 6.2 (Beckman Coulter). 
 
2.10. Statistical analyses 
A Mann-Whitney test, recommended for groups fewer than 30 mice, was conducted. 
Differences were considered significant when P < 0.05. 
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3. Results 
Production and characterization of Ad displaying ovalbumin-derived epitopes 
In the first turn we sought to determine the role of the epitope insertion site and the 
presence of flanking sequences on the vaccination efficacy of Ad displaying epitopes on their capsid. 
To that end, the immunodominant class I epitope SIINFEKL (SL) from Ova protein was genetically 
inserted, with or without flanking sequences (SL, 3SL2 and 5SL2), into either hexon (AdH-SL, 
AdH-3SL2 and AdH-5SL2) or fiber (AdF-SL, AdF-3SL2 and AdF-5SL2) proteins of a lacZ-recombinant 
Ad. All capsid-modified Ads were produced and purified at titers comparable to AdWT presenting 
a wild-type capsid (Table 1). SDS-PAGE analyses confirmed no differences in virus composition and 
integrity between capsid-modified Ad and AdWT (Fig. 1).  
The presence of the epitope coding sequence in the Ad genome was confirmed by PCR 
performed on purified virions (data not shown). Using a polyclonal anti-Ova antibody, 3SL2 and 5SL2 
epitopes were detected on denaturated, purified virions by ELISA. SL epitope was detected on 
AdH-SL but not on AdF-SL (Fig. 2). In addition, there was no difference in the ability of 
capsid-modified Ad to transduce CHO-CAR cells, cell line overexpressing Ad primary receptor 
(supplementary Fig. 1). 
 
Epitope insertion site strongly influences epitope processing efficiency  
The capacity of the epitope to be efficiently processed from the capsid protein into which it 
is inserted constitutes a mandatory step to allow the peptide to be presented by MHC-I molecules on 
antigen-presenting cells. To address specifically this question, Ad displaying Ova T cell epitope were 
incubated with FLDC as a source of APC, then RF33 T cell specific hybridoma, recognizing SL epitope 
presented by H-2K
b
 MHC-I molecules, was added. Finally, measurement of IL-2 production by ELISA in 
the co-culture supernatants was used to monitor hybridoma activation consecutive to both antigen 
processing and presentation. IL-2 production was detected after FLDC incubation with 
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hexon-modified Ad, demonstrating that both in the presence and absence of flanking sequences 
epitope inserted into hexon protein was efficiently processed. The highest release of IL-2 was 
observed for non-flanked SL epitope, and 3SL2 epitope was associated with the lowest IL-2 
production (Fig. 3a). In sharp contrast, after incubation with fiber-modified Ads, IL-2 production was 
much more modest, suggesting that the epitope presentation was less efficient than with 
hexon-modified Ad (Fig. 3b). This result suggested that the insertion site plays an important role in 
the efficiency of epitope processing by dendritic cells. However, the obtained hierarchy could be 
explained by the 20-fold difference in the total number of epitopes displayed on the surface, 
depending on the insertion site (240 x 3 and 12 x 3 for hexon and fiber, respectively). To assess the 
role of the number of epitopes incorporated into the capsid, an antigen presentation assay was 
performed by incubating FLDC with the same epitope copy number (10
4
 vp of hexon-modified Ads 
and 2x10
5
 vp of fiber-modified Ads). Again, FLDC epitope presentation was significantly better after 
infection by hexon-modified Ads compared to fiber-modified vectors, thus excluding a preponderant 
influence of epitope number on its presentation efficiency (Fig. 3c).  
 
Anti-epitope cellular responses in naive and immune mice 
Although results we obtained in vitro indicated significantly weaker processing /presentation of 
the epitope displayed in fiber protein, we decided to further assess the vaccination potential of both 
hexon-modified and fiber-modified Ads. In particular, we examined their capacity to mount 
anti-epitope cellular responses in mice immune or non-immune to Ad. To that end, C57Bl/6 mice 
were first injected intraperitoneally with PBS or AdWT (10
10
 vp) and two weeks after animals 
received one injection of epitope-displaying Ad. Ten days after this second injection, spleens were 
harvested and splenocytes were restimulated in vitro using antigen-specific peptides. Upon 
restimulation with Ad peptide, no significant difference in IFN-γ production was observed between 
splenocytes of mice injected with AdH-SL and AdF-SL, neither in naive nor in immune mice (Fig. 4). 
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However, as expected, a dramatic increase in IFN-γ production was detected for splenocytes isolated 
from both Ad-immune groups. Analysis of anti-βgal cellular responses unravelled a strong reduction 
of anti-βgal responses in Ad-immune mice, consistent with the ability of neutralizing Abs to inhibit 
gene delivery. In case of SL epitope restimulation, a significant increase in IFN-γ production was 
found for AdH-SL compared to AdF-SL, indicating that AdH-SL is more potent to elicit memory CD8
+
 T 
cell responses than AdF-SL. Additionally, comparison of splenocyte response in naive versus immune 
mice showed a tendency to reduced cellular responses in Ad-immune mice (Figure 4). Altogether, 
these results demonstrate the induction of epitope-specific CD8
+ 
T cell
 
responses upon immunization 
with Ad vectors displaying heterologous epitopes into their capsid proteins.
 
 
Kinetics of cellular responses elicited by Ad displaying ovalbumin-derived SL epitope. 
Having confirmed the ability of epitope-displaying Ad vectors to trigger epitope-specific T cell 
responses, we sought to evaluate their kinetics. As previously, mice were immunised with PBS or 
AdWT and two weeks later with either AdH-SL or AdF-SL. Mice injected twice with PBS were used as 
a control group (NI). First, we assessed the cellular responses by measuring SL-specific CD8
+
 T cells 
using tetramers and cytometry. At day 11-12 p.i., about 0.8% of tetramer-positive cells (TetOva
+
) 
were found among CD8
+
 splenocytes in AdH-SL-injected Ad-naïve mice, in comparison to 0.2-0.3% 
detected in other groups (Fig. 5A-B). Interestingly, this hierarchy between the different Ads was 
preserved at later time points, with AdH-SL triggering about 0.6% of TetOva
+
CD8
+
 T cells. 
Quantification of the number of TetOva
+
CD8
+
 T cells in total splenocytes confirmed that AdH-SL was 
more potent than AdF-SL to induce epitope-specific cellular responses (Fig. 5C). Then, with ELISPOT 
assay, we analysed the ability of isolated splenocytes to produce IFN-γ upon restimulation with 
specific peptides. At an early time point (day 11-12), the highest number of SL-specific IFN-γ 
producing cells was detected in the splenocytes isolated from Ad-naive mice immunized with AdH-SL 
(Fig.6, upper panel). Similarly to the results of splenocyte restimulation in vitro described above, 
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AdH-SL was able to trigger more robust cell responses than AdF-SL in both naive and immune groups 
of animals. In contrast, AdF-SL was less potent to elicit SL-specific T cell responses, regardless of the 
host status towards Ad. Analysis of the presence of Ad-specific IFN-γ producing cells confirmed that 
anti-Ad immunity was more vigorous in pre-immunized group. Interestingly, strong anti-βgal cellular 
responses were triggered in both Ad-naive and Ad-immune mice. Analysis of cellular responses at a 
later time point (day 25-26) disclosed the hierarchy of vector vaccination efficacy similar to the one 
obtained at the early time point, for all the experimental groups (Fig. 6, lower panel). Despite a 
decrease in the number of SL-specific IFN-γ producing cells for all the analyzed vectors, AdH-SL 
elicited the strongest T cell responses against SL epitope.  
 Altogether, these results underline the capacity of AdH-SL to elicit in vivo the amplification of 
functional SL-specific T cells, able to produce IFN-γ upon antigen encountering. 
 
Characterisation of the phenotype of SL-specific T cells elicited after administration of Ad 
displaying SL epitope.  
In the next step, we investigated the levels of CD44, CCR7, CD127, CD62L and KLRG1 
molecules on the surface of CD8
+
 CD90
+
 T cells at both time points. For all groups of immunised mice, 
at the early time point a reduction in CCR7, CD127, CD62L as well as an increase in CD44 and KLRG1 
was observed for TetOva
+
 CD8
+
 T cells when compared to total CD8
+
 T cells (Fig. 7A). At the later time 
point all groups continued to exhibit increased expression of CD44 and KLRG1 molecules on TetOva
+
 
CD8
+
 T cells compared to total CD8
+ 
cells. Interestingly, TetOva
+
CD8
+
 T cells isolated from Ad-naïve 
mice immunized with AdH-SL displayed reduced amounts of CD127 and CD62 molecules (Fig. 7B).  
Based on differential expression of CD62L, CD127
+
 T cells can be divided in two main 
lineages of memory T cells, named central (TCM) and memory (TEM) T cells. Thus, in order to measure 
the phenotype of TetOva
+
CD8
+
 T cells in immunised mice, we concomitantly analysed the data of 
CD62L and CD127 molecule expression on their surface (Fig. 7C and 7D). At the early time point the 
biggest percentage of effector cells (TE, CD62L
-
CD127
-
)
 
among the TetOva
+
CD8
+ 
T cells was detected 
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in naïve mice infected with AdH-SL (Fig. 7C and 7D). This experimental group presented also the most 
elevated amount of effector memory T cells (TEM, CD62L
-
CD127
+
).  TEM were induced more vigorously 
by AdH-SL than AdF-SL vector, regardless of host status towards Ad. On the other hand, TCM cells 
(CD62L
+
CD127
+
)
 
were reduced in AdH-SL-injected mice in comparison to AdF-SL, whatever their Ad 
immune status. At a later time point, a trend to a reduction in TEM and to an increase in TCM was 
found for all groups. Yet, AdH-SL-injected mice displayed a reduced percentage of TCM compared to 
AdF-SL. 
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4. Conclusion 
Epitope display strategy was successfully used by us [5] and others [7, 8, 18] to induce 
humoral responses. Some of this studies tried to analyzed the cellular responses against class-II T cell 
epitopes, embedded in the original sequence of B cell epitope [7] Nevertheless, the capacity of Ad 
vectors displaying class-I T cell epitopes to trigger effective anti-epitope cellular responses was never 
evaluated. Thus, in order to address this question we constructed a panel of vectors displaying T cell 
epitope SIINFEKL coming from Ova model antigen. Epitope sequences were genetically inserted (with 
or without additional flanking sequences coming from Ova) into the hexon or fiber protein of Ad5 
capsid. Vectors were produced at titers comparable to AdWT and showed correct capsid integrity, 
disclosed by SDS-PAGE. Inserted epitopes were detected by anti-Ova polyclonal antibody, with better 
epitope accessibility for hexon insertion.  
Using an in vitro antigen presentation assay, we demonstrated that Ova epitope was 
efficiently processed from capsid protein and presented to T cell specific to H-2K
b
 + SL peptide, 
leading to their activation as documented by production of IL-2. Moreover, we showed that epitope 
insertion site strongly influences the efficacy of T cell activation, with stronger activation elicited by 
AdH-SL compared to AdF-SL. The difference in inactivation is not linked to the number of epitopes 
per capsid (hexon 240 x3 and fiber 12 x 3), since upon equalizing the total number of displayed 
SIINFEKL epitopes, AdH-SL still led to a significantly stronger T cell hybridoma activation than AdF-SL. 
Additionally, the presence of flanking sequences in the vectors has weak influence, if any, on epitope 
processing. 
Then, we analysed the cellular responses induced by both AH-SL and AdF-SL in Ad-naïve and 
Ad-immune C57BL/6 mice. After ten days splenocytes were harvested and analyzed by various 
techniques in order to assess induction of cellular responses. First, we demonstrated that 
splenocytes from AdH-SL injected Ad-naïve mice were able to elicit, upon restimulation with SL 
peptide, significantly higher IFN-γ production than AdF-SL. Interestingly, the splenocyte responses 
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were reduced in AdH-SL-injected Ad-immune mice compared to AdH-SL-injected Ad-naïve mice 
(Figure 4). Then, with the use of tetramers and by cytometry analyses we measured the number of 
SL-specific CD8
+
 T cells in the spleen at two time point after virus delivery (day 11-12 and day 25-26). 
In both Ad-naïve and Ad-immune background, AdH-SL was able to elicit stronger increase in 
SL-specific T cells than AdF-SL (Figure 5). When the functionality of SL-specific T cells was analysed by 
ELISPOT, we observed that SL-specific T cells induced by AdH-SL were able to produce IFN-γ upon in 
vitro restimulation (Figure 6). 
During our studies we also documented the expression of different phenotypic markers on 
SL-specific T cells to better characterize the nature of these cells (effectors vs. memory). We 
quantified the percentage of effector, effector memory and central memory phenotype within 
SL-specific T cells. Effector cells were found to be most numerous in AdH-SL-injected mice compared 
to AdF-SL-injected mice, regardless of the mice status at the time of virus administration. 
Interestingly, the percentage of cells displaying an effector memory phenotype was reduced at day 
25-26 p.i. while an increase in SL-specific central memory T cells was observed (Figure 9). 
Altogether, our results underline that Ad displaying T cell epitopes in hexon protein are able 
to elicit functional CD8
+
 T cells with memory phenotype.  
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Tables and figures  
Table 1: Features of wild-type Ad and Ad displaying ovalbumin-derived epitopes. 
 
 
 
  
Virus 
Modified 
protein 
Adaptor Inserted peptide Adaptor 
Titer 
(× 10
12
 vp/ml) 
AdWT - - - - 7.7 ± 0.8 
AdH-SL hexon G SIINFEKL LGG 7.2 ± 0.3 
AdH-5SL2 hexon G LEQLESIINFEKLTE LGG 2.9 ± 0.7 
AdH-3SL2 hexon G QLESIINFEKLTE LGG 4.2 ± 0.5 
AdF-SL fiber SS SIINFEKL GSS 3.7 ± 0.8 
AdF-5SL2 fiber SS LEQLESIINFEKLTE GSS 4.2 
AdF-3SL2 fiber SS QLESIINFEKLTE GSS 5.8 
 
 
 
Figure 1 Silver staining of capsid
a capsid-modified Ad (AdH-SL, AdH
a 10% polyacrylamide gel. Major capsid components (black arrow)
are identified. 
-modified Ad. 10
10
 vp of either a control Ad (AdWT) or 
-5SL2, AdH-3SL2, AdF-SL, AdF-5SL2, AdF-3SL2) were separated on 
 and modified fiber 
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(white arrow) 
 
Figure 2 Detection of SL, 5SL2 and 3SL2 epitopes on virions. ELISA plates were coated with 100 ng 
of denatured viruses and incubated with a rabbit polyclonal anti
binding was detected with HRP-conjugated secondary antibody. One of two experiments is shown, 
n = 6; means + SD. **P < 0.01 and ***
  
body against the 
P < 0.001 versus AdWT. 
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Ova protein. The 
 
Figure 3 Epitope presentation assay. 
FLDC for two hours at 10
4
 vp/cell. Untreated FLDC (medium
peptide were used as controls. SL
released in the supernatant was me
100 pg/mL. One of two experiments is shown, n
same epitope copy number. Fiber
and AdH-SL were incubated at 10
 
  
(A and B) AdWT or capsid-modified Ads were incubated with 
), FLDC pulsed with Ova
-specific hybridoma was then added and the amount of IL
asured two days later by ELISA. Saturated values were plotted as 
 = 3; means + SD. (C) Epitope presentation assay at 
-modified Ads were incubated with FLDC at 2x10
4
 vp/cell. 
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 protein or with SL 
-2 
5
 vp/cell. AdWT 
 
 
Figure 4 T cell immune responses elicited by Ad displaying 
mice were injected with PBS or 
injection of 10
10
 vp of Ad displaying SL epitope into
Splenocyes harvested at day 10 p.i. were stimulated 
Production of IFN-γ in the supernatant was assessed by ELISA. One of two experiments is shown. 
Dots and bars represent specific IFN
n = 5-7; *, P < 0.05. 
  
Ova-derived SL T cell epitope. C57Bl/6 
10
10
 vp of AdWT and two weeks after received 
 hexon (AdH-SL) or fiber (AdF
in vitro with Ova (SL), Ad or 
-γ production of individual mice and the group, respectively. 
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intraperitoneal 
-SL) protein. 
βgal peptide. 
 
Figure 5 Specific T cells elicited by Ad displaying 
with PBS or 10
10
 vp AdWT and after two weeks were injected 
displaying SL epitope into hexon (AdH
early (day 11-12) and late (day 25
tetramer staining. (A) Representative do
population. (B) Percentage of Tet
Ova-derived SL epitope. C57Bl/6 mice were injected 
intraperitoneally
-SL) or fiber (AdF-SL) protein. Splenocytes
-26) time points and SL-specific CD8
+
 T cells were measured by 
t plots showing tetramers-positive cells in CD8
+
Ova
+
 T cells and (C) total number of Tet
+
Ova
+
 T cells per spleen.
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 with 10
10
 vp of Ad 
 were harvested at 
+
 T cell 
 
 
Figure 6 Functional capacity of T cells elicited by Ad displaying 
were injected with PBS or 10
10
 
10
10
 vp of Ad displaying SL epitope into hexon (AdH
harvested at early (day 11-12) and late (day 25
capacity to produce IFN-γ was assessed after restimulation with 
and bars represent the number of specific 
respectively. Dots and bars represent specific IFN
respectively. n= 5-6. 
  
Ova-derived SL epitope. C57BL/6 mice 
vp AdWT and after two weeks were injected intraperitoneally
-SL) or fiber (AdF-SL) protein
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Supplementary figures 
Supplementary figure 1 In vitro
(PBS) or infected with increasing MOI of 
fiber-modified Ads (b). βgal activity,
24 h later. Experiments run in duplicate were performed twice and representative results are shown.
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 expressed as RLU/µg of protein, was measured in cell lysates 
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ARTICLE 3 
Immune responses triggered by adenovirus displaying HCV epitopes in their capsid proteins. 
 
Abstract 
Hepatitis C virus (HCV) is a blood-born pathogen estimated to chronically infect 3% of the 
worldwide population, significantly enhancing the risk of liver cancer development. Studies in 
infected individuals showed that vigorous cellular and humoral anti-HCV responses are correlated 
with resolution of acute infection. Hence, many strategies have been evaluated to propose 
a promising vaccine candidate. Herein we report the production of recombinant adenovirus (Ad) 
vectors displaying B cell or T cell epitopes of HCV into their capsid proteins. Our results indicate that 
vectors displaying T cell epitope are capable of triggering anti-HCV cellular responses, suggesting 
potential of this vaccination strategy in fighting this pathogen infection. 
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1. Introduction 
Hepatitis C virus (HCV) infects 170 million people worldwide and is considered to be one of 
the major health burden. Due to its ability to escape the detection of the immune system, HCV can 
persist in the organism for years, leading to liver pathologies such as cirrhosis and hepatocellular 
carcinoma (HCC). Indeed, HCV infection is considered one of the main reasons of liver failure in the 
world. Until now, no effective vaccine is commercially available, and thus counteracting the HCV 
pathology relies exclusively on pharmacological approaches. For a long time the “golden standard” of 
anti-HCV therapy was a combination of IFN-α and ribavirin, both limiting virus infection in an 
unspecific manner. Recently, directly acting antivirals (DAAs), molecules which specifically target the 
virus proteins, were identified and developed. Combination of IFN-α/ribavirin with virus protease or 
polymerase inhibitors allowed to significantly increase the rate of sustained virologic response. 
However, treatment outcome is mostly depending on the virus genotype, as the majority of currently 
used DAAs do not have pan-genotypic efficacy. Also, new DAAs-based therapies are very expensive 
and associated with important secondary effects. This makes a discovery of an effective cross-
reactive anti-HCV vaccine a high priority, both to prevent the initial infection and to counteract re-
infection after successful cure with costly DAA-based [12].  
HCV is a difficult target from the immunological point of view. Virus mutates quickly and 
thus six main genotypes can be distinguished, differing significantly in their genome sequence. In 
order to ensure cross-protection against all genotypes, a conserved epitopes must be selected in the 
pathogen sequence. It has been shown that humoral responses are mostly targeting surface 
glycoproteins, E1 and E2. Cellular branch of immunity, on the other hand, is directed against 
non-structural proteins performing important functions in virus life cycle, such as NS5A polymerase 
or NS3 helicase. Many strategies of immunization against HCV have been evaluated, such as 
recombinant proteins, synthetic peptides, DNA plasmids, virus-like particles or recombinant viruses 
[1]. Nevertheless, no candidate reached the market so far. 
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Epitope display strategy is a new vaccination approach developed in order to overcome 
pre-existing anti-Ad immunity. Numerous studies confirmed that insertion of antigenic peptide into 
the Ad capsid results in triggering humoral responses against the introduced epitope. This was 
observed for both model antigen ovalbumin [6] as well as for peptides coming from different 
pathogens, such as P. aeruginosa [13] or B.anthracis [8]. With this regard, we aimed at the induction 
of anti-HCV immune responses by constructing Ad vectors displaying in their capsomers epitopes 
coming from the HCV (genotype 1B) proteins. Immunodominant conserved B cell epitopes from E2 
glycoprotein and T cell epitopes from NS3 protein were introduced into Ad5 hexon or fiber protein. 
Our results show that Ad displaying T cell epitope are capable of inducing anti-HCV cellular immunity 
in HLA-A2 transgenic mice. On the contrary, vectors displaying B cell epitopes failed to mount 
detectable anti-E2 antibody responses.  
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2. Materials and methods 
 
2.1. Virus construction and production 
AdWT (described as AE18 in [11]) is based on Ad5 and possess deletions in E1 and E3 
regions. The expression cassette containing the promoter/enhancer from the immediate early gene 
of human cytomegalovirus (CMV), lacZ gene Escherichia coli with a nuclear localization signal, and 
the SV40 late polyA signal were inserted in the place of E1 region. For the analysis of humoral 
responses, AdH-HVR, AdF-HVR and AdF-HCR vectors were constructed, all derived from AdWT, 
displaying epitopes from HCV genotype 1B. AdH-HVR and AdF-HVR contain E2 glycoprotein epitope 
HVR384-410: HTHVTGGRVASSTQSLVSWLSQGPSQK inserted into, respectively, the hexon protein in 
place of HVR5 region 269TTEAAAGNGDNLT281 or into the fiber protein knob in place of 
T539QETGDTTPS548. Similarly, AdF-HCR was obtained by inserting E2 glycoprotein epitope HCR1412-431 
QLVNTNGSWHINRTALNCNDninto the fiber HI loop. For the assessment of cellular responses, 
AdH-NS31073 and AdH-NS31406 vectors were constructed, both derived from AdWT displaying epitopes 
from HCV genotype 1B. The HVR5 region 269TTEAAAGNGDNLT281 of hexon protein was replaced with 
HCV NS31073-1081 epitope 1073CVNGVCWTV1081 or NS31406-1415 epitope 1406KLTGLGLNAV1415 to generate 
AdH-NS31073 and AdH-NS31406, respectively. AdE1E2 (kindly provided by Dr B.Bellier, UPMC) possess 
a wild-type capsid and encodes the entire E1 and E2 glycoproteins of HCV from the 1a genotype H77 
strain in the E1 region [5].  All capsid-modified viruses (Table 1 and 2) were constructed in E. coli with 
the methods of molecular cloning [3]. Viruses were obtained using previously described procedures 
[7]. They were titrated by spectrophotometry (1 OD260 = 1.1×10
12
 viral particle (vp)/ml) and stored in 
PBS–7% glycerol at −80 ◦C. 
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2.2. Cell lines 
The 293A human embryonic kidney cell line (R705-07, Invitrogen) was maintained in 
modified Eagle medium (MEM) supplemented with 10% FBS and 1% of non-essential amino acids 
(NEAA). CHO-k1-hCAR cells were kindly provided by J.M. Bergelson (School of Medecine, University 
of Pennsylvania) and were cultivated in F-12 Glutamax medium supplemented with 10% FBS and 
grown under G418 conditions. I8H4 is a stable Tcells-BW hybridoma cell line specific for HCV NS31073-
1081 epitope (kindly provided by M.Chen, Karolinska Institut) [9]. Cells were maintained in modified 
Eagle medium (MEM), supplemented with 10% FBS, 1% NEAA, and 2-βmercaptoethanol. 
 
2.3. E2 glycoprotein 
Truncated E2 glycoprotein, deprived of its transmembrane domain (kindly provided by 
K.Bienkowska-Szewczyk, Gdansk University), was produced using Bac-to-Bac
 TM
 system (Life 
Technologies. Inc.). Insect cells were infected with recombinant baculovirus encoding E2 protein. 
Medium from the cell culture was collected 72h post-infection and centrifuged 28 000 rpm for 2h to 
remove baculovirus particles. The supernatant was completed with glycerol (10% final concentration) 
and stored at -80°C. 
 
2.4. Peptides 
E2 glycoprotein HVR (QLVNTNGSWHINRTALNCND) and HCR 
(HTHVTGGRVASSTQSLVSWLSQGPSQK) botinylated peptides were purchased from GENECUST. NS3 
protein peptide 1073-1081 (CVNGVCWTV) was ordered at Proimmune. NS3 peptide 1406-1415 
(KLTGLGLNAV) and epitope 917-925 (YVLFEVFDV) from Ad hexon protein were synthesized by 
PolyPeptide. Purity of all peptides was > 90%. 
 
 195
2.5. Cell transduction 
In order to evaluate virus infectivity, CHO-k1-hCAR cells were plated out in 12-well plates 
(1×10
5 
cells/well) 48h prior to infection. Then, Ad was added at different multiplicity of infection 
(MOI, ranging from 10
2
  to 10
4
 vp/cell) in 400µl of serum-free medium. After 1h of incubation in 37°C, 
an additional 2ml of medium supplemented with 10% FBS was added and cells were incubated for 
24 hours at 37°C. Cells were then harvested and βgal activity was measured using Bio-Rad Protein 
Assay (Bio-Rad Laboratories, Hercules, Marnes-la-Coquette, France). Results were presented as 
relative light units (RLU) per microgram of proteins. 
 
2.6. Epitope detection with ELISA  
To confirm the presence and accessibility of the epitopes on the capsid surface native viral 
particles were coated on 96-well plates (Nunc, Roskilde, Denmark). Viruses were inactivated by 
30 min incubation at 56°C and subsequently denaturated with 0.1% SDS. Spectrophotometric 
measurements at 215nm and 225nm allowed determining protein concentrations, and quantities of 
non-denaturated viruses corresponding to 100ng of proteins were coated on 96-well plates. After 
overnight incubation at 4°C, wells were blocked with 5% milk PBS-Tween for 2h, then washed and 
incubated for 1 h with an anti-HCR rabbit monoclonal Ab (AP33, provided by A. Patel, Glasgow 
University). Upon washing, an anti-mouse IgG goat peroxidase-linked Ab (1030-05, Southern 
Biotechnology Associates, Birmingham, AL France) was added for 1 h and peroxidase activity was 
revealed by incubation with O-phenylenediamine dihydrochloride (Sigma–Aldrich, Lyon, France) for 
30 min. The reaction was stopped by addition of 3N HCl and spectrophotometric readings were 
performed at 490 nm. 
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2.7. FLDC preparation 
FLDC (Flt3 ligand-dependent dendritic cells) were generated from bone marrow precursors. 
Bone marrow cells were harvested from tibias and femurs of HHD mice by flushing with complete 
RPMI medium (RPMI supplemented with 5% SVF, 1% non-essential amino acids, 1% glutamine, 1% 
pyruvate and 5.10
-5
 M β-mercaptoethanol), and filtered through a 100µm cell strainer. After removal 
of blood cells by ACK Lysing Buffer (Invitrogen, Cergy-Pontoise, France), cells were resuspended and 
the concentration was adjusted at 2 × 10
6
 cells/mL. Cells (5x10
6
/well) were plated in MW6 plates, 
and recombinant human Flt3 Ligand (Flt3L) was added at 250 ng/mL. Cultures were fed with fresh 
Flt3L-complemented RPMI medium every 2-3 days. At day 10, FLDCs were harvested from the 
cultures by vigorously pipetting and labelled with Pacific blue anti-CD11b (eBioscience, CA, USA), FITC 
antiI-A
b
, PE anti-CD24, PE-Cy
TM
7 anti-CD11b and PerCP anti-CD45R/B220 (BD Bioscience, CA, USA) 
Abs. The diverse phenotypic characteristics of FLDC were confirmed using a FACS scan (BD 
Biosciences). 
 
2.8. Antigen presentation in vitro 
FLDC were seeded on a 96-well culture plate at a density of 10
5
 cells/well. Cells were 
incubated with control or capsid-modified Ads for 2 hours at 10
2
, 10
3 
or 10
4
 vp/cell in a final volume 
of 100 µL of complete RPMI medium. Controls included untreated FLDC or FLDC incubated for 2 
hours with NS31073-1081 peptide CVNGVCWTV (10µg/mL and 20µg/mL). Then, I8H4 cells were added 
(10
5
 cells/well in 100 µL) and co-cultured with FLDC during 2 days at 37°C. The response of stimulated 
hybridoma cells was assessed by determination of IL-2 concentration in the supernatants using the 
murine IL-2 ELISA Kit (BD Bioscience). 
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2.9. Determination of antigen-specific serum antibodies 
Sera were analysed for the presence of E2-, βgal- and Ad-specific Ab by ELISA. In order to 
detect anti-E2 Ab, 0.25µg of Galanthus Nivalis lectin was coated on 96-well plates (Nunc) and 
incubated overnight. After washing plates with TBS supplemented with Tween20 0.05% (TBST) and 
blocking with 5% milk TBST, 100µl of supernatant containing E2, was added to each well for 2 hours. 
For the detection of anti-βgal and anti-Ad Ab, 96-well plates (Nunc) were coated with 100ng of βgal 
(Sigma) or 100ng of denaturated AdWT viral particles per well, respectively, and blocked with 5% 
milk TBST. Subsequently, serial dilutions of the sera in 5% milk TBST were added. Then, bound Ab 
were detected as described above. Titers were defined as the reciprocal of the highest dilution giving 
an OD490 2-fold above background values. 
Sera were also analysed for the presence 2 peptide-specific Abs. Biotinylated HCR (100ng/well) and 
HVR (500ng/well) peptides were added to 96-well plates coated with streptavidin (DUTSCHER) and 
incubated overnight. After washing plates with TBST 0.05% and blocking with 5% milk TBST, different 
sera dilutions were added to each well for 2 hours.   
 
2.10. In vivo experiments 
All in vivo experiments were approved by the Gustave Roussy Institutional Animal Care and 
Use Committee. C57BL/6 female mice (seven-week-old or at the age corresponding to obtained HHD 
mice) were purchased from Harlan (Gannat, France) and were conditioned for at least one week in 
the animal facilities before beginning of the experiments. DR3 HHD mice with C57BL/6 genetic 
background express a chimeric HLA-A2 molecule expressing α1 and α2 domains of the HLA-A2.1 
fused to the α3 domain of murine H-2D
b
 and to human β2-microglobulin. In addition, they express 
HLA-DR3 molecule and are deficient in murine class-I and class-I genes. 
Viruses (10
10 
vp) in PBS or PBS alone (200µl) as a negative control were injected 
intraperitoneally. Repeated injections were performed at 2 weeks intervals with total number of 
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injections ranging between 1 and 2. Blood samples were collected sub-mandibularlly, before virus 
injection and at different time points thereafter. Mice sera were prepared and analyzed for the 
presence of anti-E2, anti-βgalactosidase (βgal), and anti-Ad Ab by ELISA as described previously.  
For the experiments assessing cellular immune responses mice were sacrificed 10 days 
after the second injection. Spleen was harvested and after obtaining singe-cell suspension it was 
filtered through a 100 µm cell strainer. After removal of blood cells by ACK Lysing Buffer (Invitrogen, 
Cergy-Pontoise, France), the cells were resuspended in Supplemented RPMI and the concentration 
was adjusted at 2.5 × 10
6
 cells/mL. Then, splenocytes were restimulated in vitro to assess their 
function.  
 
2.11. Statistical analysis 
For the statistical analysis a Mann–Whitney test was performed, recommended for groups 
fewer than 30 mice. Differences were considered significant when P < 0.05. All graphs and statistical 
data were obtained with the use of GraphPad Prism software.
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3. Results 
Production and characterization of Ad displaying HCV-derived epitopes 
In order to evaluate the induction of anti-HCV humoral and cellular responses with the 
epitope display vaccination strategy, first, epitopes were selected from structural E2 protein (HVR1 
and HCR1) or from non-structural NS3 protein (NS31038-1047, NS31073-1081 and NS31406-1415). The 
sequences encoding these epitopes were introduced by homologous recombination in E. coli in a lacZ 
recombinant Ad5. Of note, the sequence encoding NS3 epitopes was flanked or not with additional 
residues surrounding the epitope in NS3 protein. Among the 18 different viral genomes produced, 
only 6 were infectious (Table 1 and 2). AdH-HVR and AdF-HVR encoding HVR into hexon or fiber 
protein, respectively, were produced. AdF-HCR encoding HCR epitope in the fiber protein was 
produce while AdH-HCR was not rescued (Table 2). Regarding T cell NS3 epitopes, AdHNS31073 and 
AdHNS31406 bearing, respectively, NS31073-1081 and NS31406-1415 epitopes into hexon protein were 
successfully produced. AdF-NS31035 containing NS31038-1047 epitope surrounded by flaking residues and 
inserted into fiber protein was successfully produced but not its counterpart containing the same 
peptide in the hexon protein (Table 1). All 6 viruses were produced at titer comparable to AdWT 
bearing a wild-type capsid (Table 1 and 2).  
SDS-PAGE analyses of the viruses showed similar capsid composition and integrity, with an 
additional band corresponding to the modified fiber visible for vectors displaying HVR or HCR 
epitopes in the fiber protein (Figure 1A). The presence of the epitope on AdF-HCR was confirmed by 
ELISA performed on denaturated virions using AP33 monoclonal Ab (A.Patel, Glasgow University) 
(Figure 1B). All vectors displaying HCV epitopes were able to transduce CHO-k1-CAR cells expressing 
Ad5 primary receptor to the same extend as AdWT (Figure 2), thus demonstrating no modification of 
their infectivity. 
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Humoral responses elicited by Ad displaying E2 epitopes 
First, we sought to evaluate the potential of vectors displaying B cell epitopes  to induce humoral 
anti-HCV responses. C57BL/6 mice were injected twice i.p. with AdH-HVR, AdH-HCR and AdF-HVR 
(10
10 
vp). Ab responses were analysed 2 weeks after each injection but no anti-E2 titers were 
detected for neither of the virus (data not shown). Of note, the presence of anti-βgal Ab confirmed 
virus infectivity in vivo, ruling out any vector precipitation. Interestingly, immunized mice with 
AdE1E2 vector, encoding both HCV glycoproteins as a transgene (B. Bellier, UPMC) present significant 
anti-E2 Ab titers, indicating that C57BL/6 mice are capable of mouting E2-specific humoral responses. 
Then, we performed ELISA to analyse the ability of anti-E2 Abs produced in C57BL/6 mice to interact 
with HCR or HVR peptides. The results showed that HCR but not HVR peptide was recognised by anti-
E2 mouse sera (data not shown). These results indicate that HVR epitope is not an immunodominant 
E2 epitope, at least in C57BL/6 background.  
 
Processing of NS3 epitope inserted into capsid Ad proteins 
In order to confirm the presence of NS31073-1081 peptide on the surface of AdH-NS31073 and to 
evaluate epitope processing in vitro, we set up an in vitro antigen presentation assay based on the 
use of FLDC, dendritic cells derived from bone marrow precursors of HHD mice, and 
NS31073-1081-specific T cell hybridoma I8H4 (M. Chen, Karolinska Institut). FLDCs were incubated with 
AdH-NS31073 or AdWT and I8H4 cells were added 2 hours later. Measurement of IL-2 production in 
the supernatant was used as a marker of hybridoma activation, indicating the recognition of 
NS31073-1081 peptide on HLA-2 molecules displayed by FLDC. Remarkably, IL-2 was produced in 
a dose-dependent manner when AdH-NS31073 was added in the co-culture but not in the presence of 
control AdWT (Figure 3). These results demonstrate that NS31073-1081 epitope embedded in hexon 
protein is efficiently processed and presented on HLA-A2 molecules of antigen-presenting cells. 
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Cellular responses triggered by Ad displaying HCV T cell epitopes 
Having demonstrated efficient NS3 epitope processing from AdH-NS31073, we evaluated the 
capcity of Ad bearing NS3 epitopes to trigger cellular immune responses in mice. HHD mice received 
two i.p. injections (10
10 
vp) of either AdH-NS31073 or AdH-NS31406 at an interval of 14 days and were 
sacrificed 10 days after the second administration. Spleens were harvested and single cell 
suspensions of splenocytes were restimulated in vitro in different conditions. Remarkably, IFN-γ 
production in the supernatant of cells restimulated by NS31073-1081 peptide revealed the capcity of 
AdH-NS31073 to trigger CD8
+
 T cell responses (Figure 4). More importantly, IFN-γ production in vitro 
was higher upon restimulation with NS31073-1081 than with Ad peptide, emphasizing the capacity of 
AdH-NS31073 to induce anti-HCV T cell responses.  
In contrast to AdH-NS31073, AdH-NS31406 was unable to elicit in vivo cellular responses 
directed against NS31406 as documented by the absence of IFN-γ production upon specific 
restimulation. This is not due to a general lack of immunogenicity of this vector, since in vitro 
restimulation revealed induction of potent anti-Ad cellular responses (Figure 4).  
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4. Conclusions 
 
HCV remains one of the most extensively studied human pathogens. Its capacity to induce 
chronic infections, leading to hepatocellular carcinoma as well as its variability strongly highlights the 
need for an effective cross-reactive vaccine. Among numerous vaccination strategies, a new 
approach based on genetic insertion of the selectes epitopes into the Ad capsid is currently taking 
the lead. The efficiency of this strategy was already demonstrated for other pathogens, such as 
B.anthracis or P.aeruginosa. Based on these results, we evaluated the potential of epitope display 
approach in counteracting HCV infection. 
Several studies described E2 envelope glycoprotein as the main target for anti-HCV humoral 
responses. More precisely two regions named hyper conserved region (HCR) and hyper variable 
region (HVR) were described ad immunodominant epitopes. We thus selected these sequences and 
inserted them into hexon or fiber protein. Vectors with HVR epitope in hexon and fiber were 
successfully rescued. As for HCR, only vector displaying this sequence in fiber was producible. Due to 
the limited antibody availability we were able to confirm only the presence of HCR epitope on the 
surface of AdF-HCR. 
We encountered difficulties in inducing humoral anti-E2 responses with our vectors 
displaying HCR and HVR epitopes into their capsid. Further analysis with the use of positive control 
vector, AdE1E2 encoding E1 and E2 glycoproteins as a transgene, disclosed that HVR epitope is not 
recognized by anti-E2 Abs induced in C57BL/6 mice. HCR region, on the other hand was one of the 
targets of Abs induces upon immunization with the entire E2 protein. Thus it remains unclear why 
AdF-HCR vector failed to mount a detectable humoral responses and further experiments will be 
needed (increased virus dose, addition of the adjuvants) in order to assess whether HCR epitope 
presented in the context of Ad capsid can be recognized by the immune system.  
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In case of T cell epitopes, we successfully produced Ad vectors displaying NS3 epitopes 
1073-1081 and 1406-1415 inserted into the hexon protein and 1038-1047 (with flanking sequences) 
inserted into fiber protein. AdH-NS31073 was shown to efficiently stimulate IL-2 production by 
HCV-specific T cell hybridoma, demonstrating that epitope displayed on this vector can be processed 
and presented on antigen-presenting cells by HLA-A2 molecules. 
AdH-NS31073 injected into HHD mice was capable of triggering anti-HCV responses as observed 
in in vitro splenocyte restimulation assay. Interestingly, these responses were more robust than 
those directed against one Ad hexon epitope. Studies are ongoing to better characterize these T cells 
responses. 
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Table 1. Ad vectors displaying T cell epitopes from HCV NS3 protein. 
Virus Transgene Modified protein Epitope Inserted sequence Titer 
a
 (× 10
12
 vp/ml) 
AdWT βgal - - - 4.4 ± 0.8 
AdH-NS31035 
AdF-NS31035 
AdH-NS31038 
AdF-NS31038 
βgal 
βgal 
βgal 
βgal 
Hexon 
Fiber 
Hexon 
Fiber 
NS3 (1038-1047) 
QRTGLLGCIITSLTG 
QRTGLLGCIITSLTG 
GLLGCIITS 
GLLGCIITS 
n.i.
b
 
2.6 
- 
- 
AdH-NS31068 
AdF-NS31068 
AdH-NS31070 
AdF-NS31070 
AdH-NS31073 
AdF-NS31073 
βgal 
βgal 
βgal 
βgal 
βgal 
βgal 
Hexon 
Fiber 
Hexon 
Fiber 
Hexon 
Fiber 
NS3 (1073-1081) 
SFLATCVNGVCWTVYHGAG 
SFLATCVNGVCWTVYHGAG 
LATCVNGVCWTVYHG 
LATCVNGVCWTVYHG 
CVNGVCWTV 
CVNGVCWTV 
- 
- 
- 
- 
8.2 
- 
AdH-NS31403 
AdF-NS31403 
AdH-NS31406 
AdF-NS31406 
βgal 
βgal 
βgal 
βgal 
Hexon 
Fiber 
Hexon 
Fiber 
NS3 (1406-1415) 
LAAKLTGLGLNAVAYY 
LAAKLTGLGLNAVAYY 
KLTGLGLNAV 
KLTGLGLNAV 
- 
- 
6.8 
- 
a 
Mean ± SD; 
b 
n.i. – non infectious, -  non producible 
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Table 2. Ad vectors displaying B cell epitopes from HCV E2 protein. 
a
Mean ± SD
Virus Transgene Modified protein Epitope Inserted sequence Titer 
a
 (× 10
12
 vp/ml) 
AdWT 
AdE1E2 
βgal 
E1 and E2 
- 
- 
- 
- 
- 
- 
4.4 ± 0.8 
2.2 
 
AdH-HVR 
AdF-HVR 
βgal 
βgal 
Hexon 
Fiber 
HVR (384-410) HTHVTGGRVASSTQSLVSWLSQGPSQK 
4.5±0.4 
1.6±0.9 
AdH-HCR 
AdF-HCR 
βgal 
βgal 
Hexon 
Fiber 
HCR (412-431) QLVNTNGSWHINRTALNCND 
- 
3.8±0.4 
 
 
 
Fig. 1 Vector characterization in vitro
a control Ad (AdWT) or a capsid
AdF-HCR) were separated on a 10% polyacrylamide gel. Major capsid components (black arrow)
modified fiber (white arrow) are identified
ELISA plates were coated with 100 ng of denatured virus or E2
monoclonal antibody against the 
secondary antibody. One of two experiments is shown, means+SD. 
. (A) Silver staining of capsid-modified Ad. 10
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Figure 2 In vitro infectivity of capsid modified vectors. CHO-k1-hCAR cells were mock-infected (NI) or 
infected with different MOI of AdWT or capsid-modifed Ad (AdH-NS31073, AdH-NS31405, AdH-HVR, 
AdF-HVR, AdF-HCR). βgal activity was measured in cells harvested 24 h post-infection. (βgal activity 
expressed as relative light unit (RLU) per µg of protein. The representative results of at least 2 
experiments are shown. 
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Figure 3 Epitope presentation assay. AdWT (10
4
 vp/cell) or AdH-NS31073 (10
2 
-10
4
 vp/cell) were 
incubated with FLDC for two hours. FLDC incubated with different concentrations of NS31073-1081 
peptide were used as positive controls. Anti- NS31073-1081 T cells were then added and the amount of 
IL-2 released in the supernatant was measured two days later by ELISA. One of two experiments is 
shown, n=3; means+SD.  
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Figure 4 T cell immune responses elicited by Ad displaying HCV-derived T cell epitopes. HHD mice at 
two week distance received two intraperitoneal injections of 10
10
 vp of Ad displaying NS31073-1081 or 
NS31406-1415 epitope into their hexon protein (AdH-NS31073 or AdH-NS31406, respectively). Splenocytes 
harvested at day 10 p.i. were stimulated in vitro with corresponding NS3 epitope, Ad epitope or 
AdWT. Production of IFN-γ in the supernatant was assessed by ELISA. Dots and bars represent 
specific IFN-γ production of individual mice and the group, respectively. n = 4-6 
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Figure 5. Humoral responses elicited by Ad encoding E1 and E2 glycoproteins in the form of 
transgene. C57BL/6 mice were immunized intraperitoneally twice in a 2 week distance with 10
10
 vp of 
AdE1E2 od AdWT. Anti-E2 titers were determined by ELISA at day 28 and 49 after the first 
administration. Titers below 100 were plotted as 50. One of two experiments is shown, dots and bars 
represent results form individual mice (n = 5-6 mice) and means, respectively.  
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Progresses in vaccine development allowed to select the most immunogenic elements in 
the pathogen structure, reducing antigen size to a single protein or peptide. However, administration 
of highly purified, non-vectorised molecules fails to trigger adaptive immune responses. These limits 
underpinned a need for a potent vaccine platform and Adenovirus (Ad) -derived vectors are among 
the few candidates. Unfortunately, high prevalence of this virus results in pre-existing anti-Ad 
immunity, detected in the majority of population (50-90%). Various strategies aiming at overcoming 
this limitation were proposed (described in paragraph 2.3.1.), among them a new vaccination 
approach called Epitope Display, based on the genetic insertion of heterologous epitopes into Ad 
capsid. In a previous work of our lab we evaluated the influence of the epitope insertion site and the 
host status towards Ad on the vaccination potency of epitope display strategy (Lanzi et al., 2011). The 
results indicated that in Ad-immune mice vector displaying ovalbumin (Ova) B cell epitope (Ova323-339) 
into its fiber protein was by far more potent in eliciting anti-Ova antibody upon the second injection 
than Ad with Ova323-339 inserted into hexon. This boosting potential of fiber-displaying vector was 
owed to the presence of anti-Ad antibodies (Abs).  
In the present work we pursued the investigation of the efficacy of epitope display strategy. 
The results presented above will be discussed in three paragraphs. Initially, the molecular bases 
controlling the induction of humoral responses by Ad displaying Ova B cell epitope will be evaluated, 
with an emphasize on virus and host factors shaping the vaccination efficacy. Subsequently, in the 
second paragraph, I will comment on our data obtained with Ad vectors displaying Ova-derived 
CD8
+
 T cell epitope. In the following paragraph our attempts to apply epitope display strategy into 
the vaccination against HCV will be discussed, and finally I will finish by describing the future 
perspectives of this vaccination approach. 
 
1. Humoral responses elicited against a model antigen 
 
The results obtained by Lanzi et al., showed that presence of anti-Ad Abs does not impede 
the boosting potential of Ad vectors displaying Ova323-339 in fiber. This suggests that the virus 
infectivity process might not be a crucial factor influencing the efficacy of this vaccination strategy. 
Thus, in the first turn, we aimed at deciphering the molecular components, of both vector and host 
origin, dictating the remarkable vaccination potential of Ad vectors displaying heterologous B cell 
epitopes into their capsid.  
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1.1. Role of virus factors 
1.1.1. Requirement of cell infection 
In the first turn we decided to evaluate the capacity of vectors displaying Ova323-339 B cell 
epitope in the fiber or hexon protein to induce anti-Ova humoral responses in naïve and Ad-immune 
mice. We showed that these vectors were not limited by pre-existing anti-Ad immunity and induced 
detectable anti-Ova antibody titers. Moreover, vector displaying epitope in fiber elicited more robust 
anti-ovalbumin humoral responses in Ad-immune mice than in naïve animal, and anti-ovalbumin Abs 
were detectable up to 7 months after the first injection. β-galactosidase (βgal), introduced as 
a transgene, served as a control of viral genome expression. The lack of anti-βgal Abs in Ad-immune 
mice confirmed that these vectors were unable to efficiently transduce cells in vivo and to express 
βgal. The reduced anti-transgene humoral responses coinciding with unaltered levels of anti-Ova Abs 
clearly indicate that virus infectivity process and subsequent gene transfer are not indispensable 
steps in epitope display vaccination strategy.  
Previous reports indicate that Ad gene expression is not needed to mount an innate 
immunity (Muruve et al., 2004). Also, experiments with transcription-defective Ad induced 
inflammatory responses similar to the transcription-competent Ad viral particles, demonstrating that 
the activation of innate immunity is provided by Ad particle and not by products issued from viral 
genome expression (McCoy et al., 1995). Another study using Ad vector with inactivated gene 
expression (through UV-induced DNA crosslinking) showed that this modification did not hamper the 
induction of humoral response against Ova protein fused to pIX capsid protein (Johrden et al., 2013). 
All these reports support our results and confirm that gene transfer is dispensable, and suggest that 
intrinsic adjuvant capacity ensured by Ad particle provides sufficient stimulation of innate immunity 
sensors.  
Another interesting point is the influence of pre-existing anti-Ad Abs on the induced 
immune responses. We observed that Ad displaying epitope in fiber benefits from pre-Ad immunity 
in its immunogenicity. Similar observations were obtained with the use of AAV viral like particles 
(VLPs, described below) displaying epitopes of HPV, where anti-HPV humoral response was increased 
in animals pre-immunized with AAV (Nieto et al., 2012). A recent study found that anti-Ad immunity 
could potentially be advantageous in the vaccination approach, since Ad particles coated with Abs, 
while uptaken into the cells, can activate a cytoplasmic Fc-receptor TRIM21, leading to NF-κB-, IRF- 
and AP-1-dependent production of pro-inflammatory cytokines (McEwan et al., 2013). Different 
studies also showed that Ad particles coated with Abs not only are better uptaken by DCs, but also 
cause a better maturation of these cells, as reflected by an increased expression of co-stimulatory 
molecules and more vigorous production of pro-inflammatory molecules (Perreau et al., 2008). These 
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reports could explain the stronger anti-Ova titers induced by fiber-displaying vector in Ad-immune 
mice. They also further underline that the strategy of displaying heterologous epitopes in Ad fiber 
protein can be successfully used in both naïve and Ad-immune background. 
 
1.1.2. Interaction with natural receptors 
To further investigate the minimal requirements that Ad vector needs to fulfill in order to 
elicit potent humoral responses against displayed epitopes, we evaluated the role of vector 
interactions with its natural receptors. We previously reported that Ad interactions with cellular 
receptors and host factors are shaping vector tropism and inflammatory profile (Vigant et al., 2008; 
Raddi et al., 2016). Others also described that Ad binding to these molecules not only influences the 
cell entry but also results in the activation of intracellular signaling (for a review see Descamps and 
Benihoud; 2009). In order to investigate the impact of these interactions on Ad vaccination potential, 
we constructed a panel of Ad vectors simultaneously displaying Ova323-339 B cell epitope in the fiber 
protein and possessing receptor-detargeting mutations. 
Interaction of fiber protein with CAR receptor triggers downstream signaling, resulting in 
NF-κB-mediated upregulation of IL-8 production (Tamanini et al., 2006). We recently showed that 
Ad5 vector pseudotyped with Ad3 shaft induces reduced blood toxicity and cytokine production 
(Raddi et al., 2016) as well as decreased liver uptake (Raddi, in revision). We thus pseudotyped 
previously described AdF-3OVA2 vector with Ad3 shaft in order to generate a vector with reduced 
potency to interact with CAR receptor and disabled in HSPG binding due to the lack of KKTK motif 
present in Ad5 shaft. We were able to show that this mutation significantly limits anti-transgene 
antibody titers but does not have an impact on anti-Ova humoral responses. Other molecules which 
play an important role in both cell entry and innate signaling are integrins. Di Paolo and colleagues 
found that interaction of RGD motifs with β3integrins on the macrophage surface induces IL-1α-
mediated response (Di Paolo et al., 2009). Another study reported that Ad generates reduced 
inflammatory profile in β3integrin knock-out mice, confirming involvement of this molecule in the 
early innate immune responses (Browne et al., 2015). Thus, basing on previous results of our 
laboratory showing that mutation in penton base (RGD deletion) ablates Ad5 interaction with 
integrins (Vigne et al., 2003), a vector bearing this mutation was also evaluated in this part of my 
work. Similarly to the ablation of CAR and HSPG interactions, blocking the integrin binding did not 
diminished the potency of epitope display strategy. Another cell entry factor, FX, was more recently 
proposed as an element shaping Ad-induced immune responses. Doronin et al. claim that while 
bound to Ad, FX can stimulate TLR4, reinforcing innate immune responses in mice (Doronin et al., 
2012). However, a more recent study reporting no stimulation of human mononuclear phagocytes by 
Ad-FX questioned these results (Eichholz et al., 2015). We took benefit from our earlier data, showing 
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that mutation in hexon (HVR5 deletion) prevents FX binding (Vigant et al., 2008), and generated a 
vector displaying Ova323-339 in fiber and crippled in FX binding. The ablation of Ad interactions with its 
natural cell entry factor did not have any influence on anti-Ova humoral responses which were as 
potent as for AdF-3OVA2 vector. Since Ad binding to FX was shown to be responsible for strong liver 
uptake (Parker et al., 2006), our results could lead to the generation of vectors with reduced 
hepatocyte tropism and unaltered vaccination potential.  
Altogether our results raise questions how severely Ad vector can be crippled before it 
loses its adjuvant properties. With this regard we decided to combine mutations altering FX and 
integrin binding on one virus particle. This vector displayed further reduction in its in vivo infectivity, 
nevertheless presented unaltered capacity to trigger anti-Ova humoral responses, further 
underpinning our previous observations. Krause and colleagues also reported that reducing CAR- and 
integrin-dependent interaction of Ad vector displaying epitope from hemagglutinin into its fiber 
protein had no impact on the humoral responses elicited in vivo by this vector (Krause et al., 2006). 
After evaluating the role of reduced Ad gene transfer this would be interesting to analyze the 
outcome of vaccination with empty capsid (an Ad particle completely deprived of viral DNA) 
displaying Ova epitope. It is difficult to anticipate the outcome of such particles unable to drive 
de novo synthesis of viral proteins and disabled in stimulating DNA sensors such as TLR9. Some 
studies have investigated virus like particles (VLPs), generated from viral structural proteins upon in 
vitro self-assembly. In case of Ad, twelve Ad3 penton base proteins (with or without the fiber 
protein) can self-assemble into so-called dodecahedron (Dd) (Fender et al., 1997). A few attempts 
were made to use these structures as a vaccine platform. Ova fragment was fused to the penton 
base protein and Dd immunization resulted in induction of anti-Ova humoral responses (Villegas-
Mendez et al., 2010). However, since full Ad particle was not included in this study, it is hard to 
compare the vaccination performance of Dd with entire Ad capsid. One could assume that since Ad 
hexon is the main source of CD4
+
 T cell epitopes (Onion et al., 2007), weaker stimulation of T cells 
responses by these structures based solely on penton base protein will limit the capacity of 
Ova-specific B cells to differenciate, resulting in weaker anti-Ova antibody titers. Other vaccination  
strategies use adeno-associated virus (AAV) or hepatitis B virus VLPs as an epitope display platforms, 
but when non-adjuvanted these constructs induce poor innate and adaptive anti-epitope responses 
(Nieto et al., 2012; Sominskaya al., 2010). 
Altogether, our data indicate that the rupture in the signaling pathways activated upon Ad 
binding to its native receptor can be surrogated by numerous PAMPs associated with Ad particle. 
These results also further support the data obtained in our previous experiment, indicating that 
efficient infection is a dispensable factor in the process of triggering an adaptive immunity with 
epitope displaying Ad vectors.  
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1.2. Host factors 
In parallel to the investigation of the role of Ad receptors, we also evaluated innate 
immunity pathways controlling the efficacy of epitope display vaccination. Ad is known to stimulate 
TLR2 and TLR9, both of which use MyD88 as an adaptor protein (Yamagushi et al., 2007; Appledorn 
et al., 2008). Thus, in order to evaluate the impact of these signaling pathways on mounting 
anti-epitope humoral responses, we used mice deficient in MyD88, an adaptor molecule shared by all 
TLR with the exception of TLR3. Interestingly, anti-Ova humoral responses did not differ in MyD88
-/-
 
and wild-type mice, suggesting that other innate sensing pathways were involved in the induction of 
innate immunity. To the best of our knowledge, this is the first analysis of the impact of TLR/MyD88 
pathway on epitope display strategy,. Nevertheless, some teams assessed the role of MyD88 
signaling in innate as well as adaptive responses induced by transgene-encoding vectors, derived 
from Ad or other viruses. Rhee and colleagues evaluated the impact of MyD88 signaling ablation on 
Ad5-induced responses and reported significantly reduced anti-transgene CD8
+
 cellular immunity 
(Rhee et al., 2011). Interestingly, while the lack of MyD88 protein severely impairs immune 
responses, mice deficient in a single TLR develop unaltered cellular immunity. These findings indicate 
that these TLR are not critical individually but contribute together to the potent Ad innate immunity. 
Still, Yamaguchi and his team noticed that Ad reliance on TLR9 and MyD88 stimulation depends on 
the cell type, suggesting that Ad vectors can use both TLR9/ MyD88-dependent and -independent 
pathways in innate immunity induction (Yamaguchi et al., 2007). Reduction of anti-transgene cellular 
responses observed by others and unaltered B cell responses in our experiment could be explained 
by the repetitive exposure of the epitope on the surface of Ad capsid. Indeed, a previous study 
suggested that, when present in a repetitive manner, epitopes can lead to the cross-linking of B cell 
receptors and induce T cell independent humoral responses (Fehr et al., 1998). Also, Maglione and 
colleagues observed that while IgM responses against T-independent antigens are broadly impaired 
in MyD88-deficient patients, IgG antibody titers remain unaltered (Maglione et al., 2014).  
Other teams investigating the impact of MyD88 protein on vector-induced humoral 
immunity obtained results contradictory to ours. Humoral responses against Respiratory Syncytial 
virus were impaired in mice lacking MyD88 protein (Bhoj et al., 2008). Similarly, Sudres et al. 
reported that antibody titers against AAV vector were significantly reduced in MyD88
-/- 
(Sudres et al., 
2012). The discrepancy between these studies and our results could be explained by the differences 
in the vectors/viruses used, as divergent dependence on innate signaling pathways among the 
viruses have been underpinned by various studies. Still, an interesting aspect observed by Sudres et 
al. is the intrinsic B cell dependence on Myd88 signaling and ability of MyD88
-/- 
mice to restore the 
reduced total IgG titers upon infusion with wild-type B cells. Analogical observations came from Guay 
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and colleagues who assessed responses to polyoma virus (Guay et al., 2007). They proposed that 
while antiviral antibody responses are efficiently initiated in MyD88
-/-
 mice (as measured 7 days after 
injection), the establishment of long lived plasma cells is strictly dependent on intrinsic B cell MyD88 
signaling. Indeed, titers analyzed 1.5 years after the vector injection were significantly reduced for 
MyD88
-/-
 mice. Similarly, it would be interesting to evaluate capacity of AdF-3OVA2 to induce 
long-lived, epitope-specific plasma cells in Myd88 deficient mice. 
Interestingly, analysis of induced anti-Ova isotypes in our study revealed significant increase 
in IgG1 titers in Myd88
-/-
 mice, indicating the development of adaptive response of Th2 type. Rogers 
et al. with his team compared the responses induced against vector capsid and transgene in MyD88
-/-
 
and wild type mice upon administration of AAV vector encoding Ova (Rogers et al., 2015). While 
anti-Ova IgG1 levels were slightly reduced, in MyD88
−/− 
mice, anti-AAV IgG1 titers were significantly 
elevated with regard to wild-type mice. Our results showing and increase of IgG1 titers in MyD88-/- 
mice could be explained by the fact that Ova323-339 peptide integrated in the fiber protein is now an 
intrinsic capsid component. We also observed that presence of MyD88 was required for the 
production of anti-transgene IgG2a Abs. The exact molecular mechanism dictating this differences 
between anti-transgene and anti-vector responses remain to be elucidated but could be linked to the 
intrinsic nature of the antigen, its concentration or its localization. Nevertheless, one study already 
showed an impact of MyD88 signaling in B cells on Th-polarization and IgG isotype class switching 
(Rawlings et al., 2012). Also, Myd88 signaling in DC results in the production of type-I IFN and this 
cytokine was shown to result in increased IgG2a and IgG2b production and reduced IgG1 levels (Heer 
et al., 2007; Zhu et al., 2009). 
As far as TLR sensing is concerned, Ad particle coated with FX is also thought to be 
recognized by TLR4 (Doronin et al., 2012). TLR4 can use both MyD88 and TRIF as its adaptor proteins 
and thus signaling through this receptor in MyD88
-/-
 could be only partially disabled. The results 
obtained by Rhee in TRIF
-/-
 mice showed that this adaptor molecule has little impact on the cellular 
responses induced by Ad vector. Nevertheless, in order to completely evaluate the influence of TLR 
sensing on Ad vector vaccination potential, double knock-out mice (MyD88- and TRIF-deprived) 
would need to be used. 
Similarly to TLR signaling, we sought to investigate the impact of RLR sensing on the 
vaccination performance of epitope display Ad vectors. It has been shown that RNA associated with 
Ad particle is capable of stimulating the RIG-I signaling pathway (Minamitani et al., 2011). Since RIG-I 
uses MAVS as an adaptor protein, we investigated the ability of MAVS
-/-
 mice to mount humoral 
responses against the displayed epitope. Our observations indicate that, analogically to MyD88
-/-
 
mice, MAVS
-/- 
mice immunized with AdF-3OVA2 displayed anti-Ova titers as robust as wild-type mice. 
Studies analyzing the role of RIG-I in virus-induced immune responses are less numerous than those 
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investigating MyD88 protein. One group evaluated the influence of RLRs signaling in the immune 
responses to Influenza virus. They observed, that MAVS
-/-
 mice are capable of inducing both 
anti-transgene and anti-vector humoral responses as efficiently as wild-type mice. Additionally, a link 
between the stimulation of previously described TRIM21 (cytoplasmic antibody Fc-receptor) and 
RIG-I sensing was recently deciphered (Watkinson et al., 2015). The authors proposed that 
TRIM21-induced premature Ad uncoating improves viral RNA and DNA recognition by RIG-I and 
cGAS/STING, respectively. With regard to these findings, an evaluation of Ad epitope display 
approach in Ad-immune MAVS
-/-
 mice would bring an interesting insight into the way these two 
signaling pathways overlap.  
Altogether, the results of other as well as our data suggest that innate immune responses 
to Ad vector do not rely on one particular receptor or signaling pathway and rather seem to be 
regulated in an orchestrated manner by various sensors. The complexity of diverse sensors provides 
Ad vector with numerous mechanisms of innate immunity activation. In addition to previously 
discussed TLR an RLR signaling, viral DNA could contribute to the induction of inflammatory profile by 
stimulating the cGAS/STING pathway. Herpex Simplex virus induced significantly attenuated 
inflammatory responses in cGAS
-/-
 mice (Li et al., 2013). Studies using Ad vector confirmed in vitro the 
influence of cGAS/STING viral DNA sensing on the activation of IRF3-responsive genes (Lam et al., 
2014). However, no study so far analyzed the influence cGAS/STING pathway in vivo. Evaluation of 
the vaccination performance of our vector in cGAS
-/-
 or STING
-/-
 mice could bring valuable results and 
generate a set of data complementing the observations of wild-type mice immunization with empty 
vectors. Another interesting aspect to evaluate would be the determination of humoral responses 
triggered in MyD88
 -/-
 and MAVS
-/-
 mice by detargeted vectors. Determining the innate immune 
signaling pathways involved in mounting adaptive immune responses is critical in order to better 
address the safety issues and control the immunogenicity of the vector. Such increase in our 
knowledge would pave the way for the development of improved vaccine vectors. 
 
2. Induction of cellular responses by Ad vectors displaying T cell epitopes into their capsid 
 
Beside the analysis of humoral responses elicited by Ad displaying cell epitopes, in the 
second part of my thesis we sought to evaluate the potential of epitope display strategy to induce 
cellular responses. Ad vectors displaying OVA class-I T cell epitope SIINFEKL (SL) into their hexon or 
fiber proteins were previously constructed. Inserted sequence was containing either epitope alone or 
flanked with additional amino acids residues from the original Ova. Altogether, six vectors were 
produced and evaluated in vitro for their ability to be uptaken and processed by DCs (thesis 
Anastasia Lanzi). In the frame of my thesis we sought to pursue their characterization in vivo. Two 
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main questions were investigated: the role of the insertion site of the epitope and the possible 
influence of pre-existing Ad immunity. 
The results of splenocyte restimulation indicate that Ad displaying SL epitope into hexon 
protein was more potent in inducing epitope-specific T cells than AdF-SL. In parallel to in vitro 
restimulation of Ova-specific splenocytes, we also quantified by cytometry Ova-specific splenocytes 
using tetramers (H-2K
b
+SL peptide). Percentage of tetramer positive CD8
+
 cells among the total pool 
of CD8
+
 cells was the most elevated in naïve mice injected with AdH-SL. This tendency was observed 
at both early (11-12 days) and late (25-26 days) time points. Similarly, the analysis of total number of 
SL-specific CD8
+ 
cells in the spleen of naïve mice pointed at AdH-SL as the most immunogenic 
construct at the early and late stages of induced cellular responses. In order to complement our 
quantitative assessment of cellular immunity we additionally counted the SL-specific cells producing 
IFN-γ. Results were underpinning the previous observations, with the most robust cellular responses 
detected at both time points in naïve mice immunized with AdH-SL.  All these observation conjointly 
lead to the conclusion that induction of cellular responses strongly depends on the epitope insertion 
site.  
The superiority of hexon display could potentially be explained by its increased abundance 
in the Ad particle composition. Indeed, while inserted into hexon protein, epitope is present in a total 
number of 720 (3 x 240) copies while fiber display provides 36 (3 x 12) epitopes copies on one Ad 
capsid. However, results previously obtained by Dr A. Lanzi during the analysis of epitope processing 
in vitro suggest otherwise. Vectors displaying epitopes into their hexons were more potently inducing 
production of IL-2 cytokine than Ad with epitopes inserted into fibers. Thus, it is probable that this 
capacity of hexon-located epitope to be more efficiently processed and/or presented on the surface 
of APC governs its immunization potential in vivo. Stronger levels of anti-ovalbumin CD8
+
 T cells 
induced by AdH-SL while compared to AdF-SL could also be due to distinct processing pathways of 
hexon and fiber protein. After binding to a host cell and entry by endocytosis, Ad virion undergoes 
the uncoating step during which the fiber protein is separated from the capsid. Then, after 
endosome escape, the remaining Ad particle traffic to the nucleus using microtubules and finally a 
complex formed by hexon and viral DNA is able to enter the nucleus through the nuclear pore 
complex. Since the fiber and hexon protein traffic through endosomes, they should be processed 
through the endocytic pathway in antigen-presenting cells and presented by MHC class II molecules. 
The capacity of hexon protein to traffic into the cytosol on microtubules until the nucleus 
presumably makes it able to be processed and presented in antigen-presenting cells through the 
endogenous pathway. Altogether, the better CD8
+
 T cell responses obtained after mice immunization 
with AdH-SL could be linked to the efficient processing of hexon protein by the endogenous 
processing pathway. 
 224 
Both AdH-SL and AdF-SL are less efficient in Ad-immune mice, as confirmed by our results 
obtained with splenocyte restimulation, tetramer staining and ELISPOT assays. It is interesting to 
observe that pre-existing anti-Ad immunity hampers the induction of the cellular responses directed 
against displayed epitope. One could assume, that while coated with Abs, Ad particle would be 
better uptaken by antigen-presenting cells such as DCs through the FCγ receptor. Studies reported 
previously, that DCs take up immune complexes (Ad coated with Abs) more efficiently than the 
soluble antigens (Gil-Torregrosa et al., 2004). Additionally, another study reports that in the presence 
of virus coated with Abs DCs display more mature phenotype, as shown by increased expression of 
co-stimulatory molecules and robust production of pro-inflammatory cytokines (Perreau et al., 
2008). Moreover, results of Leόn et al. suggested that in the presence of immune complexes, DC 
continue to present the antigen to CD8
+
 cells even after virus clearance. (Leόn et al., 2014). This 
prolonged presentation results in delayed contraction of primary CD8
+ 
and drive the establishment of 
memory CD8
+
. Additionally, upon the identification of cytosol Fc receptor TRIM21 and its capacity to 
stimulate the production of pro-inflammatory cytokines, it is tempting to speculate that cellular 
responses induced in Ad-immune setting should be more vigorous. Our results contradict this theory. 
Still, the previous analyses were usually investigating the responses induced against the encoded 
transgene or the Ad itself. To our knowledge, this is the first report of the epitope display strategy 
with class-I T cell epitopes on Ad capsid and thus our data cannot be directly compared to other 
studies. Nevertheless, few papers reported the use of VLPs as a platform for T cell epitopes. Influenza 
class-I epitope was inserted into the external positions of Ad dodecahedron and showed the 
induction of cellular responses in immunized chickens (Szurgot et al., 2013).  Another study, also 
selecting CD8
+
 epitope from influenza, used VLPs of simian virus 40 (SV40) as a platform and 
observed induction of cellular responses in mice (Kawano et al., 2014). Still, none of these studies 
tried to assess the influence of anti-vector Abs. 
Numerous studies suggested that not only the number but also the phenotype of memory 
CD8
+
 T cells influences their protective capacity (Wherry et al., 2003). Thus, we decided to assess the 
expression level of various phenotypic markers in order to elucidate the properties of the cellular 
responses induced by our Ad vectors. More precisely, at both time points, we investigated the levels 
of CD44, CCR7, CD127, CD62L and KLRG1 molecules on the surface of harvested splenocytes. Analysis 
performed 11-12 days after the Ad vector immunization disclosed that, although some differences 
were observed between the experimental groups, SL-specific CD8
+
 subpopulation (TetOva
+
CD8
+
) 
exhibited significant alterations in the marker expression levels in comparison to the remaining pool 
of CD8
+ 
cells (TetOva
-
CD8
+
). The levels of CD44 and KLRG1 molecules were significantly increased on 
the surface of SL-specific CD8
+
 cells while reduction of surface expression of CD127, CCR7 and CD62L 
was observed. At the second time point, all groups continued to exhibit increased expression of CD44 
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and KLRG1 molecules compared to total CD8
+
 T cells. Still, only SL-specific T cells isolated from naïve 
mice immunized with AdH-SL displayed reduced amounts of CD127 and CD62L molecules, suggesting 
persistence of effector T cells in this group. 
In order to have a clearer picture of phenotypic features of SL-specific CD8
+ 
cells we decided 
to quantify the different phenotypes contributing to the total pool of induced memory cells. Memory 
T cells can be divided in two main lineages, named central (TCM) and memory (TEM) T cells. Briefly, TCM 
cells are known to reside in secondary lymphoid organs and through their proliferation capacity 
constitute a source of specific T cells, while TEM are found in peripheral tissues, providing quick 
response during antigen re-encounter. Thus, both subsets are important elements of efficient 
vaccination outcome. At the early time point (day 11-12), the biggest contribution of SL-specific 
effector cells to the total population of TetOva
+
CD8
+
 was detected in naïve mice infected with 
AdH-SL. TEM lineage was induced more vigorously by AdH-SL than AdF-SL vector, regardless of host 
status towards Ad.
 
 Interestingly, cellular responses induced by AdH-SL displayed reduced pool of TCM 
cells in comparison to fiber display, in both naïve and immune mice. Two weeks later a strong 
increase in the pool of TCM cells was observed, especially in the case of AdH-SL in the naïve 
background. Interestingly, both naïve and immune groups immunized with AdF-SL vector still 
displayed significantly increased levels of TCM. Effector memory cells, on the other hand, decreased to 
the equal levels for all four groups. When drawing conclusions from these results, it should be 
pointed out that the experiment with the kinetic study was not yet repeated. If these results are to 
be confirmed, the underlying reasons of these differences in memory phenotypes between hexon 
and fiber display will have to be elucidated.  
 
3.  Immune responses induced with Ad vectors displaying HCV epitopes 
 
In the last part of this work we aimed at constructing Ad vectors displaying epitopes from a 
therapeutic target. Our choice of hepatitis C virus (HCV) as a pathogen was dictated by its severe 
pathogenicity and lack of available vaccine. Altogether, for both B cell and T cell epitopes, we 
envisaged 18 constructions but only 6 vectors were successfully produced and infectious. 
Interestingly, the HCV sequences we were trying to insert into the Ad capsid were comparable in 
their length to the fragments we previously selected in Ova protein. This suggests that not only the 
size of the epitope but also the sequence itself influences the insertion permissiveness of Ad 
capsomers. An interesting question to be addressed would be to try to understand at which steps of 
the viral cycle Ad production is blocked. We can anticipate some defects in multimerisation of 
capsomers or in assembly of capsomers. The difficulty in producing Ad bearing HCV epitopes points 
out a limit of epitope display strategy and underlines also the importance of developing methods in 
 226 
order to predict whether a peptide inserted into this or that protein will allow efficient rescue of the 
virus.  
We encountered difficulties during vector characterization in vitro. Commercially available 
anti-E2 Abs failed to recognize the HVR and HCR epitopes on the surface of produced vectors. 
Monoclonal anti-HCR Abs confirmed the presence of this epitope on the surface of AdF-HCR vector. 
In case of T cell epitopes, due to the lack of suitable T cell hybridome availability, only one vector 
(AdH-NS31073) was characterized in an antigen processing assay. Strong production of IL-2 cytokine 
confirmed efficient antigen presentation on the surface of DCs. 
The in vivo studies with vectors displaying B cell epitopes, although repeated three times, 
failed to induce detectable anti-E2 humoral responses. Subsequent analyses of sera collected from 
mice immunized with AdE1E2 encoding E1 and E2 glycoproteins as a transgene, disclosed that 
anti-HCR but not anti-HVR Abs were produced upon immunization with full E2 protein. This questions 
the role of the immunogenicity of HVR epitope in C57BL/6 background. The lack of humoral 
responses upon mice immunization with the vector displaying HCR sequence remains to be 
elucidated. The epitope was detected on the capsid surface and we confirmed that this sequence is 
immunogenic in C57BL/6 mice. Detection of anti-βgal Abs excluded the possibility of vector 
precipitation. One of the possible explanation could be a change in epitope accessibility upon in vivo 
injection. Another possible solution might be the differences in epitope conformation while 
embedded in the natural E2 sequence and inserted into the Ad viral particle. For the future studies, it 
would be interesting to increase the dose of injected virus or add some additional adjuvant in order 
to stimulate immune responses more efficiently. 
Assessment of the induction of cellular responses by our Ad vectors was performed in HHD 
mice. This strain possess HLA-A2 molecules, capable of presenting selected NS3 epitopes. Two 
vectors were included in the in vivo vaccination studies: AdH-NS31073 whose processing was 
confirmed in vitro and AdH-NS31406. Splenocytes of animals immunized with AdH-NS31073 produced 
upon NS3 peptide restimulation quantities of IFN-γ more elevated than in the case of restimulation 
with Ad peptide. AdH-NS31406 vector failed to trigger detectable cellular responses. Still, since epitope 
presence and its processing was never assessed for this vector, we cannot conclude whether absence 
of IFN-γ production relies on the lack of vector immunogenicity or is caused by the problems in the 
epitope insertion/accessibility and its processing by DCs. The evaluation of cellular responses induced 
by HCV vectors was strongly impaired by the limited availability of HHD mice. Nevertheless, the 
results we obtained are very encouraging and the vaccination studies with AdH-NS31073 vector will be 
continued in other to better characterize anti-HCV cellular responses.  
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4. Perspectives 
4.1. Vector re-targeting  
Our result shed a new light on the epitope display strategy of vaccination. Conclusions drawn 
from the first part of this work imply that Ad capsid can be modified in the sites involved in the 
interaction with the cellular receptors and host factors without losing its capacity to mount efficient 
humoral responses gives a possibility of re-designing Ad vector biodistribution in vivo. In our study 
we produced vector crippled in both integrin and FX interactions and observed a significant reduction 
in its in vivo infectivity without altering its vaccination efficacy. Thus, a combination of multiple 
detargeting mutations on one viral particle is a very compelling perspective.  
From the vaccination point of view it would be interesting to increase virus uptake by DCs. 
A few studies already explored this possibility by inserting into the fiber protein RGD motif, capable 
of binding integrins present on the DC surface (Okada et al., 2001; Krause et al., 2013). Another team 
relied on CD40 targeting in order to increase Ad uptake by DC and their maturation (Huang et al., 
2008). Nevertheless, Ad vector used in these studies were encoding antigen as a transgene. Thus it 
would be interesting to see how such modifications would impact the immunization outcome with 
Ad displaying epitope on the capsid. Eventually, with regard to the fact that both integrins and CD40 
molecules are present on numerous cell types, targeting a molecule whose expression is more 
exclusive to DC surface would allow to reduce the vector-related toxicity and dose. Another tempting 
perspective is to combine the insertion of specific targeting motifs with the various detargeting 
mutations. 
 
4.2. Crippled vectors 
Another intriguing aspect is the generation of further crippled vectors. We already showed 
that interaction with cell receptors and host factors is not indispensable for the efficient vaccination. 
A very interesting strategy would be the development of empty capsid Ad vectors displaying 
heterologous epitopes on their surface. This would allow us to address the question of the role of 
virus DNA sensing. Although this aspect was partially investigated by immunizing MyD88
-/-
, cGAS
-/-
 or 
STING
-/- 
mice, to our knowledge no study so far obtained double deficient mice background with 
ruptures in both TLR9/MyD88 and cGAS/STING signaling pathways, both capable of sensing foreign 
DNA. AIM2/ASC is another DNA-sensing pathway that needs to be investigated. A few interesting 
studies were made with Ad dodecahedrons (Szurgot et al., 2013), but due to its less complex 
structure, this particles could exhibit different adjuvant properties. Indeed, in the Ad particle hexon 
protein is the major source of CD4
+ 
epitopes. 
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4.3.  Combining numerous epitopes on the vector surface 
Many studies describe various Ad capsomers permissive for the insertion of heterologous 
epitopes. Among them the hexon and fiber proteins are the most frequently used, but penton base 
and pIX have also turned out to be a potential insertion sites. Additionally, in the sequences of these 
proteins diverse regions capable of accommodating epitope insertion were identified (various HVR in 
hexon protein, different loops in fiber protein). It is thus tempting to combine various epitopes on 
one viral particle. This could either consist in the insertion of the same epitope in many different sites 
or alternatively in the insertion of various B cell or T cell epitopes of the same pathogen. Since, in the 
case of therapeutic vaccination, it is preferable to induce both humoral and cellular responses 
considering the results we obtained it would be especially interesting to construct vectors displaying 
B cell epitope into the fiber protein and T cell epitope into the hexon protein. 
 
4.4. Combining epitope display with transgene 
 
Combination of B cell epitope display and the same antigen in the form of transgene was 
already evaluated by others (Worgall et al., 2007; Zhou et al., 2013) and results suggested that 
although the antibody titers are not significantly increased, the antibody avidity is enhanced. This is 
related to the presence of additional CD4
+ 
epitopes. However, nobody addressed the possibility of 
combining class-I T cell epitope display with the antigen in the form of transgene. Comparing this 
dual vector with the classic recombinant vector and Ad displaying solely the epitope could shed 
a new light on the induction of cellular immunity with epitope display approach. Evaluation of the 
kinetics and phenotype of induced cellular responses would bring valuable informations, allowing to 
design effective vaccine vectors. 
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